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The early diagnosis of cancer can help direct the best treatment strategy and 
improve patients’ survival. The unique and tunable properties of nanoparticles facilitate 
the development of diagnostic imaging tools for earlier diagnosis and disease staging, and 
they can provide fundamental information on the pathological process. Nanoparticle 
probes have demonstrated to have numerous advantages over single molecule-based 
contrast agents, such as tumor-targeted delivery via the enhanced permeability and 
retention (EPR) effect, prolonged systemic circulation times to enhance imaging contrast 
efficiency, and facile surface modification for specific applications. 
The first part of this dissertation focuses on the development of radiation-
damaged nanodiamonds (DNDs), a type of carbon-based nanoparticles, for the detection 
of solid tumors using a photoacoustic (PA) imaging technique. In chapter 2 of this 
dissertation, DNDs are proposed as ideal optical contrast agents for PA imaging in 
biological tissues due to their low toxicity and high optical absorbance. A new DND with 
very high NIR absorption was synthesized by He+ ion beam irradiation. These DNDs 
produced a 71-fold higher PA signal on a molar basis than similarly dimensioned gold 
nanorods, which were considered the “gold” standard agent for PA contrast agents. In 
order to develop DNDs as a molecularly-targeted contrast agent for high resolution and 
phenotype-specific detection of breast cancer with PA imaging, in chapter 3, an anti-
Human epidermal growth factor receptor-2 (HER2) peptide (KCCYSL) was conjugated 
to the surface of PEGylated DNDs. PA images demonstrated that DNDs accumulate in 
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orthotopic HER2 positive tumors and completely delineated the entire tumor within 10 
hours.  
Chapters 4 and 5 of this dissertation describe the development of a hyaluronic 
acid (HA) polymeric nanoparticle to deliver drugs for the locoregional treatment of head 
and neck squamous cell carcinoma (HNSCC). In chapter 4, a HA-pyropheophorbide a 
(PPa) conjugate was synthesized. The anti-cancer efficacy was improved compared to the 
intravenously administered PPa molecules, and it was demonstrated that it could be 
useful for in vivo locoregional photodynamic therapy of HNSCC. In chapter 5, a pH-
tunable delivery platform of platinum-based anti-cancer drug was designed and 
synthesized to improve the therapeutic index. The systemic toxicity of cisplatin was 
significantly reduced due to the pH-controlled release of the active forms of Pt species. In 
chapter 6, a lanthanum label was non-covalently conjugated to HA polymer to track the 
in vivo bio-distribution of HA in HNSCC tumors and organs that are responsible for the 
elimination of nanoparticles. In the last chapter, an enzymatic N-deacetylation method 
was applied in the modification on HA. New synthetic routs were explored to prepare HA 
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1. Background and Objectives 
Nanostructured materials have a number of exceptional physical, chemical and 
biological properties that make them attractive for biomedical applications, such as 
imaging, diagnosis and therapy. Some organic nanoparticles, such as liposomes and 
micelles, are formed by spontaneous arrangement of amphipathic molecules. These 
systems are lack of mechanical and dynamic stability in that a homogenous size and 
geometry distribution are hard to maintain during production and storage. Inorganic 
materials, such as carbon- and metal-based nanoparticles, have unique physiochemical 
properties, which make them be promising candidates for biomedical applications.  
In particular, carbon allotropes, including graphene or graphene oxide (GOs), 
carbon nanotubes (CNTs) and nanodiamonds (NDs) (Figure 1), have shown unique 
features that are suitable as drug delivery carriers, imaging contrast agents and 
therapeutic agents. The carbon-based materials possess the properties of large surface-to-
volume ratio, rigid structure, good thermal conductivity and the potential for high 
biocompatibility. In the early stages, their applications were hampered by poor aqueous 
solubility and stability. However, advances in surface functionalization approaches 
substantially improved the solubility of carbon-based nanoparticles. In some cases, 
hydrophobicity was retained and employed to enhance the loading efficiency of water 
insoluble therapeutic agents to the target and hence improve therapeutic efficacy. 
Colloidal metal nanoparticles are formed by the reduction and crystallization of 
inorganic salts to highly ordered and rigid structures. The particle morphology can be 
precisely controlled by the synthetic chemistry to thus design particles with their specific 
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desirable physicochemical properties. Surface modification of metal nanoparticles can 
increase their biological stability, biocompatibility, blood circulation time and achieve 
targeted drug delivery of therapeutics. Multifunctional nanoparticles combine the features 
of concurrent imaging, diagnosis and therapy, and thus are platforms for theranostic 
nanomedicine.  
The goal of the first part of this thesis is to investigate carbon-based nanodiamond 
as a new photoacoustic (PA) imaging contrast agent for the early detection and outlining 
of breast cancers. The goal of the second part is to develop polymer-based nanocarriers 
for biomedical imaging and locoregional treatment of head and neck squamous 
carcinoma (HNSCC).  
2. Carbon-Based Nanomaterials  
2.1 Carbon and its nanoderivatives: chemical and physical properties 
In nature, carbon exists in different forms or allotropes depending on its electron 
configuration. Among the carbon allotropes, the most widely investigated and used are 
CNTs (sp2), GOs (sp2) and NDs (sp3). Due to the distinct hybridization, these carbon 
allotropes inherently have different properties.   
CNTs are hollow cylinder structures with sp2-hybridized carbon as the first 
reported by Iijima et al.(1). They can be made of a single layer of hexagonal graphene, 
termed single-wall CNTs (SWCNTs), or several layers of graphenes, termed multi-wall 
CNTs (MWCNTs). The preparation methods mainly include chemical vapor deposition 
(CVD) with or without catalyst, and arc-discharge.(2-5) The synthesized CNTs vary in 
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electronic properties, which are attributed to such geometric parameters as magnitude and 
chiral angle. Thus, SWCNTs show metallic or semiconducting conductivity, whereas 
MWCNTs exhibit only metallic properties.  
The first single-layer graphene was isolated from graphite, consisting of six-atoms 
arranged as a honeycomb lattice.(6) Graphene and related materials can be synthesized 
using solution processes, high temperature chemical vapor and solid growth methods. 
Especially, preparation from MWCNTs was recently developed to meet the need of high 
quality graphene for electronics and other applications.(7) Graphene has been explored in 
a variety of applications, such as electronics, sensors and catalysts, because of its good 
thermal conductivity, electrical conductivity, high specific surface area and excellent 
mechanical strength; however, biomedical applications were limited. Graphene 
nanostructures tend to aggregate in solution leading to concerns regarding 
biocompatibility in biological milieus. However, due to the successful synthesis of 
carboxylate group functionalized single layer GO sheets, hydrophilic coating such as 
polyethylene glycol (PEG) could be covalently bound to GOs.(8) The increased 
biocompatibility due to surface modification highlights the physical features of GOs and 






Figure 1. Three allotropes of carbon: a) carbon nanotubes, b) graphene and c) diamonds. 
Created by Michael Ströck (mstroeck) (Created by Michael Ströck (mstroeck)) [GFDL 
(http://www.gnu.org/copyleft/fdl.html), CC-BY-SA-3.0 
(http://creativecommons.org/licenses/by-sa/3.0/) or CC-BY-SA-2.5-2.0-1.0 
(http://creativecommons.org/licenses/by-sa/2.5-2.0-1.0)], via Wikimedia Commons
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The carbon atoms in NDs are completely sp3 hybridized and have a characteristic 
tetrahedral configuration, which leads to physical properties of extreme strength, 
hardness and high inertness compared to other nanoparticle forms of carbon. More 
importantly, nanostructured diamonds exhibit properties beneficial for biomedical 
applications compared to single crystalline diamond, including tunable electrical 
conductivity, high thermal conductivity, filed electron emission properties and good 
biocompatibility.(9) NDs are usually obtained by detonation, plasma assisted chemical 
vapor deposition, ultrasound cavitation and laser ablation techniques.(10) Such prepared 
NDs contain layers of amorphous and sp2 hybridized carbon, and the resulting surface 
pattern is determined by the production method and the subsequent purification process. 
A variety of surface treatments via oxidization or gaseous reactants can be applied to 
produce oxygen containing functional groups, especially carboxyl groups (Figure 2). 
Such modified NDs can be further modified to improve the solubility of NDs for a 
variety of specific biomedical applications, such as drug delivery and imaging.  
The presence of lattice impurities results in a remarkable feature of NDs different 
from other carbon materials; NDs are fluorescent with high quantum yields and are 
immune to photobleaching and photoblinking.(11-14) Furthermore, the large-scale 
manufacturing of NDs is achievable in a cost-effective and reproducible manner. The 
scalability has led to numerous studies and diverse applications of NDs in the past few 
years, which will increase at a rapid rate in the future. In this session, research advances 
and the progression of NDs in biomedical application, such as multimodal contrast 
agents, drug delivery carrier and therapeutic agents are summarized with a particular 
interest given to their role in biomedical imaging and drug delivery. 
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2.2 NDs in biomedical application 
2.2.1 Imaging contrast agents 
 NDs are great for fluorescence imaging because a variety of lattice defects are 
introduced in the particle core during the growth/production process (eg. [N-V]- centers). 
Fluorescent NDs (FNDs), unlike organic dyes, absorb broadly from 500 to 625 nm and 
emit fluorescence in the “optical window”, in addition to the large Stokes shift (> 100 
nm) of FNDs, which further reduces the intrinsic autofluorescence signal.(15) Organic 
dyes enter an excited state during fluorescence that makes them chemically reactive and 
subject to photobleaching. For example, Alexa Fluor 546 photobleaches rapidly within 
12s in under a typical confocal imaging condition. In contrast, FNDs present a consistent 
fluorescence signal that is stable over a period of 300s.(16) A variety of physical 
treatments can be used to further enhance the quantum yield and fluorescent properties. 
For example, high-energy proton beam irradiation and subsequent thermal annealing 
increased the quantum efficiency of FNDs to ~ 1.(17) In addition to [N-V]- centers, other 
admixtures, like silicon vacancy centers, were incorporated to improve NDs’ 
fluorescence.(18) Thus, the high contrast and stability provide large opportunity to use 
FNDs as a probe for bioimaging that overcomes the major weaknesses of organic dyes. 
ND fluorescence probes has been used to investigate the interactions of transferrin and 
the transferrin receptor on HeLa cells using a laser scanning fluorescence microscope, 
and to study cell division and proliferation as a tracker for cancer and stem cells.(19, 20) 
FNDs have been used for whole organism imaging. For example, FNDs were introduced 
into wild-type C. elegans either by feeding them or injecting FND suspension into the 
gonads. Eventually, the entire digestive system could be imaged continuously.(21)  
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 NDs have a sharp characteristic Raman peak at 1332 cm-1 that results from the 
phonon mode of carbon sp3 configuration. Since the Raman spectra of NDs is very 
unique compared to most biosystems, NDs also have potential as Raman-enhanced 
biological imaging agents. Making use of this unique property, intracellular distribution 















Figure 2. The surface of NDs is oxidized using various methods primarily that result in 















Figure 3. Raman mapping using nanodiamonds as a marker. (a) The Raman spectra of 
100-nm carboxylated ND (cND), A549 and HFL-1 cells. The Raman mapping of a HFL-
1 cell after 4-h incubation with nanodiamond at a concentration of 10 µm/ml in cell 
medium; (b) the distribution of the cell's characteristic Raman signal intensity locked in 
the 2800–3000-cm−1 region; (c) the distribution of diamond Raman peak intensity locked 
in the 1327–1340-cm−1 region, showing the nanodiamond localization relative to the cell. 
The Raman mapping of an A549 cell after 4-h incubation with nanodiamond at a 
concentration of 1 µm/ml in cell medium; (d) the distribution of cell Raman signal locked 
in the 2800–3000-cm−1 region; and (e) the distribution of diamond Raman peak intensity 




2.2.2 Particle-mediated drug delivery 
NDs can serve as highly versatile platforms for the delivery and release of anti-
cancer drug and nucleic acids due to their ease of surface functionalization and suitable 
nanoscopic size.  
Several anti-cancer drugs, such as Purvalanol A, 4-hydroxytamoxifan, 10-
hydroxycamptothecin and epirubicin, have been loaded to NDs to enhance anti-cancer 
efficacy.(25-27) NDs can enhance anti-cancer efficacy by several mechanisms: 1) the 
therapeutic efficacy could be enhanced by increased drug accumulation at tumor sites due 
to the enhanced permeability and retention (EPR) effect of nanoparticles; 2) anti-cancer 
drugs can be released from NDs in response to lower pH inside tumor cells, and 3) drugs 
can be delivered specifically to tumor cells by molecularly targeted NDs.(28-30) For 
example, NDs-doxorubicin (DOX) complexes were embedded into a parylene C polymer 
microfilm to achieve a controlled, steady and continuous DOX treatment of cancer.(31) 
Drug resistance is usually acquired after repeated chemotherapy owing to the elevated 
level of drug efflux. Interestingly, NDs-DOX overcame the drug resistance by increasing 
the influx of DOX via the endocytotic pathway, whereas the free drug can enter only by 
passive diffusion. NDs have also been employed as effective gene delivery carriers with 
good biocompatibility and high efficiency. Zhang et al. reported that NDs functionalized 
with low molecular weight polyethylenimine (PEI) could transport plasmid DNA and 
small interfering RNA (siRNA) with lower cytotoxicity and higher transfection efficiency 
compared to conventional vectors.(32, 33) 
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2.2.3 Therapeutic agents 
 NDs can be used as therapeutic agents without additional drug or cytotoxics. For 
example, NDs can be induced to produce cytotoxic nitric oxide (NO) under laser 
illumination. An impurity, the nitroso (C-N=O) group, inside the NDs can be photolyzed 
by two-photon absorption under a wavelength of 532 nm, followed by a physical 
explosion reaction of releasing NO to induce the formation of a sp3 diamond structure 
and transition to a sp2 graphite structure. The affected distance was around 90 nm, thus 
the size of NDs was enlarged more than 10 fold resulting in a popcornlike conformation 
transition. It was proposed to be used as a nanoknife, and the feasibility was tested by 
coupling NDs to growth hormone.(34) In addition, NDs have been developed for the 
applications in bone generation to increase hardness, and used as bone implant coating 
material to promote mechanical and osseointegrative properties.(35) Uses of NDs as 
substrates for neuronal growth and other applications in neurosciences have been 
proposed because of their electrical property.(36) 
2.3 Toxicity 
The safety of NDs is a critical consideration in their development for biological 
uses. Although diamond is chemically inert in its bulky crystalline form, the large 
surface-to-volume ratio at the nano-scale brings up the importance of surface chemistry. 
Yu et al. evaluated the cytotoxicity of NDs using standard in vitro cell viability assays. 
They observed that FNDs showed a slight anti-proliferative effect on human embryonic 
kidney cells at concentrations of up to 400 µg/mL.(37) By monitoring adenosine 
triphosphate (ATP) and reactive oxygen species (ROS) production, Schrand et al. 
13 
 
demonstrated that NDs were the least toxic among the carbon-based nanomaterials to 
neuroblastoma cells, including carbon black, SWCNTs and MWCNTs.(38) NDs were 
also found to affect the expression of genes in certain cell types, which was possibly due 
to the surface chemistry of NDs. Although the extent of NDs’ genotoxicity is 
controversial, the DNA damage caused by NDs was still less severe than that induced by 
MWCNT as reported by Xing et al..(39) 
The in vivo retention and distribution of NDs would influence the toxicity. It was 
investigated by labeling NDs with various radionuclides, and found that the preferred 
locations are the lungs, liver and spleen, with excretion primarily by the urinary 
system.(40) After different routes of administration, NDs did not show any noticeable 
side effects on rodents. ND biocompatibility is in part determined by the surface physical 
and chemical properties, including surface chemistry, surface charge and particle size. 
The tolerable dose of NDs is ultimately limited by their accumulation and elimination 
from the body, as NDs cannot be degraded by any known biological process. An analysis 
of histological morphology and biomedical parameters by Zhang et al. indicated that NDs 
could induce dose-dependent toxicity in their primary accumulative sites after 
intratracheal instillation.(41)  Thus, the safety of NDs still needs extensive systemic 
investigation before their use in humans.   
3. Metal-Based Nanomaterials  
Metal nanoparticles have been used by scientists, physicians, and artists for 
millennia. The 4th-century Romans developed dichroic glass vessels using dispersions of 
colloidal silver and gold nanoparticles that appeared green when lit from the front but 
turned red when light shown through them (42). In the late 19th-century, silver 
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nanocrystals were discovered to be light sensitive and gave birth to photography, while 
anti-microbial colloidal silver was a wound antiseptic until the introduction of antibiotics 
in the 1940s (43). Today, metal nanoparticles are used in drug delivery, imaging, 
diagnostic tests and therapy, due to their distinct optical, magnetic and electronic 
properties. These properties are determined by the nanostructure composition, size, shape 
and structure, and are tunable via flexible synthetic routes. 
3.1 Synthesis of metal-based nanomaterials  
3.1.1 Physical methods 
 Physical methods of metal nanoparticle production are in general capable of 
producing large, commercially useful quantities with good atom efficiency, but with 
significant external energy input. The inert gas condensation (IGC) process for producing 
metal nanoparticles was first described by Gleiter et al. in 1981 (44). Metal vapor is 
introduced to an ultra-high vacuum chamber filled with inert gas (helium or argon) by 
evaporation of the source material with an electron or ion beam. Collisions between the 
evaporated metal atoms and the inert gas induce the growth of metallic nanoparticles. 
Metal precursors also can be evaporated by high temperature plasma induced with radio 
frequency, microwave or laser energy. Although robust, the high energies inputs in these 
techniques results in a wide nanoparticle size distribution. A “soft plasma” method 
recently developed by Lee et al. produces uniformly sized, crystalline, unagglomerated 
nanoparticles(45). Platinum salts were chelated in a polymeric film and exposed to 
atmospheric pressure plasma; the plasma electrons reduced the metal salt, resulting in 
nucleation and growth of the nanoparticles, which could be finely controlled by plasma 
power and polymer length and charge.  
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Flame pyrolysis has been used for several decades to process metal salts into 
nanoparticles, such as silica and titania, at scales of metric tons/hour. However, this 
technique was limited to metals with salts of relatively high volatility and heat stability. 
The development of flame spray pyrolysis in the past decade has enabled almost all 
elemental metals to be processed into nanoparticles. A mixture of organic solvent and 
organometallic precursor are injected into the high temperature (>2000C) reactor, and the 
combustion enthalpy drives precursor oxidation, nucleation and nanoparticle growth. For 
example, Pratsinis et al. produced homogeneous Bi2O3 nanopowders by a new flame-
assisted spray pyrolysis reactor, which allowed the use of low enthalpy precursor solution 
and increased combustion enthalpy density of the flame with inexpensive fuel gas (46). In 
addition, a sol-flame method was used to achieve the synthesis of heterostructured 
Co3O4@CuO nanowires by changing the precursor solutions, followed by the flame 
annealing at high temperature (> 900 oC) for only a few seconds (47). Although large 
production volumes are possible, spray flame pyrolysis requires potentially explosive 
solvents and results in significant combustion product emissions.   
3.1.2 Chemical synthesis 
Chemical processes can produce very uniform sized nanoparticles compared to 
physical means. Salts or acids of metal atoms can be chemically reduced to form 
nanoparticles using a variable of reducing agents, including sodium borohydride, 
hydrazine and ethylene glycol, although the potential toxicity from residual contaminants 
is driving the development of less toxic reducing agents such as organic acids and sugars. 
Iablokov et al. used oleic acid to decompose dicobalt octacarbonyl into nearly 
monodisperse cobalt nanoparticles with temperature-controlled sizes between 3 and 10 
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nm; with the addition of phosphate, similarly monodisperse particles were produced up to 
16 nm. The move toward “green chemistry” emphasizes the elimination of volatile 
organic solvents in processing to increase safety and reduce environmental concerns; for 
example, monodisperse platinum nanoparticles can be produced in a single aqueous step 
using ascorbic acid to reduce the Pt(IV) salt into 32-nm dendritic nanoparticles (48). 
Processes such as these avoid the use of toxic chelators and reducing agents, although 
excess heavy metal salts still must be removed from the liquid waste streams.   
3.1.3 Bioenzymatic processes 
Plants, fungi, and bacteria in high metal environments have developed 
bioenzymatic processes to precipitate, chelate and sequester heavy metals. The yeast 
Yarrowia lipolytica sequesters heavy metals using the redox potential of high molecular 
weight phenolic polymer melanin. Solution metal ions oxidize the melanin phenones to 
quinones, producing metallic nanoparticles by reductive precipitation. Melanine isolated 
from Y. lipolytica converts aqueous silver nitrate and chloroauric acid into 7 and 20 nm 
particles of silver and gold, respectively, which can be used to produce antifungal 
coatings and paints without toxic organic fungicides (49). Low cost alfalfa biomass has 
proven to bioreduce gold, silver, europium, ytterbium, samarium and zinc into 
nanoparticles. Iron oxide (Fe2+ state) nanoparticles, which are of significant interest for 
imaging and other biological applications, can be produced by alfalfa biomass reduction 




Recovery of metallic nanoparticles from biological systems can be challenging 
due to the organic-rich heterogeneous matrix. Methods include phase separation with 
microemulsions, physical disruption of the matrix, surfactants, enzymatic treatments and 
organic extractions. The marine bacteria Shewanella reduce Pt(IV) salts to elemental 
platinum nanoparticles at room temperature and neutral conditions. The nanoparticles are 
sequestered in the periplasma, which may simplify recovery by methods such as mild 
disruption followed by centrifugation (51). 
Future investigations of metallic nanoparticles biosynthesis should focus on 
further understanding the bioreduction mechanisms, selection of organisms involved in 
the biosynthesis procedures, and optimization of the reaction, separation and purification 
conditions. 
3.2 Biomedical applications 
3.2.1 Imaging contrast agents 
Metal nanoparticles have been investigated used for the biomedical imaging 
thanks to the high photostability, superparamagnetism, X-ray absorption, K-edge energy 
and optical absorption properties.   
Localized surface plasmon resonance (LSPR) plays an important role in 
determining the optical properties and is an unparalleled characteristic of metal 
nanoparticles over other nanometerials.  LSPRs are collective electron charge oscillations 
in metallic nanomaterials that excited by an electric field at an incident wavelength. The 
occurrence of resonance results in the enhancement of light scattering, absorption and the 
local electromagnetic fields. Thus, as an imaging contrast agent, metal nanoparticles own 
18 
 
higher molar extinction coefficient as a result of their larger absorption cross-sections and 
stronger surface-enhanced Raman scattering. The LSPR induced strong optical 
absorption and light scattering from metal nanoparticles have been employed in X-ray 
computed tomography, photoacoustic (PA) imaging and optical coherence tomography 
techniques. Gambhir group designed a magnetic resonance imaging-photoacoustic 
imaging-Raman imaging (MPR) nanoparticle using Au nanoparticle as a core to delineate 
brain tumor margins noninvasively by all three modalities (52).  
Noble metal nanoparticles are the most extensively studied for imaging 
applications because of their notable shape-dependent LSPR spectra that can be 
controlled by their morphologies in the synthesis. For example, comparing to one 
absorption band of spherical Au nanoparticles, Au nanorods exhibit two bands in the 
visible and NIR wavelength regions those are assigned to a transverse and a longitudinal 
LSPR, respectively. Moreover, the longitudinal LSPR peak can be easily shifted to longer 
wavelength by increasing the aspect ratio (length/diameter) of Au nanorods. The LSPR 
characteristics in NIR region allow their applicability for deeper tissue imaging. Another 
interesting functionality of LSPR is the distance-dependent fluorescence alternation by 
metal nanoparticles, when the fluorophore is within in the strong surface plasmon field. 
Using this concept, an Au nanoparticle functionalized the DNA tweezers were designed 
and fluorescent intensity of the fluorophore responded to the addition of fuel or antifuel 
DNA strands (53). Furthermore, metal nanoparticles have been studied for the disease 
marker detection. Tumor mRNA is a specific maker to identify the stage of tumor 
progression and assess the treatment, so bi-color imaging nanomaterials were synthesized 
based on Au nanoparticles with a bi-molecular beacon for early detection of breast cancer 
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(54). This approach made use of the quenching effect of Au nanoparticles when the 
fluorophores were brought in close proximity by a stem-loop oligonucleotide. 
Fluorescence was recovered by release of the fluorophores from the particle surface 
through the specific interaction between DNA and RNA in order to realize the real-time 
detection of the tumor mRNA in cancer cells.         
The other distinct property of metal nanoparticles used in drug delivery, 
biomedical imaging and therapy is their inducible magnetization, superparamagnetism. 
Superparamagnetic metal nanoparticles are ferromagnetic particles with sizes smaller 
than 20 nm that lose their net magnetization in the absence of an external field, which 
renders the paramagnetism switchable. Among superparamagnetic nanoparticles (e.g., Fe, 
Co, Ni and Mn), single composition metal nanoparticles have the highest saturation 
magnetization; metal oxides nanoparticles possess more stable magnetism upon to 
exposure to an external magnetic field (e.g., Fe3O4); whereas, alloyed metal nanoparticles 
have shown excellent magnetic performance and chemical stability (e.g., FePt, CoPt, and 
FeCoPt). Since magnetism disappears in the absence of a magnetic field, these particles 
have a higher magnetic susceptibility and a stronger and more rapid magnetic response 
than their ferromagnetic bulk form, and thus a higher magnetic resonance imaging (MRI) 
contrast when external field is applied. This inducible magnetic property prevents particle 
aggregation and uptake by phagocytes and increases their blood circulation time. Cheon 
et al. designed and constructed a T1-T2 dual mode MRI contrast agent using the 
magnetic coupling between a superparamagnetic MnFe2O4 nanoparticle core (T2 contrast 
agent) and Gd2O(CO3)2 shell (T1 contrast agent). The coupling between layers could be 
modulated by the thickness of SiO2 in the middle for simultaneous generation of strong 
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T1 and T2 MRI contrast (55). Dual-modal bioimaging techniques have been developed to 
overcome the drawback of the relatively low spatial resolution of MRI. For instance, a 
magnetoplasmonic imaging agent was designed to combine the superparamagnetism of 
iron oxide (Fe3O4) nanoparticle for MRI and the surface plasmon resonance of Au 
nanoparticle for dark field microscopy. These two particles were assembled via the 
“click” reaction under the catalysis of Cu(I) so that the elevated levels and 
miscompartmentalization of Cu(I) could be monitored by the dual responsive imaging 
modalities with high spatial resolution (56). Moreover, Wu and co-workers introduced a 
Gd2(CO3)3:Tb nanoparticle for combined fluorescent and magnetic imaging of living 
cells to provide an excellent imaging resolution and sensitivity (57). 
3.2.2 Particle-mediated drug delivery  
A common advantage of nanoparticles over small molecules is the preferential 
accumulation in tumor when administered systemically because of the EPR effect. Metal 
nanoparticles can be designed similarly as other nanocarriers to protect the therapeutic 
agents (proteins and siRNA) from degradation in physiological environments and 
facilitate the intracellular penetration of hydrophobic chemotherapeutics. As a result, the 
systematic circulation time of active agents and thus the delivery efficiency are greatly 
enhanced by the metal nanocarries. Meanwhile, surface modification is used to enhance 
their colloidal stability in biological environments and improve targeted delivery to the 
site of interest. Mukherjee and co-workers conjugated two kinds of antibodies, epidermal 
receptor growth factor and folate receptor, on the surface of Au nanoparticle to achieve a 
dual receptor targeted system for a potential efficient drug delivery to the cells in the 
heterogeneous population of tumors (58). Yumeng et al. developed FePt@Fe2O3 core-
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shell magnetic nanoparticles to realize simultaneous T2 MRI and folate receptor targeted 
delivery of hydrophobic anti-cancer drug molecule (doxorubicin, DOX) via a proper 




Figure 4. Preparation of FePt@Fe2O3 core-shell nanoparticles and in vivo tumor MR 
imaging. (A) A scheme showing the PEGylation of FePt@Fe2O3 nanoparticles and DOX 
loading on nanoparticles by hydrophobic interactions between deprotonated DOX and 
oleic acid. (B & C) T2-weighted MR images of KB tumor-bearing nude mice at different 
time points post intravenous injection of FePt@Fe2O3-PEG (B) and FePt@Fe2O3-PEG-
FA (C) nanoparticles. (D) Relative T2 signal intensities of tumors at different times post 
injection of nanoparticles. Reprinted from Nanomedicine: NBM, 9, Liu Y, et al, 
PEGylated FePt@Fe2O3 core-shell magnetic nanoparticles: Potential theranostic 




Metal nanoparticles assisted drug delivery has unique potentials over 
conventional vehicles since the release of drugs can be triggered by external energy, such 
as lasers or magnetic fields. For example, magnetic nanoparticles can carry therapeutic 
agents directly to their target site under a magnet field and retain the drug until release is 
triggered; thereby the nonspecific distribution of drugs is minimized to avoid side effects. 
Moreover, the external stimuli resulted in the deformation of particle to liberate the drug 
molecules conjugated on the surface (60). Lecommandoux et al. used an external field to 
induce release of doxorubicin from polymersomes co-encapsulating iron oxide 
nanoparticles; in addition, the localized heating synergistically increased the anti-cancer 
activity of doxorubicin in tumorigenic tissues due to increased permeability and alteration 
of cell signally pathways (61). Localized heating of Au nanoparticles with a near-infrared 
laser was reported to enhance the permeability of delivery vehicles, such as red blood 
cells, to release a combination of drug molecules (62).    
3.2.3 Therapeutic agents 
The SPR of metal nanoparticles leads to strong scattering and absorption of light 
in the UV-Vis-NIR region, and the thermal energy converted from the absorbed light 
energy is sufficient to introduce various thermodynamic effects, including thermal 
ablation, ultra-fast heating, transient thermal expansion, particle melting and reshaping. 
Light-based therapeutics combined with metal nanoparticles have the attractive 
advantages of location specific and precisely controlled heating intensity using external 
stimuli, such as near-infrared laser energy, and minimum systemic toxicity. Noble metal 
nanoparticles are useful for photo-activated therapy due to their highly tunable optical 
properties. Different shapes of gold and silver nanoparticles, such as Au nanoshells, Au 
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nanorods, Au nanocages and Ag nanotriangles, have been demonstrated to kill cancer 
cells effectively via near-infrared light induced hyperthermia, especially with the help of 
targeting ligands conjugated to the nanoparticles. Xia et al. compared the photothermal 
capability of various Au nanostructures (Au nanohexapods, nanorods and nanocages) and 
concluded that Au nanohexapods exhibited highest cellular uptake and photothermal 
destruction of breast cancer tumors (Figure 5) (63). Gold nanoparticles also can enhance 
the efficacy of external beam radiation or acoustic cavitation in cancer therapies, as a 
result, the original therapeutic dose of radiation or ultrasonic energy can be reduced to 
minimize the destruction of surrounding healthy tissues (64, 65), The bulk of photo-
induced hyperthermia strategies utilize metal nanoparticles of gold or silver, but these 
heavy metals have the potential for bioretention and long-term toxicity. Wang and co-
workers proposed the use of magnesium nanoparticles for photothermal therapy; 
magnesium nanoparticles have near perfect biodegradability and biocompatibility, 




Figure 5. TEM images of (A) Au nanohexapods, (B) Au nanorods and (C) Au 
nanocages. (D) Cellular uptake of PEGylated Au nanostructures by MDA-MB-435 cells 
after incubation for different periods of time. (E) Plot showing 18F-FDG standarlized 
uptake values (SUVs) ratios of laser-treated tumor to nontreated tumor. (F) 18F-FDG 
PET/CT co-registered images of mice intravenously administrated with aqueous 
suspensions of PEGylated Au nanostructures, or saline. Tumors were treated either with 
(solid circle + left arrow) or without (solid circle) laser irradiation. Reprinted with 
permission from Wang Y., Comparison Study of Gold Nanohexapods, Nanorods, and 
Nanocages for Photothermal Cancer Treatment, ACS Nano, 7(3): 2068-2077 (2013). 




The magnetic properties of nanoparticles can be used for magnetothermal energy 
conversion to target hyperthermia and thermal tissue ablation. The well-known 
hyperthermic agents are iron oxide based nanomaterials, metallic nanoparticles (Mn, Fe, 
Co, Ni, etc. and their oxides), their composites and core-shell magnetic nanoparticles. 
Kobayashi and co-workers used magnetite nanoparticles for hyperthermia therapy of 
hamster osteosarcoma under an alternating magnetic field (67). Metal nanomagnets have 
been used to capture tumor cells specifically based on magnetic separation (68). This 
approach may provide a promising therapeutic tool for the differentiation of individual 
diseases and then applying a “personalized treatment”.      
Specific biological interactions of metal nanoparticles can enhance conventional 
therapeutics. For example, biosynthesized silver nanoparticles showed enhanced 
antimicrobial properties when combined with commercial antibiotics (69). Moreover, it 
was found that bare or negatively charged Au nanoparticles could inhibit amyloid-β 
fibrillation by preferentially binding to fibrils and forming the fragmented, which may 
pave a new way for the assessment and treatment of neurodegenerative disease (70). In 
addition, metal oxide nanoparticles, such as zinc oxide (ZnO) and cuprous oxide (CuO) 
nanoparticles, have been demonstrated to destroy cancer cells via apoptosis-mediated cell 
death (71, 72).       
3.2.4 Multi-functional metal nanoparticles 
Multi-functional metal nanoparticles could satisfy the need for diagnosis and 
therapy, simultaneously, by combining different properties described above for imaging, 
diagnosis, drug delivery and treatment into a single platform. This, the treatment of 
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cancer and other diseases, could be accomplished in a highly spatial and temporally 
controlled manner. El-Sayed et al. employed multifunctional gold nanostructures for 
spectroscopic detection, laser photothermal therapy, as well as targeted delivery of 
hydrophobic chemotherapeutics (73). Magnetic metal nanoparticles can combine MRI 
contrast imaging (T2) and hyperthermic destruction of tumors. Recently, gold-iron oxide 
hybrid and core-shell iron-gold nanoparticles integrating the plasmonic and magnetic 
functions were developed for both therapy and diagnostic applications (68). Xenograft 
tumors were detected by superparamagnestic iron oxide nanoparticle-based T2 MRI 
imaging, and subsequently treated via laser-assisted hyperthermic tumor ablation using 
the optical absorption of the gold nanostructure in the hybrid. Copper sulphide 
nanoparticles stabilized with gelatin have very high NIR absorbance, which was used for 
combined photoacoustic imaging and photothermal therapy. In addition, targeted 
chemotherapy could be incorporated into this theranostic platform through the enzyme-
responsive release of doxorubicin from the gelatin (74).           
3.2.5 Biosensors 
Metal nanoparticles can be used as label-free biosensors due to the shifts in their 
absorption and scattering spectra. These shifts are induced by the changes in the 
intraparticle plasmon coupling status or the local refractive index. Since noble metal 
nanoparticles exhibit the most striking LSPR feature, specificity and stability, they have 
shown very promising applications in biosensing. Strategies based on this principle have 
been applied in the detection of DNA, thrombin, growth factor protein and other proteins 
in recent years. For example, double-stranded DNA could be differentiated from single-
stranded by the enhancement of surface-enhanced Raman scattering (SERS) signal 
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intensity arising from the salt-induced aggregation and thus the plasmonic coupling of 
gold nanoparticles. Xia and co-workers demonstrated an Au nanocluster biosensor for 
detection of proteases that took advantage of the change in fluorescence intensity of 
protein-wrapped nanoclusters when the protein layer was degraded by protease-catalyzed 
hydrolysis.    
A summary of biomedical applications of metal nanoparticles is listed in Table 1. 
3.3 Toxicity 
With the increasing use of multifunctional metal nanoparticles for in vivo 
biomedical applications, the short- and long-term toxicity resulting from their novel 
physical and chemical properties is a critical issue when assessing their nano-
functionality. The various particle sizes, shapes and surface characteristics could initiate 
reactions in biological systems, giving rise unexpected acute or chronic toxicities and 
immunological effects (75). Larger gold nanoparticles (50-100 nm) accumulate highly in 
the liver and spleen and can cause severe inflammation. Smaller gold nanoparticles (1-50 
nm) can penetrate kidney tissues and are cleared more efficiently. However, a toxicity 
study of gold nanoparticles of sizes 10, 20 and 50 nm in renal tissue demonstrated that 
smaller particles interfered with antioxidant defense mechanisms and gave rise to reactive 
oxygen species, which induced more atrophy and necrosis than larger particles (76). In 
addition, extensive DNA damage can be caused by the interaction of noble metal 
nanoparticles. Platinum nanoparticles do not directly interact with DNA, but they can 
release soluble ionic species that may form Pt-DNA complexes via a mechanism similar 
to the chemotherapeutic drug cisplatin (cis-PtCl2(NH3)2) (77).  
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The toxic potential of metal nanoparticles can be significantly mitigated through 
the careful control of the nano-surface chemistry. Surface passivation by coating with 
biodegradable polymers or biological molecules and the addition of inorganic shells can 
increase the biocompatibility of metal nanostructures. For example, iron-based magnetic 
nanoparticles can catalyze the formation of excessive reactive oxygen species (ROS) and 
thus induce oxidative stress. Coating of the nanoparticles with dimercaptosuccinic acid 
(DMSA) resulted in excellent in vivo biocompatibility and no signs of toxicity (78). 
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Table 1. Summary of metal nanoparticles and their biomedical uses and toxicity. 
Metal Nanoparticles Uses Toxicity Refs 
Au 
Imaging agents, drug and nucleic acid delivery, 
photothermal therapy, radiotherapy and protein detection 
2 nm: LD50> 1.4 g Au/kg 
1.4 nm: IC50 of 30-56 µM 
15 nm: IC50 of 6300 µM 
(53, 54, 56, 58, 
62, 63, 79, 80) 
Ag 
Antimicrobial agents, drug delivery, biosensor, imaging 
agents, photothermal therapeutic agent 
4.2 nm: LD50 of 0.04 × 10-7 M (43, 69) 
Cu/Cu2O 
anti-microbe, anti-fungal additive, dietary supplement, 
photoacoustic imaging, tumor-selective chemotherapy and 
photothermal therapy 
40-110 nm: IC50 of 27.00 
µg/mL for normal mouse 
embryonic fibroblast cells  
(72, 74) 
CeO2/ Yi2O2 
Antioxidants, modulation of the degranulation process in 
human neutrophils 
6 nm: 20 µg/mL to HT22 cells (81) 
Fe/FexOy MRI, biosensor, drug carrier, hyperthermia, photothermal 10-100 nm: no cytotoxicity at a (56, 59, 60, 67, 
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therapy concentration < 100 µg/mL 68, 82) 
FePt@Fe2O3 MRI, drug carrier 
7-8 nm: 160 µg/mL to KB cells; 
no noticeable in vivo toxicity at 
a dose of 34 mg/kg within 20 
days 
(59) 
Gd2(CO3)3:Tb T1 MRI agent 
8-12 nm: no cytotoxicity at a 
concentration < 500 µg/mL 
(55, 57) 
In2O3 
Environmental air quality sensors, photostimulated ozone 
sensors 
7-12 nm, toxicity: N/A (83) 
MgO Hyperthermia therapy of tumors 80 nm: no acute toxicity (66) 
Mn MRI contrast agent 
>25 nm: induce cell death at a 
concentration > 25 nM 
(55) 
Ni/Ni Oxide Alzheimer's disease therapy 
20 nm: significant toxicity to 




350 µg/mL  
Pt Chemotherapy, biosensor 
<20 or 100 nm, no toxicity at a 
concentration < 1 mg/cm2 
(77) 
TiO2 
Enrichment and separation of phosphopeptides in 
proteomics, modulation of the degranulation process in 
human neutrophils 
50 nm: 150 mg/kg BW in mice, 
i.p. 
(85) 
TaO X-ray contrast agent 
5-15 nm: no toxicity at a 
concentration < 2.4 mg/mL 
(86) 
ZnMgO Antibacterial agent 
150-200 nm: no toxicity at a 
concentration < 1 mg/mL 
(87) 
ZnO 
modulation of the degranulation process in human 
neutrophils, cancer therapy 
50 nm: significant reduction in 





4. Combination of Carbon and Metal Nanoparticles for Theranostic Applications 
The combination of the characteristic properties of carbon and metal nanoparticles 
opens new avenue to use them as multimodal theranostic agents. Some new properties 
arise from the communication within the carbon/metal hybrids were presented by 
researchers. For example, after NDs were coupled with  gold nanoparticles via two 
complementary DNA sequences, the photoluminescence signals from N-V center of NDs 
were enhanced attributed to the plasmon field originating from gold nanoparticles.(88) 
Correspondingly, a gold decorated ND, prepared by an innovative electroless approach, 
exhibited particular plasmonic and scattering behaviors. These behaviors resulted from 
the influence of NDs on gold nanostructures, which was mainly related to the high 
refractive index of diamonds.(89) Moreover, magnetism in NDs was induced when 
graphene encapsulated iron nanoparticles were produced on the surface of NDs by solid-
state microwave arcing of a ND-ferrocene mixed powder. This dual-functional 
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Chapter II.  
Photoacoustic Contrast Imaging of Biological Tissues with Nanodiamonds 





Photoacoustic (PA) imaging, a high-resolution noninvasive imaging technique, was 
recently proposed for biomedical applications. PA imaging uses a short, focused laser 
power pulses to image tissues. Tissue components or agents that absorb the laser energy 
undergo rapid microheating and generate ultrasonic waves due to transient thermoelastic 
expansion. These ultrasonic emissions are detected by a transducer and used to 
reconstruct a 3-D image of the tissue structure based on optical absorption.(1) PA 
imaging provides better spatial resolution even in deep regions of biological tissues than 
pure optical imaging, such as optical coherence tomography (OCT) and diffuse optical 
tomography (DOT), because scattering of ultrasonic energy is lower than optical energy 
in biological tissue. Signal-to-noise ratios of 26 dB can be achieved as deeply as 40 
mm.(2),(3) Since PA imaging is an optical absorption-based technique, and also near-
infrared (NIR) laser can be tuned to the optical absorption characteristics of the structures 
of interest, PA imaging has superior contrast and specificity compared to ultrasonic 
imaging (USI). PA imaging is especially well-suited to image and characterize tumor 
vasculature, invasion, and angiogenesis in vivo,(4-6) and PA imaging can measure 
cytotoxin-induced apoptosis in tumors in vivo.(7) In clinical trials, PA has provided 
excellent contrast and differentiation of breast malignancies compared to x-ray at depths 
of nearly 5 cm.(8) 
 PA imaging contrast in tissues and vasculature can be greatly enhanced with 
exogenous optical contrast agents, such as NIR dyes, gold nanoparticles and carbon 
nanoparticles.(9-11) Compared to NIR dyes, due to the well-established surface 
modification with biologically relevant entities for the tumor-targeting studies and the 
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enhanced permeability and retention (EPR) effect that was used to image subcutaneous 
tumors, nanomaterials stand out as the most significant class of materials being explored 
for PA imaging applications.(6, 12) 
 Gold-based nanomaterials, in particular gold nanoshells, nanorods and nanocages, 
are among the most useful optical contrast agents in PA imaging due to their size- and 
shape-dependent plasmonic properties.(13) The tunability of their peak absorption in the 
NIR range renders them suitable for image-guided therapy and photothermal ablation of 
tumors.(14-16) Gold is considered relatively inert and generally non-toxic; however, gold 
nanoparticles ranging from 8 to 37 nm have induced severe sickness and mortality in 
mice.(17)  
 In previous studies, it has been demonstrated that nanodiamonds (NDs) are non-
toxic in numerous in vitro and in vivo animal studies and in a variety of different cell 
types.(18, 19) In this study, we have developed new radiation-damaged nanodiamonds 
(DNDs) with high optical absorbance in the NIR as a new contrast agent for PA imaging, 
and we compared optical absorption and imaging contrast capabilities of DNDs with 
those of AuNRs and SWNTs. 
 Natural and man-made nanodiamonds are neither fluorescent nor optically 
absorptive in the near-infrared, limiting their use for biomedical imaging. Fluorescent 
nanodiamonds (FNDs) were developed by introducing nitrogen-vacancy (N-V), Si-
vacancy (Si-V) and Ni-N complex centers by ion impaction. The vacancy band gap can 
be tailored to impact high optical absorption capacity, strong fluorescent quantum yields 
and resistance to photobleaching.(20) Due to their biocompatibility and high specific 
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surface area, folate- and transferrin-coupled FNDs have been utilized as receptor-
mediated targeting of cancer cells to investigate the uptake mechanism.(21, 22) Although 
FNDs show exceptional photostability under high power laser excitation and consistent 
fluorescence intensity after surface functionalization,(23) reductions in size affect the 
relative stability of the H3 and N-V centers in type Ia diamond. For example, the 
fluorescence intensity was decreased 81% when the particle size of 1 mg/mL FNDs was 
decreased from 350 nm to 50 nm.(24) Preferably, nanoparticles intended for long 
circulation and accumulation in leaky tumors should be less than 200 nm, and particles 
intended for lymphatic uptake and imaging generally should be between 10 and 80 
nm.(25) In addition, fluorescence imaging has poor spatial resolution at depths beyond 
one transport mean free path (~1 mm), which severely limits fluorescence imaging’s 
clinical potential.  
 In this chapter, we report the optical properties of DNDs with high NIR 
absorption and a diameter of 70 nm for use with PA imaging. Moreover, we show the 
feasibility of DNDs as contrast agent for PA imaging and capability of deep imaging both 
ex vivo and in vivo. In addition, we demonstrate that DNDs can serve as an excellent 
contrast agent in the PA imaging modality based on excellent biological compatibility 
and higher optical absorption capacity compared with AuNRs and single-wall carbon 
nanotubes (SWNT). 
2. Materials and Methods 
 All of the chemicals, including N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (EDC•HCl), N-Hydroxysuccinimide (NHS), sodium borate and sodium 
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hydroxide were purchased from Sigma-Aldrich (St. Louis, MO). Methoxypolyethylene 
glycol amine (PEG-amine, Mn 5000) was purchased from Jenkem Technology (Allen, 
TX). AuNRs were freshly prepared by the seed-mediated growth method.(26) Atomic 
Absorption Spectroscopy was performed on a VarianSpectrAA GTA-110 with a graphite 
furnace to determine the concentration of Au. Transmission Electron Microscopy (FEI 
Tecnai F20 XT Field Emission TEM) was used to determine mean dimensions of 25 × 82 
nm and 18 × 90 nm for 760 nm and 840 nm AuNRs, respectively. SWNT were purchased 
from Unidym (Sunnyvale, California) with dimensions of 1.2 × 600 nm and molecular 
weight of ca. 1.04 × 106 g/mol. 
2.1 DND and PEGylated DND synthesis.  
 The conjugation of PEG-amine to DNDs followed a standard carbodiimide-
mediated coupling procedure. Briefly, 2 mg of DNDs were dissolved in 2 mL of sodium 
borate buffer (10 mM, pH 8.5), followed by sonication (Sonicator FS110, Fisher 
Scientific) for 30 min. EDC•HCl (4 mg) and NHS (4 mg) were added to the DND 
solution, which was stirred at room temperature (ca. 20 oC) for 0.5 h to form the amine-
reactive DND intermediates prior to addition of a 0.5-mL solution of PEG-amine (10 
mg). After stirring overnight, the PEGylated DNDs were purified by centrifugation at 
10,000 × g for 5 min, and the precipitate was washed three times with DI water. 
Hydrodynamic diameter of PEGylated DNDs in aqueous solution was determined using a 
ZetaPALS (Brookhaven Instrument Corporation). All measurements were carried out 






Figure 1. TEM image of DNDs. Insert shows particle size distribution of DNDs with 











2.2 Peak wavelength and in vitro sensitivity.  
 The peak optical characterization of the DNDs was measured using the 10-MHz 
transducer (37.5-mm focal length; 65.81% -6-dB fractional bandwidth, V315, Olympus 
NDT). DNDs suspended in DI water were injected into clear Tygon tubing (1 mm ID, 
1.78 mm OD) and imaged by PA imaging at different laser wavelengths. Both of the 
transducer and the tubing with DNDs suspension were immersed in the water. 
Measurements were repeated 5 times and were referenced to DI water. The laser fluence 
used in peak wavelength and sensitivity experiments were 18 mJ/cm2 and 16 mJ/cm2, 
respectively. For peak wavelength experiments, signals from DNDs suspension were 
acquired at each wavelength using a same tubing. For the in vitro sensitivity experiment, 
DND suspensions at different concentrations were injected into tubing for signal 
detection. A peak absorption wavelength (820 nm) was used to determine the sensitivity 
of detection. The optical absorbance of DND was measured in a Molecular Devices 
SpectraMax (Sunnyvale, California, US). Integrating sphere measurements were taken 
with a Hitachi U-3900 spectrometer with aφ60 integrating sphere. 
2.3 Ex vivo imaging in raw chicken breast. 
 The DNDs were suspended in water (41.67 g/mL, 20 L) and injected into a raw 
chicken breast at differing depths. The 25-MHz transducer (15-mm focal length; 61% −6-
dB fractional bandwidth, I3-2506-R, Olympus NDT) was used to image the breast 




2.4 In vivo imaging in mice. 
 Balb/c mice were anesthetized using isoflurane and placed on a thermostatic pad 
for PA imaging, in accordance with protocols approved by the IACUC. A 30-µL 
suspension of DNDs (90.3 g/mL, 0.238 nM) in 10% phosphate buffered saline (PBS) 
was injected subcutaneously into the lower back of a mouse. The 5-MHz transducer (35-
mm focal length; 70% -6-dB fractional bandwidth, SU-108-013, Sonic Concepts) was 
used to image the injection area. Afterwards, the imaging depth was measured by 
injecting DNDs into the ventral side of the thigh of mouse, and PA images were taken 
from the dorsal side. The laser fluence used in both ex vivo and in vivo experiments was 
18 mJ/cm2. 
The human head and neck squamous cell carcinoma (HNSCC) cells, MDA-1986, 
were prepared in PBS at a concentration of 2 × 107 cells/mL, and were kept in an ice bath 
before injection. Mouse is anesthetized with 1.5% isoflurane in 1:1 oxygen-air mixture, 
and a 50-µL cell suspension was injected subcutaneously into the oral sub-mucosa of a 
mouse using a 30-ga needle. Mouse is ready for PA imaging when the head and neck 
tumor obtained dimensions of ca. 5 × 5 mm, as measured with a digital caliper. The 
mouse was maintained under anesthesia on a warm pad and underneath the membrane in 
the center of the bottom of the water tank during the entire imaging process. Between the 
skin and the membrane, ultrasound gel was applied as a coupling medium. The breathing 
rate of mouse was visually monitored and maintained at one breath per two seconds. PA 
images of the head and neck areas were obtained as background images before injecting 
PEG-DNDs particles. After determining the depth of the detector’s focal point (2 - 3 mm) 
along with the imaging resolution of ca. 270 µm, 32 µg of particles were administrated 
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intravenously via the tail vein. The tumor areas were scanned continuously and 
repeatedly at a rate of 20 min per scan at a laser wavelength of 820 nm.  
3. Results  
 DNDs were prepared by ion irradiation of natural (type Ia) diamond powders at a 
high dosage (~3 × 1015 He+/cm2). This high-dose irradiation created a high concentration 
(up to 3000 ppm) of vacancies in the diamond crystal lattice. These vacancies, 
predominantly present in neutral form, are termed as GR1 defect centers. After irradiation 
to create the vacancies and subsequent strong acid treatments, characteristic diffraction 
patterns of diamond (111), (220) and (311) peaks were clearly observed in radiation-
damaged nanodiamonds (data not shown), which indicated that there was no significant 
damage to the crystal lattice of natural diamond.  
 The experimental setup for PA imaging of DNDs is shown in Figure 2. The deep 
reflection-mode PA imaging system is capable of sub 0.2-mm resolution at depths of 19 
mm and penetration of up to 38 mm.(28) In this study we used a configuration we 
previously described,(3) which uses a 532-nm Q-switched Nd:YAG laser (Surelite III, 
Continuum) to pump an optical parametric oscillator laser (Surelite OPO PLUS, 
Continuum) with 6-ns pulses at 10 Hz. The output is conveyed through an optical 
condenser to generate a ring-shaped illumination, which is depth focused in tissues using 
a condenser lenses and a focused transducer. The beam diameter was 7 mm at the tissue 
surface, and the laser intensity was restricted to 20 mJ/cm2 in accordance with the laser 
safety limits recommended by the American National Standards Institute (ANSI). The 
generated PA signal recorded by the transducer was amplified through a pre-amplifier 
(5072PR, Olympus-NDT) and then collected by a PC through an A/D Scope Card 
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(CS21G8-256MS, Gage) with a 125-MHz sampling rate for analyzing and forming PA 
images.  
 The optical characteristics of the DNDs were measured by PA, absorbance 
spectroscopy with an integrating sphere (Figure 3). The optical absorbance did not have a 
clear maximum due to high optical scattering. An integrating sphere measurement 
indicated decreasing absorbance from 590 to 780 nm (Figure 3a), similar to the PA signal 
trend from 700 to 780 nm (Figure 3b). The PA signal and integrating sphere absorbance 
where in agreement up to about 950 nm, with the exception of the PA maximum at 820 
nm. The integrating sphere absorbance increased beyond 950 nm whereas PA signal 
intensity decreased. This may be due in part to our laser system’s reduced intensity at 



















Figure 3. Optical characteristics of DNDs suspended in DI water as a function of 













 The PA signal amplitude peaked at 700 nm with a second peak at 820 nm. 
Wavelengths between 700 and 900 nm are ideal for NIR imaging of biological tissues, 
since the absorption contributions of hemoglobin, water, and Mie scattering are weak 
compared to wavelengths below 700 nm. We used 820 nm for subsequent PA imaging of 
the DNDs. Figure 4 indicates a non-linear increase in peak-to-peak PA signal amplitude 
with increasing DNDs concentration, and moreover, obvious PA signal differences 
between deionized (DI) water (0.0034±0.0006 V) and DNDs water suspension were 
observed above the concentration of 0.8 g/mL (0.0219±0.0004 V). At higher DND 
concentrations, the penetration depth of light into the highly scattering medium decreases, 
and thus the laser intensity at the focus area decreases. Therefore, the PA signal 
amplitude gradually levels off at higher concentrations of DNDs.  
 The DNDs were then imaged in raw chicken breast as an ex vivo model. The 
maximum-amplitude-projected (MAP) image of the chicken breast tissue after the 
injection of DNDs at a depth of 3 mm (Figure 5a) shows the regions with and without 
DNDs presented obviously. The DND injected area increased contrast by 446% 
compared to the background chicken breast tissue, with a relative standard deviation 
(RSD) of 33%. A B-scan showed that DNDs can be imaged at a depth of ~9.5 mm with 
















Figure 5. Photoacoustic images taken after injecting DNDs into chicken breast tissue. (a) 
MAP image; (b) Corresponding photograph of DNDs in chicken breast tissue (dashed 









 The DNDs were next imaged after subcutaneous injection into the lower back of a 
mouse. The injection site and the path along which the needle was withdrawn are clearly 
visible against the tissue background (Figure 6a). The DNDs enhanced the PA signal 
contrast 919% with a 34% RSD. In a second injection at ca. 3 mm into the hip of the 
mouse (Figure 6b), the DNDs enhanced the contrast 567% compared to surrounding 
tissues with a 19% RSD. 
 PEGylated DNDs in a size of 135 nm were injected into a mouse bearing head 
and neck tumor intravenously via the tail vein. As shown in PA B-scan images (Figure 
7b), rapid accumulation of DNDs in the tumor region was observed within two and a half 
hours due to the enhanced permeability and retention (EPR) effect. The maximum 
accumulation occurred at 8 h post-injection. After 8 h, the PA signal contrast of the tumor 












Figure 6. Photoacoustic images taken after injecting DNDs subcutaneously at (a) the 










Figure 7. a) Photograph of a mouse bearing head and neck cancer (dashed black window 
showing the imaged area), b) PA images (B-scan images corresponding to the dashed 
blue line in (a)) of region of interest (ROI) before and at different time points after the 
injection of DNDs. 
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 To further understand the signal enhancement of DNDs, we collected and 
compared the PA signals of DNDs at 820 nm wavelength to AuNRs with longitudinal 
absorption wavelengths of 760 nm and 840 nm, and to SWNTs with a maximum 
absorption wavelength of 970 nm. The concentrations of different nanoparticles were 
adjusted to achieve similar PA intensities in order to limit non-linearity effects in the 
comparison. The PA amplitudes of DNDs, AuNRs and SWNTs were calculated on an 
atom and particle basis using the following equation: 
                                               Vn = Amp (𝐶𝑎𝑡𝑜𝑚⁄  or 𝐶𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒)                                  (1) 
where Vn is PA amplitude in volt per number concentration, Amp is PA amplitude, Catom 
is the number concentration of gold or carbon atoms, and Cparticle is the number 
concentration of DNDs, AuNRs or SWNTs. 
 The PA amplitude of DNDs was 1.76 and 1.58 times stronger than AuNRs of 760 
and 840 nm, respectively, on an atom basis. On a weight basis, the DNDs produced a 
signal and 29- and 26-fold greater than AuNRs. On a nanoparticle molar basis, the DNDs 
produced a signal 71and 64 times greater than the two AuNRs samples despite similar 
longitudinal dimensions. When compared with SWNT, DNDs exhibited 1.67 and 621-
fold greater PA amplitude basing on atom and particle molar concentration, respectively, 







































281.0±1.7 1.05 5.3310-3 3.21×1021 87.5×10-21 
aLaser fluence: 18 mJ/cm2; bMass concentration; cCalculated by Cm·NA/Ar 
dPA signal comparison on an atom basis 













DNDs 277.9±11.3 0.04 1.05×10-10 6.35×1013 44.8×10-13 
SWNT  
(970 nm)  









268.3±3.6 1.11 7.09×10-9 4.27×1015 62.8×10-15 
AuNRs 
(840 nm) 
281.0±1.7 1.05 6.71×10-9 4.04×1015 69.6×10-15 
eCalculated by Cm/Mparticle, where MDND~0.63fg and MAuNR~0.26 fg 











 Previously, we reported the PA imaging of type Ib diamond nanocrystals 
conjugated with gold nanoparticles.(29)  FNDs have negatively charged (N-V)- centers, 
giving red fluorescence emission at 600-800 nm. However, these FNDs do not provide 
high PA signal intensity in the absence of the gold conjugate. DNDs have GR1 neutral 
centers, which have very low fluorescent quantum yields (ca. ~1% at room temperature); 
however, the GR1 defects have a zero-phonon line at 741 nm with an absorption tail 
extending to ~800 nm.(30). With the feasibility of producing a high concentration of GR1 
centers in the particles, DNDs are well suited for PA imaging applications without the 
addition of optically active gold conjugates. 
 The improved PA contrast with DND compared to AuNR may be due in part to 
both the optical absorbance and the high thermal conductivity of DNDs. Diamond is 
known to have the highest thermal conductivity among the natural materials. For 
example, the thermal conductivity for single crystal diamond is 1200 W/m·K, which is 
over three times greater than that of copper at 20 oC.(31) The interfacial thermal 
conductance is the inverse of the interfacial thermal resistance, which is a measure of an 
interface's resistance to thermal flow. Therefore, lower interfacial thermal resistance or 
higher interfacial conductance of nanoparticles leads to faster heat transfer from the 
particles to the ambient medium, which is DI water or biological fluids in this study and 
this may result in stronger PA signals. However, this explanation does not fully explain 
the improved signal compared to SWNTs, which have larger on-axis thermal 
conductivities in excess of 30,000 W/m·K despite low off-axis conductivity of ca. 1.52 
W/m·K.(32) Also, the effects of thermal diffusion are generally thought to be negligible 
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over the short excitement pulse length used for PA imaging.(33) Hydrogen bonding could 
also play a role in the improved PA amplitude of DNDs. Chen et al. found that silica-
coated AuNRs produced three-fold higher PA signals than uncoated AuNRs, because the 
hydroxyl groups of the silica surface were able to form hydrogen bonds with water and 
lowered the interfacial thermal resistance.(34) The surface of SWNTs and unmodified 
nanodiamonds are very hydrophobic, and the hydrogen bonding interactions between the 
carbon atoms and the water are very weak.(35) However, the surface of our DNDs was 
prepared by strong oxidative acid pretreatment to have carboxyl groups,(36) which are 
strong hydrogen bond acceptors in water. As a result, the interfacial thermal conductance 
of DNDs may be higher due to the very hydrophilic surface exposed to the aqueous 
milieu.  
5. Conclusion 
 In summary, DNDs can be synthesized with sub-100 nm nanoscopic dimensions 
and with high optical absorption in the near infrared wavelengths ideal for optical 
contrast imaging. Our ex vivo and in vivo results indicate that DNDs are superior to 
AuNRs and SWNTs for PA imaging based on improved optical absorption and known 
low toxicity.(37) Compared with AuNRs and SWNTs, DNDs have better PA amplitude 
on a mole and weight basis. We envision that PA imaging with surface functionalized 
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Breast cancer is a leading cause of death in women, and 12% of the world's 
women will develop breast cancer in their lifetimes, although great progress in screening 
and treatment has been made in recent decades (1). In approximately 25% to 30% human 
breast cancers, human epidermal growth factor receptor 2 (HER2) is overexpressed on 
the surface of the tumor cells. HER2-positive breast cancers progress rapidly, and these 
patients have a poor prognosis and lower overall survival if untreated (2). Therefore, 
there is a great need to develop effective diagnostic techniques for early detection of 
HER2-positive tumors.     
Photoacoustic (PA) imaging is an emerging non-invasive and non-ionizing 
biomedical imaging modality that combines the high spatial resolution of ultrasound 
techniques and the excellent contrast of optical imaging with the help of various contrast 
agents (3-5). Within the photoacoustic effect, light is absorbed by either the tissue or 
exogenous agents in the tissue and converted to ultrasound energy via transient thermal 
elastic expansion. The attenuation of acoustic energy is 1000 times weaker than that of 
light in biological tissues, thus PA imaging has a greater penetration depth of up to 
several centimeters compared to 1-2 mm for optical imaging techniques (6-9). PA can 
image blood vessels, hemoglobin oxygenation and tumor angiogenesis with high contrast 
using the unique absorption spectra of endogenous hemoglobin and melanin (10-13). The 
utilization of exogenous contrast agents has greatly enhanced PA imaging sensitivity and 
specificity, which are intrinsic disadvantages of traditional biomedical imaging 
modalities, such as computed tomography (CT) and ultrasound (UT) (14-17). Organic 
dyes, quantum dots (QDs) and plasmonic nanoparticles have been used as contrast agents 
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in PA imaging. Among these, contrast agents having high optical absorbance in the near-
infrared (NIR) region are more attractive since the PA signal contribution from normal 
tissue and hemoglobin is minimum and the Mie scattering effect is relatively weak at 
wavelengths between 700 and 1100 nm. In addition to strong absorption in the NIR range, 
other properties of contrast agents that must be considered include toxicity, size, stability 
and surface chemistry. Some biocompatible dyes, including methylene blue and 
indocyanine green, have been used in PA imaging (18). However, low molecular weight 
organic dyes are both non-specific in their localizations and are rapidly cleared from the 
plasma by the renal system, and fluorescent agents suffer from blinking and 
photobleaching which limit their clinical application, even though conjugation to 
nanoparticles can render them a suitable size for passive tumor uptake and retention. 
Plasmonic nanoparticles are the most developed PA contrast agents due to their tunable 
absorption and much stronger optical absorption than dyes based on the surface plasmon 
resonance (SPR) effect. Gold nanorods are used extensively in PA imaging because of 
their relatively simple synthesis, very strong SPR absorption in the NIR range, and ease 
of surface functionalization for the addition of targeting ligands (19, 20). However, gold 
nanorods or nanobones melt and thus deform under intense laser light irradation. 
Although this strategy has been used to release DNA oligonucleotides and drugs (21, 22), 
gold nanoparticles do not provide a consistant and stable PA signal at a specific 
wavelength during the whole imaging process. In addition, the long-term toxicity of gold 
nanoparticles has to be considered in further human applications (23). 
Owing to the excellent biocompatibility and exceptional optical stability, 
nanodiamonds (NDs) are an outstanding optical contrast agent and drug carrier for 
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biomedical applications (24). By introducing nitrogen vacancy centers as a fluorophor in 
the NDs, fluorescent nanodiamonds (FNDs) exhibit competitive advantages over organic 
fluorescent dyes and QDs due to the long-term stability and low toxicity as an in vivo 
contrast agent (25-27). Recently, alternative strategies for using nanodiamonds as 
imaging contrast agents have emerged. By making use of the detectable electron spin 
resonance of nitrogen-vacancy centers, different shapes of nanodiamond targets within 
chicken breast tissues were imaged with a spatial resolution of ca. 800 µm (28). Carbon-
dots (CDs) with tunable and strong photoluminescence produced by hydrothermal 
oxidation of nanodiamonds have been utilized for cell imaging (29). Fabrication of 
nanodiamonds with a diethylenetriaminepentaacetic acid (DTPA) - Gadolinium chelate 
improved the signal intensity on T1-weighted magnetic resonance images (30).  
In this chapter, a HER2 targeting moiety was conjugated to irradiated PEGylated 
NDs (PEG-INDs) to enhance the PA imaging sensitivity and contrast of HER2-
overexpressing breast tumors. The HER2 receptor has been employed in pre-clinical 
research and the clinic as a molecular target for breast cancer drug delivery, tumor 
imaging and anticancer therapy (31-34). However, the large size, limited stability and 
costs of antibodies limit the use for nanoparticle targeting. As a result, a six-amino acid 
peptide (KCCYSL) that targets HER2 was identified using phage display technology. 
Peptide conjugates offer the benefits of simplified production, flexible conjugation on 
terminals and enhanced cell permeability (35-37). PA imaging combined with targeted 
INDs can provide high contrast of HER-positive tumors for identification of tumor 
growth and margins.   
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2. Materials and Methods  
2.1 Materials and chemicals  
N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC•HCl), N-
Hydroxysuccinimide (NHS), sodium borate, sodium hydroxide, ethylenediamine 
tetraacetic acid (EDTA), adenosine 5’-diphosphate (ADP) sodium salt and potassium 
chloride (KCl) were purchased from Sigma-Aldrich (St. Louis, MO). Amine-PEG2000-
amine was purchased from Jenkem Technology (Allen, TX). Fetal bovine serum (FBS) 
was purchased from Fisher Scientific (Pittsbrugh, PA). Dulbecco's Modified Eagle's 
Medium (DMEM) was purchased from Lonza (Allendale, NJ). Anti-Human epidermal 
growth factor receptor 2 (anti-HER2) peptide (KCCYSL) was synthesized by 
conventional means (36). 4T1.2-neu murine cancer cells were provided by Dr. Zhaoyang 
You (University of Pittsburgh, Pittsburgh, PA). 4T1.2 breast cancer cells were provided 
by Dr. Beth A. Vorderstrasse (Washington State University, Pullman, WA) and used with 
the permission of the Peter MacCallum Cancer Centre (East Melbourne, Australia). 
Deionized (DI) water was used for preparing all of the solutions.  
2.2 Synthesis and characterization  
Natural diamond powders (type Ia) with a median size of 0.125 μm were obtained 
from Microdiamant (NAT 0-0.25). They were grounded mechanically in a tungsten 
carbide (WC) vial containing 5 WC balls (10 mm in diameter) and mounted on a high-
energy shaker mill (8000M, SPEX) for 45 min. Particles in the size range of 35 nm were 
extracted by centrifugation from the ball-milled diamonds after cleaning in mixed aqua 
regia-hydrogen peroxide solution (1:19, v/v) gently heated to 85 °C for 1 hr, followed by 
extensive washes with DI water (38). The extracted 35-nm NDs were then irradiated with 
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40-keV He+ at a dose of ca. 3 × 1015 ions/cm2 (39). After purification in concentrated 
H2SO4-HNO3 (3:1, v/v) at 100 °C in a microwave reactor for 3 hr, the He
+-irradiated NDs 
(or called INDs) were thoroughly washed with DI water and stored at room temperature 
before use.    
The conjugation of amine-PEG-amine and anti-HER2 peptide with INDs followed 
a standard carbodiimide-mediated coupling procedure (40, 41). Briefly, 2 mg of INDs 
were dissolved in 2 mL of sodium borate buffer (10 mM, pH 8.5), followed by sonication 
(Sonicator FS110, Fisher Scientific) for 30 min. EDC•HCl (4 mg) and NHS (4 mg) were 
added to the IND solution, which was stirred at room temperature (ca. 20 oC) for 0.5 hr to 
form the amine-reactive IND intermediates prior to addition of a 0.5-mL solution of 
amine-PEG2000-amine (10 mg). After stirring overnight, the amine-PEG-INDs were 
purified by centrifugation at 10,000 × g for 5 min, and the precipitate was washed three 
times with DI water. To synthesize the HER2-PEG-INDs, the carboxyl terminus of the 
anti-HER2 peptide (1 mg) was pre-activated by mixing with EDC•HCl (4 mg) and NHS 
(4 mg) for 0.5 hr in DI water, followed by addition of the amine-PEG-IND (2 mg) 
aqueous solution. The mixture was stirred for 18 hr and the resulting nanoparticles were 
separated from the solution by centrifugation, washed with DI water three times, and 
dried in a SpeedVap (Labconco).           
The yield for the amount of HER2 targeting peptide on the surface of PEG-INDs 
was calculated by UV/Vis absorbance measurement. After incubation with a certain 
amount of anti-HER2 peptide and centrifugation, the supernatants from the HER2-PEG-
INDs suspensions were collected separately (n = 3). Seventy microliter of fluorescein 
isothiocyanate (FITC) solution in acetone (2 mM) was added to 30 µL of 20× diluted 
82 
 
supernatant of the reaction, followed by incubation at 50 °C for 5 hr. The UV/Vis 
absorption of HER2-FITC conjugates in the supernatant were recorded at 440 nm and 
analyzed based on a standard curve of HER2-FITC solutions. The amount of HER2 
targeting peptide conjugated to the surface of PEG-INDs was determined by calculating 
the amount of anti-HER2-peptide consumed in the reaction, which was 8.643 ± 5.490 × 
10-5 mol/g.   
Characteristic peaks in Fourier-transform infrared spectra (IRAffinity-1 FTIR 
Spectrophotometer, Shimazu) confirmed the coating of PEG and anti-HER2 peptide on 
the INDs. Hydrodynamic diameters and zeta potentials of IND particles in aqueous 
solution were determined using a ZetaPALS (Brookhaven Instrument Corporation). All 
measurements were carried out with five replicates. The morphology of INDs was 
determined with high-resolution Transmission Electron Microscopy (TEM) (FEI Tecnai 
F20 XT Field Emission TEM) using a lacey carbon coated copper grid (TED PELLA, 
Redding, CA).   
Optical absorption spectra of INDs suspended in DI water (1 mg/mL) were 
measured at room temperature by using a UV-Vis spectrophotometer (U-3310, Hitachi) 
in a glass cuvette with an optical path of 10 mm. Un-irradiated NDs were used as the 
reference. The optical characterization of the INDs was performed using the same PA 
setup as described in our previous study (42). A DI water suspension of INDs was 
injected into Tygon tubing (1 mm ID, 1.78 mm OD), which was immersed in water. The 
PA amplitude of INDs at different wavelengths was recorded with five replicates.  
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2.3 Cell Culture and in vitro cytotoxicity 
Murine mammary tumor 4T1.2 is known for its highly metastatic pattern, which 
mimics closely to that of human breast cancer. 4T1.2-neu was established by the 
transformation of 4T1.2 to express oncogene HER2/Neu (43). The 4T1.2 and 4T1.2-neu 
breast cancer cells were cultured in DMEM containing 10% FBS and 1% L-glutamine at 
37 °C supplied with 5% CO2 under a humidified environment. The 4T1.2-neu cells 
(5000/well) were seeded onto 96-well plates in  100 µL of culture media and incubated 
for 24 hr. HER2-PEG-INDs in 10 µL of PBS were added at a series of final 
concentrations (10, 50, 100, 150 and 200 µg/mL). After incubation for 48 h, the cell 
viability was evaluated by the Resazurin-blue assay.  
2.4 Cellular uptake and imaging 
To quantify the cellular uptake of INDs and image nanoparticles inside the cells, 
INDs, PEG-INDs and HER-PEG-INDs were labeled with a fluorescent dye. Briefly, 500 
µg of PEG-INDs or HER2-PEG-INDs were dissolved in 500 µL of sodium borate buffer 
(10 mM, pH 8.5), followed by the addition of Cyanine7 (Cy7) NHS ester (100 µg in 10 
µL of DMSO). The mixture was stirred overnight at room temperature in the dark and the 
resulting nanoparticles were separated from the solution by centrifuge, washed with DI 
water/ethanol (v/v, 1:1) three times and dried in a SpeedVap concentrator (Labconco 
Corp.). To determine the cellular uptake of PEG-INDs and HER2-PEG-INDs, cells were 
seeded onto 12-well plates at a density of 25 × 104 and incubated for 24 hr. 4T1.2-neu 
cells were treated with Cy7-PEG-INDs or Cy7-HER2-PEG-INDs at a final concentration 
of 5 µg/mL (based on INDs), whereas 4T1.2 cells were treated with Cy7-HER2-PEG-
INDs at a final concentration of 5 µg/mL (based on INDs) followed by incubation at 37 
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°C for 6 hr. Then the cells were washed three times with 3 mL of PBS and removed after 
incubation with 50 µL lysis buffer [5 mmol/L EDTA, 10 mmol/L NaOH, 10 mmol/L Tris 
base, 150 mmol/L NaCl and 1% (v/v) Triton X-100] for 10 min at room temperature. 
Another 450 µL of DI water was added to each well, and the fluorescence intensity of the 
resulting cell lysate samples were analyzed based on a standard curve of free Cy7 NHS 
ester solution prepared in 1:3 (v/v) lysis buffer/DI water. The cell protein content was 
quantified using a Pierce™ BCA protein assay (Thermo Scientific). For the HER2 
competitive inhibition experiments, cells were exposed to anti-HER2 peptide (0.75 
µg/mL) for 1 h before the incubation with Cy7-PEG-INDs or Cy7-HER2-PEG-INDs (10 
µg/mL based on INDs) for 3 hr. The cell lysis procedures and analysis methods were 
identical to the cellular uptake study.       
All cell imaging experiments were performed using a Nikon Eclipse 80i 
epiflurescence microscope (Melville, NY) with a 60x1.40 oil objective, and a Hamamatsu 
ORCA ER digital camera (Houston, TX) was used to acquire images. Cells were seeded 
onto poly-L-lysine precoated glass coverslips (BD, Franklin Lakes, NJ) in 12-well culture 
plates at a density of 50,000 cells per well and grown overnight. 4T1.2-neu cells were 
treated with or without 32 µg of PEG-INDs or HER2-PEG-INDs (based on INDs), 
whereas 4T1.2 cells were treated with or without 32 µg of HER2-PEG-INDs (based on 
INDs) followed by incubation at 37 °C for 4 hr. Then the cells were washed three times 
with 3 mL of PBS before imaging. For the fluorescent imaging, 4T1.2-neu cells were 
treated with Cy7 labeled PEG-INDs or HER2-PEG-INDs (5 µg/mL based on INDs), 
whereas 4T1.2 cells were treated with Cy7 labeled HER2-PEG-INDs (5 µg/mL based on 
INDs) followed by incubation at 37 °C for 4 hr. The cell lysosomes were stained with 
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LysoTracker® Blue DND-22 (4 µM) for 30 min. After three washes with 3 mL of PBS, 
the coverslips were placed on the slide glasses for imaging. The live cells were 
immediately imaged using a XF143 filter set (Omega Optical, Brattleboro, VT) for Cy7 
labeled nanoparticles and UV-2E/C filter set (Nikon, NY) for LysoTracker® Blue. 
2.5 Photoacoustic imaging  
The experimental setup for PA imaging of biological tissues has been described 
before (42, 44). The deep reflection-mode PA imaging system is capable of sub 0.2-mm 
resolution at depths of 19 mm and penetration of up to 38 mm (45). A 532-nm Q-
switched Nd:YAG laser (Surelite III, Continuum) pumped an optical parametric 
oscillator laser (Surelite OPO PLUS, Continuum) with 6-ns pulses at a repetition rate of 
10 Hz, and an optical condenser transformed the laser output to a ring-shape illumination, 
which was confocal with the ultrasonic transducer in the targeted area. The illumination 
beam had a diameter of 7 mm on the tissue surface, and the laser fluence was 18 mJ/cm2, 
which was lower than laser safety limits (20 mJ/cm2) recommended by the American 
National Standards Institute (ANSI). A 5-MHz transducer (35-mm focal length; 70% -6-
dB fractional bandwidth, SU-108-013, Sonic Concepts) collected the photoacoustic 
signals, which were amplified by a pre-amplifier (5072PR, Olympus-NDT) and then 
collected by a PC through an A/D scope card (CS21G8-256MS, Gage) with 8-bit 
resolution and a 125-MHz sampling rate for forming and analyzing PA images using 
MATLAB® software (Mathworks, Natick, MA).  
Animal studies used female BALB/c mice in accordance with an approved 
protocol under the guidance of the Institutional Animal Care and Use Committee at the 
University of Kansas. The murine breast cancer cells, 4T1.2 and 4T1.2-neu, were 
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prepared in PBS at a concentration of 2 × 107 cells/mL, and were kept in an ice bath 
before injection. Mice were anesthetized with 1.5% isoflurane in 1:1 oxygen-air mixture, 
and a 50-µL cell suspension was injected subcutaneously into the right mammary fat pad 
under the second nipple and along the lateral line of the mice using a 30-ga needle. Mice 
were ready for PA imaging when the breast cancer tumors obtained dimensions of ca. 5 × 
5 mm, as measured with a digital caliper.  
Before each imaging experiment, the animals were anesthetized with a mixture of 
ketamine (87 mg/kg body weight) and xylazine (13 mg/kg body weight). The right breast 
areas of mice were depilated using surgical hair removal lotion to avoid the interference 
from hairs to ultrasound propagation. The mice were maintained under anesthesia on a 
warm pad and underneath the membrane in the center of the bottom of the water tank 
during the entire imaging process. Between the skin and the membrane, ultrasound gel 
was applied as a coupling medium. The breathing rate of mice was visually monitored 
and maintained at one breath per two seconds. PA images of the breast tumor areas were 
obtained as background images before injecting PEG-INDs or HER2-PEG-INDs particles. 
After determining the depth of the detector’s focal point (2 - 3 mm) along with the 
imaging resolution of ca. 270 µm, particles were administrated intravenously via the tail 
vein. The tumor areas were scanned continuously and repeatedly at a rate of 20 min per 
scan at a laser wavelength of 820 nm.  
The signal intensity of the tumor area was measured using ImageJ software (v 
1.46r, http://imagej.nih.gov/ij/). PA images were converted to grayscale images, followed 
by the quantification of PA signal intensity of the tumor region by measuring the mean 
gray values (unit: gray/pixel). The extent of signal enhancement was calculated with the 
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following equation: increase in PA signal = [(intensity of each time point - intensity of 
background image) / intensity of background image)] × 100%.   
2.6 Hemolysis and platelet coagualtion assay 
Fresh rat whole blood from a female Sprague-Dawley rat was stabilized with 
EDTA. Serum was removed from the blood sample by centrifugation at 1200 × g for 5 
min at room temperature, and the remaining red blood cells (RBCs) were washed 5 times 
with isotonic PBS and then diluted 10 times with the same solution after the last wash. 
Diluted RBCs suspension (0.02 mL, ca. 4 × 108 cells/mL) was added to the nanoparticle 
suspension (0.08 mL) prepared with PBS at a concentration of 100 μg/mL. After 
vortexing, the mixtures were incubated at room temperature for 2 h, and then samples 
were centrifuged for 5 min at 1500 × g to remove nanoparticles and intact RBCs. The 
absorbance of the hemoglobin in the supernatant at 570 nm was measured. Triton X-100 
(1%) and PBS were used as positive and negative controls, respectively. 
Platelet aggregation was assessed by tracking changes in the particle size using a 
Coulter particle counter (Coulter Multisizer 4, Beckman Coulter, Pasadena, CA). Fresh 
rat whole blood was withdrawn and placed in heparinized tubes (BD Vacutainer® 
Lithium Heparin 37 USP unit, BD Franklin Lakes, NJ). Blood was centrifuged at 150 × g 
for 15 min to obtain platelet-rich plasma (PRP). PRP was pretreated with ADP sodium 
salt (0.5 µM), PBS, or INDs (20, 50 and 100 µg/mL). The mixtures were incubated at 37 
°C for 3 min. After dilution in Isoton II electrolyte (Coulter Electronics), particle sizes of 
platelet aggregates were measured using a 50-µm aperture tube. 
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2.7 Clearance of INDs from blood 
Mice bearing breast cancer tumors (4T1.2-neu, ca. 5 × 5 mm tumor) were 
administered PEG-INDs or HER2-PEG-INDs (2 mg/kg B.W.) by intravenous injection 
via the tail veins. Whole blood was collected (50 µL) via the submandibular vein at 15 
min, 30 min, 60 min, 3 h, 5 h, 9 h and 12 h post-injection and stabilized with EDTA. 
INDs content in whole blood was determined in a method similar to that of Yuan et al. 
with some modifications (Diamond & Related Materials 18 (2009) 95-100). Briefly, 25 
µL of whole blood was digested in a 100-µL mixture of 65% HClO4 and 30% H2O2 (v/v, 
1:1), and then heated at 50 °C for 5 min. After the whole blood dissolved, 125 µL of 67% 
HNO3 was added. The solution was heated at 50 °C to make a transparent solution in ca. 
10 min. The digested solution was neutralized with NaHCO3 and diluted to 0.5 mL with 
DI H2O. This solution was used directly for UV/Vis absorption measurements at 350 nm. 
2.8 Histopathological examination  
Animals were euthanized 12 hr after injection of INDs or saline, and the kidneys 
and livers were resected and fixed in 10% formalin. A blinded board-certified pathologist 
at Lawrence Memorial Hospital (Lawrence, KS) conducted pathological examinations; 
sections and recut sections of kidneys and livers in both groups were stained with 
hematoxylin and eosin (H & E) and microscopically examined. 
2.9 Blood biochemical parameter analyses and complete blood counts (CBC) 
A BALB/C mouse was injected intravenously with 35 µg (based on INDs) of 
HER2-PEG-INDs via the tail vein. Blood was withdrawn at 12 h post-injection,and sent 
to Kansas State Veterinary Diagnostic Lab for a complete blood count (CBC) and to 
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evaluate liver function by measuring serum levels of aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT). Blood from non-treated mouse was tested as a 
control.  
2.10 Statistical analysis  
GraphPad Prism 5 software was used for statistical analysis. The difference 
between two data sets were analyzed using t-test, while a one-way ANOVA was used for 
analyzing the differences among experimental and control groups. In all comparisons, a p 
value of ≤ 0.05 [marked with an asterisk (*) in figures] was considered to be statistically 
significant.    
3. Results  
3.1. Synthesis and characterization 
The TEM image of the bare INDs after radiation and acid treatment is presented 
in Figure 1. INDs exhibited quadrilateral shapes with an average diameter of ca. 38 nm. 
For INDs irradiated by 40-keV He+ ions at a dose of ca. 3 × 1015 He+/cm2, our 
previous experiments have estimated that they contain an ensemble of vacancies with a 
density in the range of ca. 3000 ppm (39). Creating vacancies in such a high density often 
results in amorphization of diamond as well as severe broadening of the optical 
absorption bands (46, 47). No distinct zero-phonon line corresponding to GR1, i.e. the 
isolated neutral vacancy center, could be detected at 741 nm (48). Instead, the UV-Vis 
spectrum of the INDs shows a monotonic increase in absorbance from 850 to 450 nm 
(Figure 2), similar to those of carbon black and other carbon nanomaterials (49). PA 
signal amplitude showed a similar decreasing trend from 680 nm to 900 nm (Figure 2a). 
Optical absorption spectra of PEG-INDs and HER2-PEG-INDs were recorded and 
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overlaid with that of INDs. Due to the ignorable optical absorption of PEG2000 and anti-
HER2-peptide after 400 nm, PEG-INDs and HER2-PEG-INDs showed similar absorption 
spectra as that of INDs (Figure 2b).  
Since photoacoustic imaging is an absorption-based technology, the PA signal 
amplitude decreased in proportion to the decline of the optical absorption in the tunable 
wavelength range of the PA imaging system. Although the small bump at 720 nm in the 
PA spectrum is not shown in the UV-Vis absorption spectrum, the signal intensity 
dropped 50% from 700 nm to 840 nm, which was the same trend as the absorption 
spectrum. The tumor areas of mice bearing breast cancer were imaged at 820 nm. 
Although INDs had stronger absorption and thus higher contrast against background 
tissues at 700 nm comparing to 820 nm, the signal contributions from blood vessel would 
also be greater (50). An imaging wavelength of 820 nm was chosen for in vivo studies 
because the absorption of hemoglobin and Mie scattering is minimized, and the PA signal 














































Conjugation of amine-PEG-amine (MW 2000) and anti-HER2 targeting peptide to 
the INDs was verified by FTIR (Figure 3). The appearance of the characteristic peaks of 
the PEG, at 1250 and 1035 cm-1, confirmed the presence of the coating on the surface of 
bare INDs. In addition, the FTIR spectrum of HER2-PEG-INDs displayed the same 
intense peaks as anti-HER2 peptide at 1656 and 1521 cm-1, corresponding to the 
stretching vibration of the amino group on lysine and hydroxyl group on tyrosine, 
respectively. The band at 1200-1260 cm-1 resulted from the -OH stretching vibration in 
the serine.  
In addition to the FTIR spectra, the coating of PEG and HER2 targeting peptide 
was further confirmed by the hydrodynamic diameters and zeta potentials of the INDs 
and the surface-functionalized INDs. Table 1 shows the progressive increase in particle 
size and decrease in negative charge of the nanoparticle surfaces. The decrease in the 
negative charges was due to the introduction of amino groups from amine-PEG-amino 










Figure 3. Infrared spectra of IND, PEGylated INDs (PEG-INDs), HER2-PEGylated 















Table 1. Particle sizes and zeta-potentials of INDs, PEGylated INDs and HER2 targeting 
peptide conjugated PEG-INDs. 
Particles Diameter (nm) Ζeta-potentials (mV) 
INDs 38.3 ± 0.0 -36.49 ± 1.27 
PEG-INDs 56.0 ± 0.1 -33.07 ± 1.44 



















Both FTIR spectra and increased particle sizes are consistent with the introduction 
of HER2 targeting peptide onto the INDs via the linkage to amine-PEG-amine.  We 
assumed ca. 10% of the carboxyl groups on the INDs were reacted with amine-PEG-
amine, which was described similarly before, and that amino group on INDs were 
conjugated with anti-HER2 peptide in a 1:1:1 ratio. Consequently, yield for the amount 
of targeting peptide on the surface of INDs was expected to be ca. 10-5 mol/g(51). Using 
UV-absorbance, the labeling was determined to be ca. 8.6 × 10-5 moles of HER2 
targeting peptide per gram of PEG-IND nanoparticles (see Supporting Information).    
3.2 Cytotoxicity, cellular uptake and cellular imaging 
In order to evaluate the cytotoxicity of HER2-PEG-INDs and the potential for 
biological applications, 4T1.2-neu cells were incubated with particles for 48 h at 
concentrations ranging from 10 to 200 µg/mL. As shown in Figure 4, there was a dose-
dependent decrease in cell viability above 10 µg/mL, and the cells retained viability up to 
90% at concentrations of 10 and 50 µg/mL after 48 h. However, a reduction in cell 

























The targeting ability of anti-HER2-peptide to HER-overexpressing breast cancer 
cells was evaluated by measuring the intracellular fluorescence intensity after treatment 
of HER2-positive and –negative cells with Cy7-labeled INDs. In Figure 5a, significantly 
increased cellular accumulation of HER2-PEG-INDs by 4T1.2-neu cells was observed. 
This result can be explained by that HER2-PEG-INDs was taken up via HER2 receptor 
mediated endocytosis. Thus, a competitive inhition assay was performed to confirm the 
target-specific uptake behavior of anti-HER2 peptide conjugated INDs. Not surprisingly, 
remarkly suppressed internalization of HER-PEG-INDs by 4T1.2-neu cells was found as 
anti-HER2 peptide (0.75 µg/mL) was added to the media 1 hr before the addition of INDs 
(Figure 5b). This result suggested that the uptake of HER2-PEG-INDs was hindered 
effectively by reducing the availability of  HER2 receptors on the surface of 4T1.2-neu 
tumor cells. In contrast, the internalization of PEG-INDs by 4T1.2-neu cells and HER2-











Figure 5. Cellular uptake of INDs by 4T1.2 or 4T1.2-neu breast cencer cells without (a) 



















The cellular uptake anti-HER2 peptide was confirmed in vitro by the brightfield 
images of INDs interactions with HER2 receptor positive and negative breast cancer cells 
(4T1.2-neu and 4T1.2 cells) (Figure 6). As negative controls, 4T1.2-neu breast cancer 
cells were treated with non-targeted PEGylated INDs (4T1.2-neu cells + PEG-INDs) and 
HER2 negative 4T1.2 cells were treated with targeted PEGylated INDs (4T1.2 cells + 
HER2-PEG-INDs). The clusters of IND particles present black spots in the cells. There 
was no obvious accumulation of INDs in the control groups after 4 hr of incubation 
(Figure 6b and 6d). By contrast, HER2-PEG-INDs, which contain the HER2 targeting 
peptide, accumulated to a greater degree inside cells and on the cell membranes (Figure 
6e). This indicated that the HER2-specific peptide increased the cellular uptake of HER2-
PEG-INDs by HER2 over-expressing cells. This result was further confirmed by 
comparing the fluorescence images of breast cancer cells incubated with Cy7 labeled 
INDs (Figure 7). The amount of HER2-PEG-INDs internalized by HER2-overexpressing 








Figure 6. Brightfield images of murine breast cancer cells. (a) Non-treated 4T1.2-neu 
cells, (b) 4T1.2-neu cells treated with PEG-INDs, (c) Non-treated 4T1.2 cells, (d) 4T1.2 
cells treated with HER2-PEG-INDs and (e) 4T1.2-neu cells treated with HER2-PEG-
















Figure 7. Fluorescent images of murine breast cancer cells. A-D panels, 4T1.2 cells were 
treated with HER2-PEG-INDs; E-H panels, 4T1.2-neu cells were treated with PEG-
INDs; I-L panels, 4T1.2-neu cells were treated with HER2-PEG-INDs. Panels in the first 
column, brightfield images of murine breast cancer cells; panels in the second column, 
the LysoTracker® Blue co-staining; panels in the third column, Cy7 labeled nanoparticle 










3.3 In vivo PA imaging 
Prior to the injection, a region of interest (ROI) was selected on the right side of 
the breast and defined as background (BG). The depth of the detector’s focal point was 
adjusted so as to obtain the best spatial resolution. BALB/C mice were injected with 
identical amounts of INDs via the tail vein. Once the depth of the detector’s focal point 
was determined, PA images of the same areas were taken with 1-hr intervals and 
processed to remove the skin’s signal as illustrated in Figure 8. The three control groups 
were the HER2 positive tumor model (4T1.2-neu) treated with saline (Figure 8a), HER2 
positive tumor model (4T1.2-neu) treated with PEG-INDs (Figure 8b) and the HER2 
negative tumor model (4T1.2) treated with HER2-PEG-INDs (Figure 8c). In the PA 
images, the blood vessels (BVs) were highlighted because of the relatively higher optical 
absorption of hemoglobin over normal optically transparent tissues. Signal intensity did 
not significantly increase in the saline group until 8 hrs post-injection (Figure 8a). 
Beginning at 2 hrs post-injection, the blood contrast was enhanced as indicated by the 
colorbars in the figures, and signal intensity peaked at 4 to 6 hrs in each group. 
Meanwhile, IND particles progressively migrated from the blood vessels into internal 
tumor regions, presumably due to the enhanced permeability and retention (EPR) effect 
and retention by the HER2-positive cancer cells. The HER2-positive breast cancer model 
treated with HER2-PEG-INDs had higher signal enhancement around the tumor region 
that finally delineated the entire tumor (dashed circle in Figure 8d) at 8 hrs, compared to 




Figure 8. PA images of ROI before and at different time points after the injection of 
saline or INDs and photographs of ROI. a) 4T1.2-neu tumor model injected with saline, 
b) 4T1.2-neu tumor model injected with PEG-INDs, c) 4T1.2 tumor model injected with 
HER2-PEG-INDs, d) 4T1.2-neu tumor model injected with HER2-PEG-INDs, e) 
increase in PA amplitude of tumor areas plotted as time post-injection, f) nanoparticle 





The hemolytic activity of INDs was conducted by a colorimetic assay of the iron-
containing protein hemoglobin released by damaged cells upon exposure to INDs. As 
shown in Figure 9a, all INDs did not induce RBC destruction at the concentration as high 
as 100 µg/mL. In order to further investigate the hematocompatibility of INDs, platelet 
aggregation behavior was performed by incubating INDs with PRP at 37 °C for 3 min 
and measuring the averaged particle sizes of platelet aggregates. Compared to the 
positive and negative controls (Figure 9b), the average particle size did not significantly 
change at the highest concentrations tested (100 µg/mL). In addition, no platelet 
aggragation was induced by INDs at lower concentrations (data not shown). Furthermore, 
the hematology biocompatibility of INDs with mice was assessed by measuring the 
hematological parameters, including leukocytes, lymphocytes, erythrocytes and mean 
hemoglubin, and biomakers of liver damage, aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT). The results in Table 2 showed that there were no 
significant changes in these parameter values and thus no significant inflammation 
induced after exposure to HER2-PEG-INDs, compared to saline. 
3.4 Histopathological examination 
No significant histopathological abnormalities were observed in the kidneys, lung 
nor livers of mice injected with INDs compared to saline injected mice, and no 
inflammation was observed by H&E staining (Figure 11), which demonstrated no 







Figure 9. Hemolysis and platelet coagulation studies of INDs with rat RBCs and PRP. a) 
hemolysis percentages measured for INDs incubated with RBCs at a concentration of 100 
µg/mL, and b) Partical size of platelet aggregates measured for  INDs incubated with 
PRP at a concentration of 100 µg/mL. The experiments were repeated in triplate (*** p < 











Table 2. Biochemical and hematology parameters of mice injected with HER2-PEG-





















Leukocyte count (K/µL) 1.2 3.4 
Segmented neutrophil concentration 
(K/µL) 
0.4 0.9 
Band neutrophil concentration (K/µL) 0.0 0.0 
Lymphocyte concentration (K/µL) 0.7 2.5 
Monocyte concentration (K/µL) 0.1 0.0 
Eosinophil concentration (K/µL) 0.0 0.0 
Basophil concentration (K/µL) 0.0 0.0 

















Erythrocyte concentration (M/µL) 9.49 9.87 
Hemoglobin (g/dL) 15.0 15.6 
Hematocrit (calculated, %) 44 45 
Hematocrit (spun, %) 44 45 
Mean cell Volumn (fL) 47 45 
Mean cell hemoglubin (pg) 16 16 




Plasma protein by refractometry (g/dL) 6.0 6.0 
 























Figure 11. Representative H&E stained images of kidneys, livers, lung and tumor 














The HER2 receptor is overexpressed in 25% to 30% breast cancers and has been 
exploited as a molecular target for delivery of drugs and nanoparticles for biomedical 
applications (52, 53). The HER2-targeting peptide (KCCYSL) is relatively small, but it 
exhibited high affinity (295 ± 56 nmol/L) to the HER2 receptor (37). Due to its small size, 
this anti-HER2 peptide can be conjugated to the surface of nanoparticles with higher 
density in comparison to larger HER2-targeting antibodies. As a result, cellular uptake 
was enhanced leading to rapid entrance of nanoparticles into the tumor cells. In addition, 
the peptide-targeting moiety may have less immunogenicity and cytotoxicity than 
antibody-based ones because of its lower molecular weight (54). Uptake of the peptide-
nanoparticle conjugate in 4T1.2-neu breast cancer cells was appreciably higher than that 
of PEGylated INDs (Figure 5a). Meanwhile, owing to the specific binding of HER2-
PEG-INDs to the tumor, the nanoparticle clearance rate from blood circulation was 
decreased and the loss of nanoparticles was minimized (Figure 10) (55). For this reason, 
limited accumulation and rapid clearance of non-targeted INDs in the control groups 
made it difficult to differentiate the tumor regions in PA images. Whereas, the tumors in 
mice treated with HER-PEG-INDs were fully delineated by strong contrast between the 
tumor regions and surrounding tissues. This result is further confirmed by the prolonged 
retention time within tumors in the HER2 targeted treatment group. The prolonged 
presence of contrast agent in the tumor is critical for PA assisted cancer detection. So, the 
signal intensity of the tumor region was monitored and compared between two 
consecutive scans until a decrease in signal amplitude was observed. The maximum 
accumulation of HER2-PEG-INDs in HER-overexpressing tumor bearing mice was at 8 
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hrs post-injection, contrasted with 6 hrs in the control groups (Figure 8f, p < 0.05, n = 3).  
Furthermore, the HER2-PEG-INDs had a more rapid uptake and a relatively slower 
clearance rate in the HER2-positive tumor model. The PA signal was significantly 
enhanced in the HER2-positive tumor region after 2 hrs (Figure 8e), and there was no 
evidence of a signal decrease until 11 hrs post-injection (Figure 8d). However, in the 
HER2-negative and non-targeted control groups, PA amplitude increased slowly and then 
declined rapidly within one hour (Figure 8b and 8c). Since the rate of extravasation from 
the poorly formed blood vessels into the tumor region and the rate of clearance are two 
major factors that affect the nanoparticle accumulation in the tumor, strong binding 
between the HER2-targeting peptide and HER2 receptor on the cell surface may favor the 
retention of HER2-PEG-INDs. Thus, even though PEG-INDs and HER2-PEG-INDs may 
have a similar opportunity to leak from the blood vessels due to the EPR effect, the 
differences in such factors as retention and cellular uptake resulted in quite different 
tumor accumulations of INDs and thus the accumulative PA signal enhancement.  
Owing to the EPR effect, nano-sized particles or macromolecules administrated 
intravenously escape renal clearance and tend to leak out from the abnormal vasculature 
and accumulate in solid tumors (56). However, Li M.L. etc demonstrated that gold 
nanoshells could not actually enter the necrotic tissues of tumor but accumulated within 
the tumor cortex, and the nanoshells delineated the tumor margins when imaged by PA 
microscopy at a wavelength of 800 nm (57). The absence of INDs within the tumor core 
can be explained by both the necrotic feature and high interstitial pressure of tumor cores 
(58). In addition, the observation of no INDs on the top surface of the tumor may be 
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explained by the pressure from the water tank above the tumor area, which may hinder 
the circulation and particle accumulation.  
Among carbon-based nanomaterials, NDs are considered to be less toxic than 
carbon nanotubes and graphene oxide (59). This is mainly because of diamond’s unique 
properties of sp3 electron configuration, chemical inertness and especially due to the 
purification process in strong acid used to remove impurities and graphitic surface layers 
(24). It has been demonstrated that carboxylated NDs internalized by macropinocytosis 
and endocytosis pathways did not show noticeable cytotoxicity or affect cell proliferation 
and differentiation (60), which was also indicated by our cytotoxicity study (Figure 4). In 
vivo biodistribution of NDs has been studied by positron emission tomography after 
labeling nanoparticles with 18F. The lungs, spleen and liver were the primary 
accumulating locations of NDs, and particles were excreted in urine beginning at 2 hr 
after i.v. administration (61). On the basis of this study, we collected the kidneys, lung 
and liver 12 hr after injection of HER2-PEG-INDs for histopathological examination, and 
we did not observe any indications of toxicity (Figure 11). This is consistent with other 
reports of the in vivo biocompatibility of NDs after multiple routes of administration (62, 
63). In addition, the long-term biocompatibility of INDs 12 weeks after intraperitoneal 
injection has been demonstrated by our group in a prior report (26). Although the toxicity 
of these HER2-PEG-INDs needs to be systematically investigated and analyzed 
comprehensively before application in the clinic, our results have shown the 






In this work, non-toxic, stable and targeted non-fluorescent INDs were 
successfully developed as a novel in vivo PA imaging contrast agent and shown to 
facilitate the optical contrast enhancement of breast tumor margins. The conjugation of 
PEGylated INDs with anti-HER2 peptide lead to an enhancement in the internalization by 
HER2 overexpressing tumor cells (4T1.2-neu) and longer residence time in the region of 
HER2 positive tumor. We expect this targeted IND-PA imaging platform to provide a 
new oppotunity for sensitive phenotype specific detection of tumors.  
6. Futher perspective 
With the outstanding advantages of high optical absorption, photostability and 
biocompatibility, targeted IND conjugates can be used as a molecularly selective contrast 
agent for photoacoustic detection of cancers. The HER2 targeting peptide significantly 
improved the efficiency and specificity of delivery of INDs to HER2-positive breast 
tumors. It is expected that HER2-targed INDs may offer an effective means for early 
detection of HER2-positive breast cancers.   
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Head and neck squamous cell carcinomas (HNSCC) and epithelial carcinomas 
constitute the majority of malignancies in the head and neck region, and it is the sixth 
most common cancer worldwide. Cancers in the head and neck region can arise from a 
variety of tissues in the upper aerodigestive tract, which include the oral cavity, nasal 
cavity, pharynx, larynx, sinuses, and other related soft tissues and bones.(1) Within head 
and neck carcinomas, 90% of malignancies are HNSCC amounting to approximately 
780,000 new cases each year.(2) HNSCC is a heterogeneous disease originating from the 
most superficial tissues throughout the head and neck area.(3) Early diagnosis and 
treatment of local HNSCC improves quality of life as well as disease prognosis. 
Currently, locally advanced HNSCC carries a 5-year survival rate of approximately 80%, 
while locally advanced disease with lymph node involvement has a 60% survival.(4) 
Although earlier detection can improve outcomes dramatically, there remains a need for 
more effective and less invasive treatments for patients presenting with early locally 
advanced tumors.(5)  
Current treatments for localized cancers include surgery, radiation and systemic 
chemotherapy, all of which have significant limitations. To preserve critical tissues of the 
face and neck, surgical margins are generally not aggressive; however malignant cells 
beyond the surgical field often cause recurrence.(5, 6) Furthermore, while tissue-sparing 
chemotherapy and radiotherapy can help preserve speech and swallowing in locally 
advanced disease, they achieve only modest improvements in survival.(7, 8) Even when 
used conservatively, these conventional treatments can cause long-term vascular damage 
and irreversible injury in key surrounding tissues, including oral mucosa, muscle and 
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bone. Furthermore, dose-limiting oral toxicity can compromise therapeutic efficacy via 
dose reduction, treatment delay, or incomplete treatment. There is thus a need for 
effective, safe, reliable and minimally invasive treatment modalities for managing locally 
advanced HNSCC.  
Photodynamic therapy (PDT) uses a photosensitizer that is activated by focused 
optical energy to generate reactive oxygen species that can selectively destroy abnormal 
tissues. PDT has been used to treat a variety of cancers because it is non-invasive and can 
be repeated without cumulative side effects.(9) Because unirradiated photosensitizers 
have minimum toxicities, PDT is a promising modality for HNSCC, and it has been used 
for early stage oral HNSCC.(10) Unfortunately, most PSs are lipophilic and aggregate 
readily in aqueous milieu such as the oral cavity. In addition, PSs have low selectivity for 
abnormal tissues. Thus, various nanocarriers have been developed to enhance PS 
accumulation in malignant tissues, including polymeric nanoparticles, micelles, 
liposomes and polymeric conjugates.(11-15) Nanocarriers can improve PS solubility and 
tumor uptake via prolonged blood circulation time, and the enhanced permeability and 
retention (EPR) effect, which is a unique property of nanoparticles in some solid tumors. 
However, in small micrometastatic disease the EPR effect is minimal,(16, 17) which 
presents difficulties in treating locally advanced HNSCC where the lymph nodes draining 
the primary tumor can harbor significant micrometastatic disease. To target these local 
nodes, hyaluronic acid (HA) may be an ideal PS carrier. HA is a natural polysaccharide, 
composed of D-glucuronic acid and D-N-acetylglucosamine.(18-20) HA can enter the 
lymphatic system rapidly and has a natural tropism for CD44 receptors overexpressed in 
highly metastatic cancer cells.(21, 22) Prior HA-photosensitizer conjugates have been 
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reported to improve PDT selectivity and efficacy in vitro.(23, 24) Furthermore in these 
HA conjugates, the formation of self-organizing nanoparticles in aqueous solutions auto-
quenched PSs photoactivities such as fluorescent intensity, singlet oxygen generation and 
phototoxicity until the HA backbone was degraded by intracellular enzymes or reactive 
oxygen species (ROS) within activated macrophage cells. However, taking advantage of 
HA’s specific lymphatic uptake and nodal retention properties to enhance in vivo PDT of 
metastatic cancers has not previously been reported.  
In addition to outstanding biophysical properties of HA, PDT can decrease the 
metastatic potential of cancer cells,(25) we sought to develop a formulation of a PS that 
could be administered locoregionally, and could concentrate the PDT PS in locally 
advanced HNSCC tumors and their draining parotid lymph nodes. When synthesizing a 
novel PS-hyaluronan conjugate, we chose the PS PPA because it exhibits an intense 
absorption band (Q-band) in the NIR range with a high absorption coefficient (ɛ668 ~ 4 × 
104 M-1 cm-1), and it has high singlet oxygen quantum yield (ΦΔ ~ 0.5 in toluene).(26, 27) 
These characteristics make PPA an excellent photosensitizer for use in PDT. Moreover, 
the carboxyl substituent is available for conjugation to the adipic acid dihydrazine (ADH) 
linker on HA. Because of its high hydrophobicity, PPa exists preferentially as crystals in 
aqueous suspension, so direct subcutaneous injection in the head and neck region is not 
feasible.  However, conjugating PPa to HA carriers dramatically improved water 
solubility of PPa.  Equally importantly off-target toxicity could be minimized by direct 
subcutaneous administration to the tumor-bearing area of the head and neck, thus 
localizing the drug. 
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2. Materials and Methods 
2.1 Materials.  
Sodium hyaluronan (35,000 Da) was purchased from Lifecore Biomedical 
(Chaska, MN). PPa was purchased from Frontier Scientific (Logan, Utah). 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) was purchased from Chem-Impex International, Inc. 
(Wood Dale, IL). N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride 
(EDC•HCl), adipic acid dihydrazide (ADH) and TWEEN® 80 were purchased from 
Sigma-Aldrich Co. (St. Louis, MO). Other chemicals and organic solvents, N, N-
Diisopropylethylamine (DIPEA), N, N-dimethylformamide (DMF) and dimethyl 
sulfoxide (DMSO), and cell culture supplies were purchased from Fisher Scientific 
(Pittsburgh, PA). Dulbecco's Modified Eagle's Medium (DMEM) was purchased from 
Lonza (Allendale, NJ). LysoTracker® Blue DND-22 (ex/em, 373/422 nm), 4’, 6-
Diamidino-2-Phenylindole (DAPI, ex/em, 358/461 nm) and Singlet Oxygen Sensor 
Green (SOSG) were purchased from Life Technologies™ (Grand Island, NY). The 
MDA-1986 human oral squamous carcinoma cell line was kindly provided by Dr. Jeffery 
Myers (The University of Texas, M.D. Anderson Cancer Center, Houston, TX).  Double 
distilled water (ddH2O) was used for preparing all of the aqueous solutions.  
2.2 Synthesis and characterization of HA-ADH-PPa.  
The conjugation of PPa to HA was accomplished by using an ADH linker. 
Briefly, 100 mg of sodium hyaluronate was dissolved in 20 mL of ddH2O, followed by 
addition of ADH (200 mg) and EDC•HCl (24 mg). The pH of the mixture was adjusted 
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to ca. 5.0 using 1-N HCl, and the mixture was stirred at room temperature (ca. 20 oC) for 
20 min to form the HA-ADH intermediates. The resulting solution was neutralized using 
1-N NaOH, dialyzed against ddH2O (Thermo Scientific™, SnakeSkin™ Dialysis Tubing, 
MWCO 3,500 Da) for 24 hr and lyophilized (Labconco 2.5 Plus FreeZone, Kansas City, 
MO). To synthesize the HA-ADH-PPa, the carboxyl terminus of PPa (5 mg, 9.35 µmol) 
was pre-activated with HATU (14.2 mg, 37.3 µmol) and DIPEA (13 µL, 74.6 µmol) in 4 
mL of DMF for 0.5 hr prior to the addition of the HA-ADH (100 mg, 25 mg/mL) 
aqueous solution (Scheme 1). The reaction was allowed to proceed overnight protected 
from light at room temperature. The unreacted PPa was removed by precipitation in 
excess ddH2O, and the supernatant was further dialyzed (MWCO 3,500 Da) against a 











Scheme 1. Synthesis of HA-ADH-PPa 
 













Spectrofluorometry (ex/em 400 nm/680 nm, Shimadzu RF-5301PC 
Spectrofluorophotometer, Columbia, MD) and UV/Vis spectrophotometry (675 nm, 
Molecular Devices SpectraMax Plus, Sunnyvale, CA) were used to determine the degree 
of conjugation. A solution of HA-ADH-PPa (1 mg/mL) was prepared in 1:5:94 (v/v/v) 
TWEEN® 80/DMSO/ddH2O (solution A). Calibration solutions (2.5, 5, 8, 10 and 20 
µg/mL) were prepared by dissolving PPa in solution A with HA-ADH (1 mg/mL). Gel 
permeation chromatography (GPC) was used to confirm the conjugation by comparing 
the elution time of HA-ADH and HA-ADH-PPa. GPC analysis was performed on a 
Shodex HQ-806 M column thermostated at 40 oC with 5-mM ammonium acetate (pH 5) 
as the mobile phase at a flow rate of 0.8 mL/min, and peaks were detected using an 
evaporative light scattering detector (ELSD, 70 oC) and an UV/Vis detector at 600 nm. 
To observe the morphology of HA-ADH-PPa nano-conjugates, a drop of 10 mg/mL 
solution in ddH2O was placed on a lacey carbon coated copper grid (200 mesh, TED 
PELLA, Redding, CA), and high resolution transmission electron microscopy (TEM) 
(FEI Tecnai F20 XT Field Emission TEM) images were recorded at an accelerating 
voltage of 200 ekV. 
2.3 Singlet oxygen generation.  
The generation of singlet oxygen from PPa or HA-ADH-PPa was quantitatively 
evaluated using SOSG. Photoirradiation was performed using a diode laser (HL6750MG, 
Thorlabs, Newton, NJ; power: 50 mW; wavelength: 685 nm), which was driven by a 
laser diode current controller (LDC220, Thorlabs, Newton, NJ). The light beam 
illuminated directly above the cell holder of the fluorescent spectrometer with a power 
density of 7.5 mW/cm2. Free PPa (10 µM) or HA-ADH-PPa (10 µM of PPa) with 10-
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nmol/mL SOSG in 400 µL of 1% TWEEN® 80 and 5% DMSO solution in PBS were 
placed in a 5 mm × 5 mm quartz cuvette and irradiated continuously for 5 min, and the 
fluorescence intensity was acquired every 30 s at ex/em wavelengths of 505/525 nm with 
a 5-mm slit width. The shutter was closed between acquisitions.  
2.4 Cellular uptake and exclusion.  
MDA-1986 cells were cultured in DMEM media containing 10% fatal bovine 
serum (FBS) and 1% L-glutamine at 37 °C in a 5% CO2 incubator. To determine the 
cellular uptake of PPa and HA-ADH-PPa, cells were seeded onto 6-well plates with a 
density of 1 × 105 cells/well and incubated for 24 hr. The original media was replaced 
with 1:5:94 (v/v/v) TWEEN® 80/DMSO/media containing free PPa (1.89 µg/mL) or HA-
ADH-PPa (1.89 µg/mL of PPa). Cells were incubated for another 1, 2, 5, 8, 24 and 48 hr 
at 37 °C in dark. The media were then removed, and cells were washed with 3 mL of 
PBS and removed after incubation with 250 µL lysis buffer [5 mmol/L EDTA, 10 
mmol/L NaOH, 10 mmol/L Tris base, 150 mmol/L NaCl and 1% (v/v) Triton X-100] per 
well for 10 min at room temperature. Another 750 µL of ddH2O was added to each well, 
and the resulting cell lysate samples were transferred to 2-mL eppendorf tubes and 
centrifuged at 20,000 × g for 5 min. The fluorescence intensity of the supernatants was 
obtained and analyzed based on a standard curve of free PPa solution prepared in 1:3 
(v/v) lysis buffer/ddH2O. The cell protein content was quantified using a Pierce™ BCA 
protein assay (Thermo Scientific).       
To examine the exclusion of PPa or HA-ADH-PPa from MDA-1986 cells, the 
cells were seeded onto 6-well plates at a density of 2.8 × 105 cells/well for 24 hr and 
treated with the same concentrations of PPa and HA-ADH-PPa as used in the cellular 
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uptake study. Cells were incubated for 1 hr after treatment, followed by washes with PBS 
and incubation with fresh media for another 0.5, 1, 2, 6 or 12 hr. For the HA competitive 
inhibition experiments, MDA-1986 cells were exposed to HA (10 mg/mL) for 24 hr 
before the incubation with HA-ADH-PPa or PPa for 5 hr. The cell lysis procedures and 
analysis method were identical to cellular uptake study.  
2.5 Cellular localization.  
All cell imaging experiments were performed using a Nikon Eclipse 80i 
epiflurescence microscope (Melville, NY) with a 60x 1.40 oil objective, and a 
Hamamatsu ORCA ER digital camera (Houston, TX) was used to acquire images. The 
MDA-1986 cells were seeded onto poly-L-lysine precoated glass coverslips (BD, 
Franklin Lakes, NJ) in 12-well culture plates at a density of 50,000 cells per well and 
allowed to grow overnight. Subsequently, cells were treated with PPa (6.48 µg/mL) or 
HA-ADH-PPa (6.48 ug/mL of PPa) in 1:5:94 (v/v/v) TWEEN® 80/DMSO/media 
followed by incubation at 37 °C for 5 hr. The cell nuclei and lysosomes were stained with 
DAPI (10 µg/mL) for 5 min and LysoTracker® Blue DND-22 (4 µM) for 30 min, 
respectively. After three washes with 3 mL of PBS, the coverslips were placed on the 
slide glasses for imaging. The live cells were immediately imaged using a yellow 
fluorescent protein (YFP, ex/em, 500/535 nm) filter set (Nikon, NY) for imaging PPa and 
Ultraviolet excitation (UV-2E/C, ex/em, 360/400 nm) filter set (Nikon, NY) for imaging 
DAPI and LysoTracker® Blue DND-22 separately.  
 2.6 In vitro phototoxicity.  
The MDA-1986 cells (5000/well) were seeded onto 96-well plates in 100 µL 
culture media and incubated for 24 hr. The media were then replaced with 1:5:94 (v/v/v) 
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TWEEN® 80/DMSO/media containing HA-ADH-PPa or free PPa with a series of 
different PPa concentrations (8.1 ng/mL to 8.1 µg/mL). After incubation for 24 hr, cells 
were washed with fresh culture media three times and maintained in fresh media during 
irradiation with a 671-705 nm filtered halogen light (5.89 mW/cm2) for 0, 2, 5 or 10 min. 
Two days after irradiation, the cell viability of irradiated cells was evaluated by 
Resazurin-blue assay.  
2.7 In vivo fluorescence imaging.  
Female NU/NU mice were used under the guidance of the Institutional Animal 
Care and Use Committee at the University of Kansas. To minimize skin autofluorescence 
caused by chlorophyll in feed, mice were fed a low chlorophyll feed (Harlan 2918 
irradiated diet, Harlan Laboratories, Indianapolis, IN) for at least two weeks before 
imaging. A 50-µL MDA-1986 cell suspension (3 × 107 cells/mL) in PBS was injected 
into the oral sub-mucosa of a mouse using a 30-ga needle. When tumors grew to a size 
range of ca. 40 to 80 mm3 [tumor volume = 0.52 × (width)2 × (length)], 50 uL of PBS 
containing HA-ADH-PPa [0.5 mg/kg body weight (B.W.) of PPa] was injected 
subcutaneously into the cheek of  the animal, which were anesthetized with 1.5% 
isoflurane in oxygen. The injection area was fluorescently imaged from 5 min to 48 hr 
using a CRI Maestro Flex fluorescence imager (CRI Inc., Woburn, MA) equipped with a 
503 -555 nm filtered halogen excitation light and a 580 nm longpass emission filter. The 
fluorescence intensity of the tumor site was quantified using ImageJ and the following 
equation: 
Corrected Total Fluorescence = Integrated Density - (Tumor Area × Mean Fluorescence 
of Normal tissue). 
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2.8 In vivo PDT treatment.  
NU/NU mice bearing head and neck tumors were prepared in an identical manner 
as described above. When tumors reached ca. 40 to 80 mm3 in size, mice were randomly 
divided to four groups: saline s.c. group (N = 4), HA-ADH-PPa s.c. group (0.5 mg 
PPa/kg B.W., N = 4), PPa i.v. group (0.5 mg PPa/kg B.W., N = 4), HA-ADHPPa s.c. 
group (0.8 mg PPa/kg B.W., N = 3). At 6 hr (PPa i.v. group) or 24 hr (HA-ADH-PPa 
s.c.group) post-injection, the primary tumor and the parotid lymph nodes were irradiated 
by a diode laser with a laser intensity of 150 J/cm2 at 685 nm. The treatment was repeated 
4 times at a frequency of once per week, or terminated early if the tumors disappeared. 
The therapeutic response of each group was monitored by measuring the tumor volume 
with a digital caliper. The animals were euthanized when tumor size reached 1000 mm3 
or the tumor became ulcerated.  
2.9 Statistical analysis.  
GraphPad Prism 5 software was used for statistical analysis. The difference 
between two data sets were analyzed using t-test, while a one-way ANOVA was used for 
analyzing the differences among experimental and control groups. In all comparisons, a p 
value of ≤ 0.05 [marked with an asterisk (*) in figures] was considered to be statistically 
significant.    
3. Results 
 3.1 Synthesis and physical characterization of HA-ADH-PPa conjugate.  
HA-ADH-PPa was synthesized by the conjugation of the carboxyl group on PPa 
to the glucuronic acid of HA via a dihydrazide linker. The conjugation between PPa and 
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HA-ADH was verified based on the equivalent retention times at approximately 10 min 
using a GPC coupled with ELSD (dotted) and UV/Vis detection (dashed, 600 nm) 
(Figure 1). In addition, HA-ADH-PPa displayed a slightly smaller hydrodynamic volume 
compared to HA (solid) on GPC. This was possibly due to the reduced repulsive 
interactions among the carboxylate anions on HA-ADH-PPa after conjugation.(28) The 
absorption and fluorescence spectra of HA-ADH-PPa conjugate and free PPa are shown 
in Figure 2. To collect their individual spectra, HA-ADH-PPa, free PPa and a physical 
mixture of HA and PPa were prepared in 1:5:94 (v/v/v) TWEEN® 80/DMSO/ddH2O, as 
free PPa is insoluble in purely aqueous solutions. Compared with free PPa and the 
physical mixture, HA-ADH-PPa conjugates have broader PPa absorbance peaks at both 
the Soret band region around 400 nm and the Q band region around 670 nm (Figure 2a). 
In addition, the Soret band and the Q band of HA-ADH-PPa conjugate have a blueshift of 
approximately 30 nm and a redshift of approximately 10 nm, respectively. This 
phenomenon was also observed by Savellano and his co-workers on their PPa-
immunoconjugates.(29) Moreover, HA-ADH-PPa and PPa showed identical fluorescence 
emission spectra with maximum emission wavelengths of 673 nm when excited at 419 
nm (Figure 2b). The absorbance intensity at 675 nm and the fluorescence intensity at 
400/600 nm (ex/em) were measured to calculate the loading degree of PPa on the HA-
ADH polymer, which was determined to be 2% (wt/wt). In addition, a TEM image was 
collected, which showed that the HA-ADH-PPa nanoparticles were spherical with a 
diameter of ca. 7-8 nm (Figure 3). The conjugates could not be sized by dynamic light 
scattering due to the fluorescent overlap with the red laser used in available instruments 




Figure 1. Chromatograms of HA (ELSD, solid) HA-ADH-PPa conjugates generated by a 










Figure 2. UV-Vis spectra (a) and fluorescence emission spectra at an excitation 
wavelength of 419 nm (b) of HA-ADH-PPa polymer nanoparticle (dash-dot), free PPa 



















3.2 Singlet oxygen generation of PPa from HA-ADH-PPa.  
Upon laser irradiation PPa generates singlet oxygen that kills tumor cells. The 
release of the singlet oxygen can be analyzed qualitatively by monitoring the increase in 
fluorescence intensity of SOSG solution due to the production of strong green fluorescent 
SOSG endoperoxide when SOSG reacts with singlet oxygen. Figure 4 shows the 
fluorescence intensity at 525 nm as a function of photoirradiation time for detecting the 
generation of singlet oxygen. In the absence of laser irradiation, the rates of singlet 
oxygen generation from free PPa and HA-ADH-PPa were decreased significantly. 
Moreover, there was no obvious difference observed in the rates of singlet oxygen 
generation between free PPa and HA-ADH-PPa. It is reported that SOSG endoperoxide is 
also an efficient singlet oxygen photosensitizer,(30) thus we measured fluorescence 
intensity of an SOSG solution without PPa or HA-ADH-PPa. The result suggested that 







Figure 4. Measurements of 1O2 generation using SOSG as a reporter probe. (***, P ≤ 












3.3 Cellular internalization and exclusion of HA-ADH-PPa and PPa in MDA-1986 
cells  
The cellular uptake behavior of HA-ADH-PPa was monitored as a function of 
incubation time (1, 2, 5, 8, 24 and 48 hr) and compared with the same concentration of 
free PPa by measuring the intracellular fluorescence intensity of PPa. As shown in Figure 
5a, both free PPa and HA-ADH-PPa showed increased cellular accumulation as the 
incubation time was increased. Although the intracellular concentration of HA-ADH-PPa 
was lower than that of PPa, it was noted that the accumulative internalization of HA-
ADH-PPa increased by ca. 5 times in 48 hr, comparing to ca. 1.4 time increase in 
intracellular content of free PPa. The more efficient cellular uptake of HA-ADH-PPa was 
possibly due to the more effective endocytosis by the cancer cells and slower passive 
diffusion of free PPa in to the cells. After 1 hr exposure to HA-ADH-PPa and PPa (1.89 
µg/mL) and subsequent incubation in PPa-free cell culture media, the intracellular 
concentrations of PPa were determined. As shown in Figure 5b, more than 90% of free 
PPa molecules were cleared from the cells via passive diffusion across plasma membrane 
into PPa-free media in 2 hr; whereas, more than 70% of PPa remained in the MDA-1986 
cancer cells 2 hrs after HA-ADH-PPa treatment. It took more than 12 hr, 5 fold longer 
than that of free PPa, for HA-ADH-PPa to be excluded from cells below detectable 
limits. This result suggested that PPa molecules were transported by HA nanoparticles 
via an endocytic pathway, and PPa was slowly released from HA in the cells. To 
determine whether the cellular uptake of HA-ADH-PPa nanoconjugates is regulated by 
the receptors for HA, cells were pretreated with excess amount of HA to saturate specific 
HA-receptors on the surface of tumor cells, potentially inhibiting the uptake of HA-
ADH-PPa but not free PPa. It was shown that pretreatment with 10 mg/mL HA for 24 hr 
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prior to the addition of HA-ADH-PPa caused a significant (ca.20%) reduction in the 
cellular uptake compared to the non-pretreated cells (Figure 5c). Whereas, the 
internalization of free PPa remained unaffected by the exposure to 10 mg/mL-HA. This 
result indicated that the internalization of HA-ADH-PPa nanoconjugates was inhibited by 
blocking HA receptors, and thus a receptor-mediated endocytic pathway was important 
for HA-ADH-PPa uptake.   
Confocal fluorescence imaging was used to further evaluate the different 
pathways by which HA-ADH-PPa and PPa entered cells. The confocal images of MDA-
1986 cells preincubated with HA-ADH-PPa and PPa for 5 hr are shown in Figure 6 A-L. 
Meanwhile, co-staining experiments were performed using DAPI and LysoTracker® 
Blue to determine the subcellular organelles, cell nuclei (blue) and lysosomes (red), 
respectively. It was noted that the clear green fluorescence surrounded the cell nuclei in 
both Figure 6 F and L, indicating that neither HA-ADH-PPa nor PPa entered the cell 
nuclei. Moreover, significant co-localization of HA-ADH-PPa with lysosomes was 
observed. However, internalized PPa molecules were partially co-localized with 




Figure 5. (a) Cellular uptake by MDA-1986 cells after incubation with HA-ADH-PPa 
(solid) and PPa (dashed) for 1, 2, 5, 8, 24 and 48 hr. (b) Cellular exclusion by MDA-1986 
cells after 1 hr treatment with HA-ADH-PPa (solid) or PPa (dashed), followed by washes 
with PBS and incubation with fresh media for another 0.5, 1, 2, 6 and 12 hr. (c) Cellular 
uptake by MDA-1986 cells after pretreatment with 10 mg/mL HA (24 hr) and incubation 




Figure 6. Confocal fluorescence microscopy of MDA-1986 cells treated with HA-ADH-
PPa or PPa, and constained with DAPI and LysoTracker® Blue. Left panels are 
photosensitizer fluorescence images (A & D, HA-ADH-PPa; G & J, free PPa). Middle 
panels show the LysoTracker® Blue (B & H) and DAPI (E & K) co-staining, with right 






3.4 Cellular phototoxicity of HA-ADH-PPa 
Cellular internalization experiments showed that the intracellular fluorescence of 
PPa plateaued at ca. 24 hr (Figure 5a). Therefore, MDA-1986 cells were incubated with 
HA-ADH-PPa at a series of PPa concentrations for 24 h, followed by washing with PPa-
free media and light irradiation at a fluence of 5.89 mW/cm2 and compared to free PPa. In 
the absence of light, the photosensitizer does not generate singlet oxygen and therefore 
did not exhibit cytotoxicity, so negligible cytotoxicity of both HA-ADH-PPa and PPa on 
MDA-1986 cells up to PPa concentrations of 4 µg/mL was observed without light 
irradiation in Figure 7d. However, the cell viability at a PPa concentration of 8.1 µg/mL 
remarkably decreased with 2 to 10 min irradiation (Figure 7a-c), and the cytotoxicity of 
PPa increased as the light irradiation time increased (Table 1). It could be assumed that 
intracellular concentration of PPa in HA-ADH-PPa treated cells was comparable to that 
of free PPa treated cells. For example, after 24 hr incubation with drugs, the uptake of 
free PPa in MDA-1986 cells was ca. 1.7 times higher than that of HA-ADH-PPa (Figure 
5a), whereas, the amount of free PPa excluded by cells within 30 min was 2.8 times 
greater than that of the polymeric conjugates (Figure 5b), and hence the PPa 
concentrations in both groups were roughly equal. However, in corresponding 
phototoxicity experiments, the IC50 values of HA-ADH-PPa were higher than those of 
free PPa in response to every light doses tested (Table 1). The lower PDT efficiency may 
be due to subcellular localization of HA-ADH-PPa, which underwent endosomal 




Figure 7. Inhibition of HNSCC MDA-1986 cell growth by HA-ADH-PPa (solid lines 










Table 1. IC50 values of HA-ADH-PPa or free PPa in MDA-1986 cells at different 
irradiation duration 
IC50 (µg/mL of PPa)
a 
Irradiation time 10 min 5 min 2 min 
HA-ADH-PPa 1.42 ± 1.50 3.05 ± 0.79 4.13 ± 0.55 
PPa 0.47 ± 0.51 0.45 ± 0.10 2.58 ± 1.18 















3.5 In vivo fluorescence imaging.  
An orthotopic murine tumor xenograft was established by injecting highly 
tumorigenic human HNSCC MDA-1986 cells into the buccal mucosa of nude mice. The 
primary tumor invaded the mandible and metastasized to the parotid and cervical lymph 
nodes. The incidence of distant metastasis has been verified in our previous study.(31) 
The intrinsic fluorescence of the photosensitizer, PPa, enables the detection of HA-ADH-
PPa in the region of lymphatic metastases using fluorescence imaging in vivo. Thus, HA-
ADH-PPa was injected adjacent to the primary tumor; and fluorescent images of the head 
and neck area were obtained at various time points from 0 to 48 hr. As shown in Figure 8, 
HA-ADH-PPa nanoconjugates were drained toward and accumulated effectively at both 
of the periphery of the neoplastic tissue and the peripheral locoregional lymphatics 
(parotid lymph nodes) in 24 hr, which is possibly due to the lymphangiogenesis and 
lymphatic metastasis. Moreover, the exact location of the tumor was clearly outlined as a 
result of the intense fluorescence signal emitted by the surrounding tissues and lymph 







Figure 8. Fluorescence images of the head and neck area of a mouse at 5 min and 24 hr 
post-injection of HA-ADH-PPa. Dashed circle and × indicate the primary tumor and the 











3.6 In vivo PDT treatment.  
In order to evaluate the therapeutic potential of HA-ADH-PPa compared to free 
PPa, four groups of female nude mice bearing HNSCC xenografts were treated with 
saline s.c., free PPa i.v. (0.5 mg/kg B.W.), HA-ADH-PPa s.c. (0.5 mg/kg PPa) and HA-
ADH-PPa s.c. (0.8 mg/kg). Laser irradiation was conducted at 6 hr post-injection of free 
PPa and 24 hr post-injection of HA-ADH-PPa. These time points were chosen based on 
observations by in vivo imaging of the Tmax of fluorescence in the tumor region after s.c 
injection of HA-ADH-PPa or tail vein i.v. injection of PPa (data not shown). The tumor 
growth rates of the three groups, including saline s.c., free PPa i.v. (0.5 mg/kg B.W.) and 
HA-ADH-PPa s.c. (0.5 mg/kg PPa) after four consecutive treatments were compared to 
evaluate the therapeutic efficacy of HA-ADH-PPa nanoconjugates (Figure 9a). It was 
found that HA-ADH-PPa s.c. combined with laser treatment caused significant tumor 
suppression. The final mean tumor size was ca. 300 mm3 after 25 days, which was 60% 
smaller than that of the non-treated group. As shown in Figure 9b, survival rate was 
greatly improved for the mice treated with HA-ADH-PPa s.c. (0.5 mg/kg PPa) compared 
to the non-treated and free PPa i.v.(0.5 mg/kg) treated groups. No statistically significant 
difference was observed between the non-treated and the free PPa i.v. (0.5 mg/kg) 
groups. In addition, tumors on all three mice treated with HA-ADH-PPa s.c. (0.8 mg/kg 
PPa) disappeared completely after the 2nd treatment at week 2 with no recurrence by the 
end of this study (Figure 9). The result of the in vivo treatment indicated that as a drug 
nanocarrier HA greatly enhanced the anticancer efficacy of PPa in relative to the 






Figure 9. Measurement of tumor size. (a) Female NU/NU mice were administered saline 
s.c., HA-ADH-PPa s.c. (0.5 mg/kg PPa, N=4; or 0.8 mg/kg PPa, N=3) and free PPa i.v. 
(0.5 mg/kg PPa, N=4). (b) Survival curve of treated and untreated NU/NU mice. (c) 
Picture of a NU/NU mouse with HNSCC before and after 2 weekly treatments of with 








PPa is a second-generation photosensitizer used in PDT, following Photofrin 
which was FDA approved for esophageal cancer and Barrett’s esophagus. Pheophorbide- 
and pyropheophorbide-based PDT, were first reported by Bellnier et al. in 1993.(32) 
Unlike Photofrin, PPa compounds have absorption wavelengths higher than 600 nm 
which substantially enhances laser light penetration depth in tissues. In addition, PPa 
show increased singlet oxygen generation efficiency, reduced skin photosensitivity 
duration, and minimal dark toxicity. A variety of PPa derivatives were designed in the 
recent years, including alkyl ether derivatives. Henderson et al. showed that increasing 
alkyl chain length increased photosensitizer hydrophobicity, which resulted in higher 
accumulation in tumor sites after intravenous administration.(33) However, the intensive 
aggregation of more hydrophobic PPa derivatives in aqueous environments compromised 
their singlet oxygen quantum yields and reduced PDT efficiency. One way to overcome 
these solubility and stability issues is to produce a bioconjugate between a functional 
group of photosensitizers and a highly water soluble polymeric material.(27) Xu et al 
designed highly water-soluble PS conjugated polymers to disperse PSs and enhance two-
photon singlet oxygen generation and PDT activity for simultaneous two-photon imaging 
and PDT treatment.(34, 35) Choi et al. prepared Chlorin e6 (Ce6)-conjugated polymeric 
nanoparticles via redox-responsive cleavable disulfide linkers, which were specifically 
degraded by redox agents (eg. glutathione) within cancer cells.(36) We looked at HA 
polymeric nanoparticles which are highly water-soluble, biodegradable and 
biocompatible; furthermore lymphatic vessels and nodes concentrate HA.  Therefore HA 
polymeric nanoparticles may be advantageous for delivering concentrated PPa for 
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locoregional treatment of primary tumors and local lymphatic metastasis. We achieved a 
2% (wt/wt) loading degree of PPa on HA-ADH and observed no aggregation of HA 
polymer with association of PPa molecules. However, when loading degree was 
increased to 3% (wt/wt) by increasing the stoichiometric ratio of PPa to HA-ADH, the 
solubility of HA was significantly decreased; this could possibly be due to irreversible 
aggregation of PPa in aqueous solution and increased occupation of ADH amino groups 
(data not shown). An added advantage of the lower loading value arises in that native HA 
is transported via lymphatic vessels to lymph nodes where it is catabolized by receptor-
mediated endocytosis followed by lysosomal degradation. A lower loading degree of PPa 
on HA-ADH may thus better preserve the binding specificity and affinity of HA to the 
receptors in the lymphatic system, such as LYVE-1 on the wall of lymph vessels.(37) 
HA-ADH-PPa was synthesized via a covalent amide bond linkage of the carboxyl 
group on PPa to HA-ADH. In aqueous solution the resulting conjugates could be self-
assembled into nanoparticles where HA forms the hydrophilic shell and PPa forms the 
hydrophobic core. The particle size was determined to be ca. 7-8 nm by TEM (Figure 3) 
when sample solution was prepared at a concentration of 10 mg/mL, and a 35-kDa HA 
polymer was estimated to have a size of about 2 nm.(38) This suggests that 3 or 4 HA 
polymers were associated to form each nanoparticle via hydrophobic interactions among 
PPa molecules. The self-organizing behavior of polymer is very concentration dependent, 
thus their relationship is usually described using critical micelle concentration (CMC), 
critical aggregation concentration (CAC) or critical self-quenching concentration (CQC). 
The CQC of HA-PS conjugates was investigated by Li et al and found that the micelle-
like nanoparticles were formed significantly when the polymer concentration was higher 
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than 0.1 mg/mL and PS concentration was higher than 0.013 mg/mL.(24) However, in 
our work, no polymer aggregation was detected (Figure 1), and thus no photoacitivity 
quenching was expected due to the lower loading degree of PPa on HA-ADH. 
Singlet oxygen is the main therapeutic agent produced in PDT, so the two 
fundamental requirements for a successful PS polymer-based carrier are that (1) the 
nanocarrier should not significantly quench singlet oxygen and (2) the PS encapsulated 
polymer matrix is permeable to newly generated singlet oxygen.(39) As shown in Figure 
4, no significant difference in the rates of singlet oxygen generation was observed 
between HA-ADH-PPa and free PPa at same concentrations of PPa under increased light 
intensity up to 2.35 J/cm2, suggesting that HA-ADH-PPa nanocomposite neither 
quenched or entrapped singlet oxygen nor blocked its diffusion into the intracellular 
domains.  
Intracellular localization of HA-ADH-PPa and free PPa after a 5-hr incubation 
was observed via confocal microscopy and lysosomal and nuclear staining.  In Figures 6 
F and 6 L, green fluorescent puncta associated with PPa were widely distributed in 
cytoplasma, which houses target organelles crucial in PDT efficacy including 
mitochondria, endoplasmic reticulum and Golgi apparatus. In addition, significant co-
localization of HA-ADH-PPa with lysosomes was observed in Figure 6c, suggesting that 
the HA-ADH-PPa internalization may have occurred via an endocytotic pathway. In an 
attempt to better understand the uptake of nanoconjugates versus free PPa by MDA-1986 
cells, intracellular PPa concentration was measured after a 1 hour PPa treatment. Only 
10% of free PPa was retained by cells after 2 hours, versus 60% of HA-ADH-PPa 
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polymeric conjugates (Figure 5b). This may be due to enzymatic degradation of HA-
ADH-PPa by lysosomal hyaluronidase followed by release of PPa into the cytosol. A 
similar PS release pattern from HA nanoparticles was also observed by Yoon H. Y. et al. 
in their in vitro release study, in which ca. 40% of Ce6 was released while incubating 
Ce6-HA with hyaluronidase at 37 °C.(40)  
Free hydrophobic PPa molecules have been demonstrated to target vulnerable 
hydrophobic organelle membranes within cells, such as mitochondrial membranes, in 
which apoptotic response is induced following PDT.(41) In contrast, confocal 
microscopy showed that HA-ADH-PPa localized primarily in lysosomes (Figure 6c). It is 
well documented that singlet oxygen is unable to diffuse beyond the intracellular 
compartment where it is being produced, and the lysosomes are less critical organelles 
than mitochondria in photosensitizing process.(42) Thus subcellular localization may 
account for the lower phototoxicity of HA-ADH-PPa. The ability to concentrate HA-
ADH-PPa at the treatment site could help compensate for its lower phototoxicity.       
To evaluate the therapeutic efficacy, mice bearing MDA-1986 tumors were 
treated with either (a) HA-ADH-PPa (0.5 mg/kg PPa) injected directly into peri-tumoral 
subcutaneous tissue, or (b) free PPa injected i.v. into the tail vein. Tumor growth was 
suppressed more successfully by s.c. HA-ADH-PPa (0.5 mg/kg PPa) than by i.v. free PPa 
treated mice (Figure 9a). The result of the tumor response suggests that s.c. HA-ADH-
PPa nanoconjugates achieved enhanced therapeutic efficacy relative to the conventional 
i.v. PPa.  Reasons might include the specific lymphatic drainage of the HA nanocarrier, 
and the direct localized route of drug administration.  
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Post-irradiation skin edema is one of the most common side effects of PDT 
treatment.  Such edema was observed in HA-ADH-PPa treated mice.(43) Edema was not 
observed in mice treated with the free PPa or saline. Furthermore, tumors in mice treated 
with a higher dose of HA-ADH-PPa (0.8 mg/kg PPa) demonstrated hemorrhage 
suggesting notable efficacy. All three high-dose mice were cured after two treatments, 
and treated tissues recovered readily during the course of one week. This rapid healing 
might be due to the reparative and protective effects of HA, which has been used widely 
in for healing cutaneous wounds, burns and ulcers.   
Topical, transdermal and intratumoral application of photosensitizers has been 
shown to have several advantages over traditional intravenous administration, including 
higher tumor uptake, reduced systematic toxicity and skin photosensitivity.(44, 45) 
However the intrinsic hydrophobicity of PS dictates use of non-aqueous solvents that 
carry pharmaceutical and toxicological side effects.(46) The excellent water solubility of 






This study describes a novel polymeric HA nanocarrier conjugated to the 
photosensitizer PPa for intratumoral and intralymphatic delivery.  It also demonstrates the 
novel compound’s use in treating a focal malignancy and its locoregional lymphatics. In 
HNSCC tumor-bearing mice, in vivo efficacy and survival were greatly improved versus 
conventional PDT. This strategy for local and intralymphatic delivery could potentially 
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The anti-tumor activity of cis-diamminedichloroplatinum(II) (cisplatin) was 
initially discovered in 1969, followed by extensive research related to the use of platinum 
complexes on the treatment of cancer. These platinum compounds undergo aquation to 
lose labile chlorine ligands in vivo to form reactive species cis-[Pt(NH3)2(OH)(Cl)]  (Pt-
monoaqua) and cis-[Pt(NH3)2(OH)2] (Pt-diaqua).(1) The aqua ligands are easily displaced 
by the bases on DNA, forming [PtCl(guanine-DNA)(NH3)2]
+, subsequently [Pt(guanine-
DNA)2(NH3)2]
2+ via displacement of the other chloride ligand. Therefore, the aquated 
platinum complexes are able to form intra- and inter-strand DNA crosslinks in tumor 
cells, which interfere with cell division and DNA repair and in turn induce cell death.(2) 
At present, cisplatin is the most widely used of the platinum compounds in the clinic for 
the treatment of solid tumors. Applications include head and neck, testicular, ovarian, and 
gastric tumors; and, in combination with other chemotherapeutic agents, squamous cell 
carcinoma and small cell lung carcinoma.(3, 4) 
However, the critical toxicity, typically nephrotoxicity and ototoxicity, are 
significant limitations to the use of cisplatin.(5) Research on synthesis and testing of 
novel small molecule platinum complexes has been conducted to find new platinum 
chelate based compounds that improve the therapeutic index. Changes in platinum ligand 
structure not only affect the efficacy of platinum chelates on various tumor types but also 
alter the toxicity profile. For instance, when the chloride leaving groups were replaced 
with a cyclobutane-dicarboxylate ligand, the resulting compound, carboplatin, had a 100-
fold lower rate of hydrolysis and a longer retention half-life in the body compared to 
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cisplatin. As a result, the less reactive compound reduces systemic toxicities, whereas 
antitumor activity is retained.(6) 
In order to improve the efficacy and therapeutic index of small platinum 
molecules, many other small platinum molecules have also been synthesized and tested 
as potential therapeutic agents. Most of them were not acceptable because of one or more 
of following issues: loss of activity, low solubility in aqueous solution, poor stability or 
severe side effects. Research has also been conducted on both combination therapy and 
formulation changes to improve the therapeutic index of approved platinum complexes. 
However, there is still a need for new platinum molecules, which will exhibit sufficient 
solubility and stability in aqueous solutions, capability of crosslinking DNA and 
ultimately improved therapeutic index. 
Improvements in therapeutic index might be achieved by a tumor cell targeting 
strategy, in which intra-tumoral drug level and systemic circulation time can be greatly 
enhanced. Due to the importance of the enhanced permeability and retention (EPR) effect 
used in drug delivery to cancer tissue, one extensively reported method of tumor targeting 
involves the labile conjugation of platinum molecules to a polymer or other 
macromolecule, resulting in the concentration of drug molecules in tumors much higher 
than that in normal tissues.(7) Polymer-platinum conjugates have been reported to 
improve tumor treatment by enhanced solubility, targeting tumors by the EPR effect and 
thus improving the therapeutic index by reducing exposure to healthy tissue. For 
example, our group has extensively investigated the conjugation of cisplatin to a polymer 
of disaccharides, hyaluronan (HA), for the passive targeting of active platinum molecules 
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to solid tumors, such as breast cancer tumor, head and neck cancer tumor and 
melanoma.(8-12) This water soluble conjugate was named “HylaPlat”. It is completely 
biocompatible and biodegradable within cells by hylaronidase and significantly improves 
cisplatin solubility in biological fluids. Moreover, hyaluronan has a strong affinity for the 
CD44 receptor which is up-regulated in tumors compared with normal tissue. Thus, 
HylaPlat combined active and passive targeting pathways for the delivery of platinum 
chelats. However, the platinum complexation to hyaluronan was via a labile ester bond, 
which is cleaved easily in the biological environment and leads to the formation of the 
very toxic platinum molecules (Pt diaqua). In addition, platinum is released from the 
polymer at a relatively high rate after entering the systemic circulation and the passive 
tumoral uptake of platinum is not improved even with the help of polymer nanocarriers. 
In this work, pure N,O-diammineplatinum chelates were designed and prepared by 
grafting a Nα-acetyl-lysine linker to the HA backbone. The conversion of O,O-platinum 
chelates to the N,O-platinum complex was thermodynamically preferred providing a 
stable platform for the treatment of cancer. 
2. Materials and Methods 
2.1 Materials 
Sodium hyaluronan (75,000 Da) was purchased from Lifecore Biomedical 
(Chaska, MN). Nα-Acetyl-L-lysine was purchased from Chem-Impex International Inc. 
(Wood Dale, IL). Dowex(R) 50W-X8 cation exchange resin was purchased from Bio-
Rad (Hercules, CA). N-hydroxysulfosuccinimide (sulfo-NHS) was purchased from 
ChemPep Inc. (Wellington, FL). N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (EDC•HCl), tetrabutylammonium hydroxide solution (55-60% in H2O), 
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hyaluronidase from bovine testes (type I-S, 400-1000 units/mg solid) and silver nitrate 
(AgNO3) were purchased from Sigma-Aldrich Co. (St. Louis, MO). Cisplatin was 
purchased from Qilu Pharmaceutical Inc. (Shandong, China). Other chemicals and 
organic solvents, CD44/H-CAM antibody, chlorpromazine hydrochloride and cell culture 
supplies were purchased from Fisher Scientific (Pittsburgh, PA). Dulbecco's Modified 
Eagle's Medium (DMEM) was purchased from Lonza (Allendale, NJ). The MDA-1986 
human oral squamous carcinoma cell line was kindly provided by Dr. Jeffery Myers (The 
University of Texas, M.D. Anderson Cancer Center, Houston, TX).  Double distilled 
water (ddH2O) was used for preparing all of the aqueous solutions.  
2.2 Synthesis of hyaluronic acid-tetrabutylamonium (HA-TBA) salt 
One gram of sodium hyaluronate was dissolved in water at a concentration of 2-5 
mg/mL, followed by the addition of 10 grams of cation exchange resin (Dowex 50W-
X8). The mixture was stirred at room temperature overnight. The resin was removed by 
filtration, and the filtrate was neutralized with TBA-OH solution (55-60% in water) and 
freeze dried to afford orangish or pinkish polymer. 1H-NMR (400 MHz, D2O) δ (ppm): 
4.46 (d, J = 6.8 Hz, 1H), 4.36 (d, J = 6.8 Hz, 1H), 3.74-3.25 (m, 10H), 3.12-3.08 (t, J = 
8.4 Hz, 8H), 1.92 (s, 3H), 1.60-1.52 (tt, J = 8 Hz, 8H), 1.27 (qt, J = 7.2 Hz, 8H), 0.85 (t, J 





Scheme 1. Synthesis of HA-lys-Pt 
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2.3 Synthesis of HA-Nα-Acetyl-L-lys (HA-lys) 
Two hundred milligrams of HA-TBA was dissolved in 10-mL of dimethyl 
sulfoxide (DMSO) for 10 min. After the solution turned clear and homogenous, 123.6 mg 
of EDC-HCl and 140 mg of sulfo-NHS were added, and the mixture was allowed to stand 
at room temperature. After 2 hours, 121.3 mg of Nα-Acetyl-L-lysine was added to the 
solution with another 4 mL of DMSO. The resulting reaction solution was stirred at room 
temperature for another 22-24 hours. The final product was purified by dialysis (10,000 
MWCO) against water for 4 hours, sodium chloride solution (100-mM) for 2 hours, 
followed by two water changes over another 18 hours. The purified solution was filtered 
through a PES syringe filter (0.22-µm) and concentrated using a centricon filter (10,000 
MWCO) before the SD was determined by 1H-NMR. 1H-NMR (400 MHz, D2O) δ (ppm): 
4.57-4.29 (m, 2H), 4.06 (dd, J = 5.6 Hz, J = 7.6 Hz, 1H), 3.74-3.25 (m, 10H), 1.95 (s, 
3H), 1.94 (s, 3H), 1.66-1.58 (m, 2H), 1.43 (tt, J = 6.4 Hz, 2H), 1.12 (m, 2H).  
2.4 Synthesis of HA-cis-[Pt(NH3)2(N
α-Acetyl-L-lysine)] (HA-lys-Pt) 
Cisplatin (60 mg, 200 µmol) was added to 3 mL of warm water. The resulting 
suspension was combined with AgNO3 (68 mg, 400 µmol) and allowed to stir for 1 day at 
room temperature in the dark. After AgCl2 was removed by centrifuging at 4,000 rpm for 
10 minutes, the supernatant was further filtered by syringe filter (nylon, pore size 0.22-
µm) to obtain cis-[Pt(NH3)2(OH)2].  
One hundred and twenty-five milligrams of HA-lys was dissolved in 15 mL of 
water, to which 815 µL of cis-[Pt(NH3)2(OH)2] (27 mg/mL on cisplatin basis) was added, 
and the pH of the mixture was monitored and adjusted using 1-N NaOH to keep it at 
~5.0. The reaction was allowed to proceed at 40 °C for 1 day and 50 °C for 2 days in the 
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dark. The resulting solution was filtered through a nylon syringe filter (pore size 0.22-
µm) and transferred to dialysis tubing with 10,000 MWCO. Final product was purified by 
dialysis against water for 4 hours, sodium phosphate solution (100 mM NaCl, 10 mM 
NaH2PO4, pH 7.4) 2 hours, and two water changes over another 18 hours. 
13C-NMR (500 
MHz, D2O) δ (ppm): 190.2, 178.0, 174.9, 174.0, 103.1, 100.5, 82.4, 79.8, 76.2, 75.3, 
73.5, 72.4, 68.4, 65.2, 60.5, 54.3, 42.7, 36.0, 28.4, 24.1, 22.5, 21.7. 
2.5 Release of platinum from HA-lys-Pt 
 Release studies were conducted in phosphate buffered saline (PBS, 12 mM 
sodium phosphate, 137 mM NaCl, pH 7.4) at 37 °C. A 0.1-mg/mL HA-lys-Pt solution 
(concentration on cisplatin basis) was added into a dialysis tubing with 10,000 MWCO. 
The dialysis tubing was placed in the buffer. At pre-determined intervals 100-uL samples 
were collected and kept at -20 °C until analysis. Samples were diluted 1,000 fold using 
1% HNO3 prior to ICP-MS analysis.  
2.6 Hyaluronidase degradability of HA-lys-Pt 
 The hyaluronidase (HAdase) specificity of HA-lys-Pt was evaluated by 
incubating 1.5-mg/mL HA-lys-Pt (concentration on HA basis) with 5-µg/mL HAdase in 
sodium phosphate buffer containing 140-mM NaCl, 16-mM NaH2PO4 and 7-mM 
Na2HPO4 at pH 6.4 at 37 °C for up to 24 hours. One hundred microliters of digested 
samples were collected at 0, 1, 2, 4, 6, and 24 hours and stored at -80 °C until analysis. 
Samples (N=3) were diluted 5 fold using mobile phase at the time of analysis by size 
exclusion chromatography (SEC) with a Shodex OHpak SB-804 HQ column, coupled 
with a refractive index (RI) detector. The mobile phase was 5-mM ammonium acetate 
buffer (pH 5.0). The flow rate was 0.8 mL/min. The column temperature was 40 °C. The 
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injection volume was 80 µL. Solutions of HA with different molecular weights in mobile 
phase were used as calibration standards. 
2.7 Purity analysis in HPLC 
 The content of small molecule platinum species including free cisplatin, Pt-
monoaqua and Pt-diaqua were quantified using an HPLC equipped with a UV detector 
and an Alltech® 250 mm × 4.6 mm M/M RP8/cation column. The mobile phase was 
sodium phosphate solution (10 mM, pH 3.0) at a flow rate of 0.25 mL/min. The column 
temperature was 25 °C. A mixture of platinum species was used as internal standards. A 
series of cisplatin solutions in saline were used as calibration standards. Prior to HPLC 
analysis, 1 mL of HA-lys-Pt solution (1.8 mg/mL on cisplatin basis) was placed in a 4 °C 
refrigerator, transferred into a centricon centrifugal filter unit (10,000 MWCO) on the 
fourth day and was spun on a centrifuge at 4,000 rpm at 4 °C for 10 min. The filtrate was 
immediately injected into the HPLC. The peaks of cisplatin, Pt-monoaqua, and Pt-diaqua 
were detected by a UV detector at 283 nm.  
2.8 Cytotoxicity of HA-lys-Pt 
 Cell growth inhibition was determined in 96-well plates using head and neck 
squamous cell carcinoma cells, MDA-1986 or murine breast cancer cells, 4T1.2-neu. 
Plates were seeded with 3,000 cells/well in 90 uL of media (6 replicates/sample). Ten 
microliters of HA-lys-Pt conjugate solution was applied after 24 hours. Resazurin blue in 
10 µL of PBS was applied to each well with a final concentration of 5 µM after another 
72 hours. After 4 hours, the well fluorescence was measured (ex/em 560/590 nm) 
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(SpectraMax Gemini, Molecular Devices), and the IC50 concentration was determined as 
the midpoint between drug-free medium (negative) and cell-free (positive) controls.  
2.9 Toxicity in mice 
 The toxicity of HA-lys-Pt was evaluated in healthy Balb/c mice (n=3). Three 
Balb/c mice were injected subcutaneously with 20, 30, 40 and 67 mg/kg HA-lys-Pt. The 
body weights and toxic reactions of the animals were monitored weekly up to 2 months.  
2.10 Tumor efficacy 
 The MDA-1986 human head and neck squamous cell carcinoma cells were 
prepared in PBS at a concentration of 2 ×107 cells/ml. Female NU/NU mice were 
anesthetized under 2% isoflurane in O2, and 50 µL of cell solution was injected into the 
oral sub-mucosa of the mice using a 27-ga needle. The murine breast cancer cells were 
prepared in PBS at a concentration of 2 ×107 cells/ml. Female Balb/c mice were 
anesthetized under 2% isoflurane in O2, and 50 µL of cell solution was injected into the 
mammary fat pad of the mice using a 27-ga needle. All procedures in the animal study 
were approved by the Institutional Animal Care and Use Committee of the University of 
Kansas. 
 The primary tumors with sizes between 50 to 100 mm3 were observed on the 
cheeks or breast areas within 2 weeks after cell implantation. The tumor growth was 
monitored twice weekly by measurement with a digital caliper in two perpendicular 
dimensions, and the tumor volume was calculated using the equation: tumor volume = 
0.52 × (width) 2 × (length). When the tumor size reached 50-100 mm3, HA-lys-Pt was 
administered subcutaneously next to the tumor at a dose of 20 mg/kg on the basis of 
177 
 
cisplatin. Cisplatin was administered intravenously via tail veins at a dose of 10 mg/kg. 
The drugs were given weekly for 3 consecutive weeks.  
3. Results 
 We attempted to design a new linker between the HA nanocarrier and cisplatin for 
the release of Pt drug in a controlled manner. The approach includes a covalent bond that 
connects the linker to the HA backbone, and thus the modified HA nanocarrier was 
expected to be stable in the blood stream. The chemical modification of HA has been 
performed widely on the carboxylate group of HA due to the numerous conjugating 
strategies and coupling reagents available.(13) Because HA has high solubility in water 
and extremely low solubility in organic solvents, the amidation reactions are usually 
conducted in aqueous solutions. EDC is the most commonly used carbodiimide in the 
amidation reaction, not only because its HCl salt form is soluble in water, but also 
because its byproduct in the coupling reaction is a non-toxic urea derivative. However, in 
terms of reaction mechanism, the drawbacks of the EDC-mediated amidation reaction are 
not insignificant.(14) The rapid hydrolysis of O-acylisourea, in addition to the 
rearrangement of O-acylisourea to the unreactive N-acylurea form towards primary 
amines, results in the low reaction efficiency and the formation of unwanted HA-N-
acylurea byproduct. Although the use of NHS decreases the occasion of hydrolysis, the 
formation of N-acylurea was not completely suppressed (data not shown). This was 
possibly due to the slow formation or the relative rapid hydrolysis of of HA-succinimidyl 
ester (t1/2 of 40 min at pH 6.0). Thus, the commonly used HA sodium salt was converted 
to a TBA salt for solubilization in organic solvents. Not surprisingly, no HA-N-acylurea 
byproduct was found in the final HA-lys conjugates. After reacting with Pt-diaqua, 
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followed by the extensive dialysis against water to remove unbound Pt complex and 
sodium phosphate buffer to remove loosely bound Pt complex, the loading degree of Pt 
was determined by inductively coupled plasma mass spectrometry (ICP-MS) to be 6-8% 
on a cisplatin weight basis. The purity of the HA-lys-Pt solution post-dialysis and 4 days 
after keeping the solution at 4 °C were tested by HPLC. It was found that none of the 
hydrolyzed Pt species (Pt-monoaqua and Pt-diaqua) existed (Figure 1).  
 Degradation of HA in the body occurs in any of three ways. These include being 
attacked by free radicals, enzymatic action and hydrolysis. Excellent biocompatibility and 
total biodegradability open up various medical applications of HA in dermatology, 
wound healing and drug delivery. Thus, it is critical to preserve its biodegradability after 
chemical modification and drug loading. Herein, biodegradability of HA-lys and HA-lys-
Pt was examined by incubation with testicular type hyaluronidase that breaks down the 
HA backbone on its β (1,4) link.(15) The HA, HA-lys and HA-lys-Pt degradation curves 
are shown in Figure 2a. Similar to HA, both HA-lys and HA-lys-Pt maintained HAdase 
specificity and degradability. It was also noticed that the apparent MWs of the lysine 
linker conjugated polymer and Pt complex loaded nanoconjugates are smaller than that of 
sodium hyaluronate. Also noted was a decreasing degradation rate in a sequence of 
sodium hyaluronate, HA-lys and HA-lys-Pt. This was probably due to the use of 
ammonium acetate buffer (5 mM) as the mobile phase (pH 5.0), in which carboxylate 
groups on HA were deprotonated. Thus, an increase in hydrodynamic volume of the HA 
polyelectrolytes was observed due to the repulsion between the carboxylate anions. 
However, owing to the covalent amide linkages, carboxyl groups were covered randomly 
and thus the repulsion was diminished.(16) Not surprisingly, HA-lys exhibited a slight 
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increase in elution time and lower calculated molecular weights.  At the same time, the 
creation of a 5-member ring of Pt complex further occupied most of the carboxyl groups 
of the Nα-Acetyl-lysine linker and provided two positive charges so that the 
hydrodynamic volume of HA-lys-Pt gave the smallest calculated molecular weights as 
















Figure 1. Chromatograms of Pt species mixture solution and the filtrate of HA-lys-Pt 
solution generated by cation exchange HPLC. 
 
























 Drug delivery vehicles are expected to release active agents effectively and 
specifically at the disease site, rather than a negligible drug release at the target or a rapid 
dissociation of drug from carriers in the systemic circulation, resulting in a low 
therapeutic efficacy. Consequently, the release profiles of Pt from HA-lys-Pt were 
evaluated via dialysis against PBS at physiological pH of 7.4, and acetate buffered 
solution at a pH of 5.5 at 37 °C to simulate the acidic environment of tumor interstitium 
and cell endosomes. The platinum concentrations in tubing were measured and plotted as 
the percentage of cumulative drug released against time in Figure 3. The drug release 
followed pseudo-first-order kinetics with half-lives of 24-hr and 2-day in acetate buffer 
and PBS, respectively. The faster release of Pt(II) ions in an acidic environment was 
expected and is attributed to the acid lability of the Nα-acetylamido ligand. It is 
protonated easily by acid, followed by de-chelation from the Pt(II). Pt(II) was released 
from the HA-lys nanocarriers in the form of Pt-diaqua complex. This result suggests that 
the enhanced release of Pt aqua-active intermediate form at low pH can be an advantage 
in the formation of Pt-purine -DNA adducts, and in turn in the in vivo treatment of solid 










 When cisplatin was conjugated to the carboxylate groups of hyaluronan, the 
nanoconjugate, HylaPlat, exhibited a similar anti-proliferative activity as the cisplatin on 
the human head and neck squamous cell carcinoma (HNSCC) cell line, MDA-1986. The 
in vitro toxicity of the conjugates was due to the released active forms of Pt species upon 
hydrolysis.  The anti-proliferative effects of HylaPlat and HA-lys-Pt conjugates is likely 
due to one or both of the pathways that are carrier-mediated endocytosis of 
nanoconjugates, followed by the release of the drug, or free drugs internalization via 
passive diffusion or active transport following the cleavage of the drugs. The antitumor 
effect of HA-lys-Pt was initially evaluated by the use of MDA-1986 human head and 
neck cancer, A2058 human melanoma and 4T1.2-neu murine breast cancer cell lines. As 
shown in Table 1, the HA-lys-Pt exhibited a decreased potency compared to cisplatin and 
HylaPlat. This is probably due to the relatively slower release of the free drugs from HA-
lys-Pt (t1/2 = 2 days in PBS) compared to HylaPlat (t1/2 = 10 hours in PBS). Active Pt 
species were almost completely cleaved from HylaPlat during the 3-day incubation. 
However, within the same period, HA-lys-Pt partially released hydrolyzed drug, which 








Table 1. IC50 of Pt-based anti-cancer drugs on MDA-1986, A2058 and 4T1.2-neu cancer 
cells. 
Tumor Cell Line Cisplatin (µM) HylaPlat (µM) HA-lys-Pt (µM) 
MDA-1986 8.1 ± 2.4 8.6 ± 1.6 21.4 ± 5.9 
A2058 12.1 ± 6.8 14.6 ± 9.0  84.8 ± 38.3 













 In order to assess if HA-lys-Pt treatment produces sub-acute toxicity in mice 
during the course of the study, body weights and toxic reactions of healthy Balb/c mice 
were monitored twice per week up to two months (Figure 4). All of the mice remained in 
good condition and had body weight losses within 40%. Mice administered at doses of 20 
and 30 mg/kg body weight (on ciplatin basis) began to gain body weight from the sixth 
day post injection, whereas  mice injected with 40 mg/kg HA-lys-Pt maintained its body 
weight at a lower level during the third week post-injection and grew back to normal 
body weight in another week. Toxic reactions including lethargy, paralysis, and 
respiratory depression were not observed during the entire study.   
 An orthotopic xenograft model of human HNSCC was established to examine the 
anti-cancer efficacy of HA-lys-Pt. Tumors on mice in the control group reached a size of 
approximately 1000 mm3 within 6 weeks after tumor cell implantation. In comparison, 
the average tumor growth of mice treated with HA-lys-Pt began to show a lower rate 
immediately after the first treatment in the beginning of the third week. Tumor 
progression was delay by four weeks after s.c. Pt therapy (p = 0.0029). As shown in 
Figure 5a, the treated animals developed tumors of an average size less than 200 mm3 by 
the end of the sixth week, and the survival rate was significantly extended relative to the 
control group (Figure 5c). The disease condition of each individual animal is reported in 
Table 2. In contrast to less than 5% body weight loss of mice treated with a single dose of 
20 mg/kg, body weight loss reached a high of slightly more than 20% right after the third 




Table 2. PR=Partial Response (>30% reduction); PD=Progressive Disease (>30% tumor 















HA-lys-Pt s.c. SD SD PR PR PR SD 















Figure 4. Changes in mice body weights after administering HA-lys-Pt s.c. at doses of 











Figure 5. a) Size measurement of head and neck tumors, b) changes in mice body weights after administering HA-lys-Pt s.c. after 




Polymer therapeutics provide the opportunity to bind anti-cancer drugs during 
transportation to the tumor, tumor cell entry by the endocytic route, and targeted and 
specific release of the active drug on demand. The idea of linking a platinum agent to the 
water-soluble, biocompatible polymer was initially developed by Gianasi et al. in 
1999.(17) The HPMA copolymer platinates showed significant antitumor activity against 
B16F10 murine melanoma tumor model. Moreover, the intravenously administered 
polymer platinates exhibited lower toxicity, longer retention time in blood circulation, 
and substantial increase in bioavailability when compared with cisplatin. The significant 
improvement in therapeutic index was mainly due to tumor selective deposition of 
polymers in suitable size, which enabled the EPR effect.   
However, it was known that the carboxylate is a relatively poor ligand for 
chelation of platinum species. Thus a lower maximum tolerated dose (MTD) and higher 
in vitro cytotoxicity of HPMA-spacer-COO-Pt was observed in accordance with the rapid 
hydrolytic release profiles at both pH 7.4 and 5.5. A tunable release of platinates is more 
desirable. For example, a cleavable spacer, Gly-Phe-Leu-Gly, was employed to graft 
platinates onto HPMA polymer, so that the HPMA-Gly-Phe-Leu-Gly-en-Pt was degraded 
preferentially by the lysosomal thiol-dependent proteases to liberate active Pt species.(17) 
Interestingly, a thermodynamically stable N,O-amidomalonate cis-
diamineplatinum (II) complex was found unexpectedly when a kinetically stable O,O-
amidomalonate cis-diamineplatinum (II) underwent rearrangement.(18) Such polymer 
conjugated N,O-chelates showed beneficial properties for the treatment of cancer, such as 
having a sustainable release profile, enhanced tumoral uptake and low systemic toxicity. 
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However, although the MTD of N,O-chelates was increased to as high as 400 mg Pt/kg, it 
did not display the significantly improved anti-tumor activity compared to carboplatin at 
a lower treatment dose (60 mg Pt/kg). This may be due to the slow intracellular release of 
active Pt species from N,O-amidomalonate chelate to bind DNA effectively, as well as 
the slow cellular uptake of polymer conjugates via the pinocytic route.(7) Consequently, 
a relatively more reactive Pt chelate was designed and tethered onto the carboxyl groups 
on the HA polymer through the C6-amine moiety of L-lysine. The labile COO-chelate 
was formed on both the HA backbone and Ac-L-lysine, but only the Ac-L-lysine ligand 
was converted to the Ac-N,O-species at pH 5, the preferred configuration being a five-
membered chelate ring in the Pt complex. The use of amino acids as Pt ligands along 
with the five-member ring chelate formation was initially reported by Erickson et al in 
1968,(19) followed by extensive investigation on anti-tumor activity and comprehensive 
characterization by Appleton et al in the 1990s.(20-23) 
Due to the importance of consistent toxicity and anti-tumor efficacy for Pt 
complex, it was necessary to prepare a well-defined and well-controlled Pt complexation 
to release active Pt-species in a single pattern. The reaction solution was treated with 
sodium phosphate solution (100 mM NaCl, 10 mM NaH2PO4, pH 7.4) to remove any 
highly labile Pt species to produce a pure lower Pt releasing complex. The HA-lys-Pt 
displayed tunable release profiles in PBS at pH 7.4 (t1/2 ~ 2 days) and in acetate buffer at 
pH 5.5 (t1/2 ~ 24 hours), which can be attributed to the acid lability of the Nα-acetylamido 
ligand. This indicates that HA-lys-Pt could be transported safely and steadily under 
normal physiological condition during systemic circulations. Subsequently, a rapid 
release of Pt species from HA-lys was activated within the low pH environment of the 
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tumor.  The reason for the enhanced rate of platinum release observed at a lower pH is 
that the N,O-chelate was probably first converted back to the intra-polymer or inter-
polymer O,O-chelate. The Nα-acetyl group was protonated primarily in highly acidic 
conditions and dechelated from the Pt center. It was previously determined that about 
20% conversion from N,O-chelate to O,O-chelate could be obtained at pH 5.0-5.5 within 
20 hours and as high as 68% was achieved within 20 hours at pH 4.0-4.5, which is the 
lysosomal pH for the enzymatic degradation of macromolecules under endocytosis.(24)  
A triggered release of active Pt molecules at the tumor site was achieved, improving the 
therapeutic efficacy. The reduced systemic toxicity was demonstrated by the improved 
MTD. As shown in Figure 4, the subcutaneously administered HA-lys-Pt increased the 
MTD of cisplatin 4 times compared to intravenous injection. Therefore, by using polymer 
conjugation the biologically active platinates can be concentrated substantially in solid 
tumor tissues, providing an opportunity to overcome Pt resistance.   
HA-lys-Pt showed lower cytotoxicities on all three cancer cell lines. Polymer 
conjugates usually display high IC50 values due to their slow uptake by cells via the 
pinocytic route compared to small drug molecules. (7) However, Lee et al demonstrated a 
45 times higher cellular uptake of Pt-conjugated polymer-caged nanobin than the cellular 
internalization of cisplatin, and attributed this stark contrast to the endocytotic pathway 
for uptake of nanoparticles. With this point still in question, our future work on this 
project will focus on the cellular uptake mechanism of HA-lys-Pt nanoconjugates, so as 





In summary, we have demonstrated that the therapeutic efficacy of HA-lys-Pt 
polymeric conjugates through a synergy of the tunable release of active Pt species from 
locoregional treatment of HA-lys-Pt and improved tumoral uptake via the EPR effect. 
These results suggest that the HA-lys-Pt nanoplatform can provide a new therapeutic 
approach for the treatment of a wide spectrum of cancers. In addition to the attenuated 
systemic toxicity, the unique characteristics of HA polymer, and the strong affinity to cell 
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Chapter VI  
Development of a Lanthanum-Tagged Chemotherapeutic Agent HA-Pt to Track the 





The dissemination of cancer cells, referred to as cancer metastasis from the 
primary tumor to organs through the bloodstream to distant organs and lymphatic vessel 
to their draining lymph nodes (LNs), is the leading cause of cancer death(1). Compared 
with blood vessels, lymphatic vessels are more prominent in developing metastatic 
growth and spreading metastases of epithelial cancers. The detection of metastases in 
regional or sentinel lymph nodes (SLNs) indicates the poor prognosis with a decreased 
chance of survival. In fact, lymphatic vasculatures not only act as conduits for tissue-
invading tumor cells to distant sites in the body, but also play a critical role in facilitating 
the dissemination of cancer cells (2).   
Lymphangiogenesis is the growth of newly formed lymphatic vessels. 
Lymphangiogenesis is promoted by overexpression of lymphangiogenic growth factors 
released by cancer cells, mainly including vascular endothelial growth factors-A, C and D 
(VEGF-A, C and D), which also enhance the LN metastasis. Peritumoral and 
intratumoral lymphatic networks are short of drainage capability due to their disorganized 
microvessels similar to tumor blood vasculatures. However, the structural irregularity 
makes tumoral lymphatic vessels tend to leak and thus susceptible to invasion by 
malignant cells. Moreover, VEGF-C is known to facilitate lymphatic pumping and flow, 
which further promotes tumor spread via tumor-draining lymphatics (3).  
In head and neck squamous cell carcinoma (HNSCC), lymphatic metastasis is a 
more critical prognostic factor for patients’ survival than other routes, due to the 
preferential spread of malignant cells to roughly 60-70 lymph nodes in the head and neck 
area. Lymphangiogenesis is determined to occur in most clinical cases of HNSCC, 
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wherein heterogeneously distributed intratumoral and peritumoral lymphatic vessels were 
identified. The lymphagiogenic growth factors in HNSCC could be present throughout 
almost the entire tumor, with especially high expression of VEGF-C and D at the 
invasive front tumor region (4). 
Glycosaminoglycan Hyaluronic acid (HA), a natural extracellular matrix 
mucopolysaccharide, plays a critical role in inflammatory response, wound healing and 
neoplasia. HA is a principle ligand for CD44 that is overexpressed in many cancer cells 
(5). HA also targets the lymphatic vessel endothelial hyaluronan receptor (LYVE-1) for 
clearance in the lymphatic system (6-8). LYVE-1 is expressed specifically on lymphatic 
endothelium and has been applied as a molecular marker in the studies of lymphatic 
trafficking and tumor-induced lymphangiogenesis (9). LYVE-1 plays an important role in 
the uptake of HA by lymphatic endothelial cells. After rapid uptake by lymphatic vessels, 
HA is mobilized, turned over and catabolized within distant lymph nodes, before entering 
circulation for uptake by the liver (10). Thus, HA has been used as an idea nanocarrier for 
the delivery of anticancer agents for the treatment of lymphatic tumors, such as 
lymphatically metastatic breast cancer and HNSCC. Cai and Forrest have demonstrated 
stable HA-Platinum (HA-Pt) nanoparticles for prolonged lymphatic retention and 
improved tumor tissue deposition (10). Moreover, high water solubility of HA facilitated 
the subcutaneous administration of HA-Pt for loco-regional treatment so that 
bioavailability and efficacy of nanoconjugates were dramatically improved compared to 
intravenous cisplatin (CDDP) (10, 11). For example, mice bearing HNSCC xenografts 
had significantly increased intratumoral concentration of Pt post subcutaneous injection 
of HA-Pt compared to the animals treated with i.v. CDDP (12). It is probably due to the 
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formation of a HA-Pt drug depot after the local injection, which released the drug 
sustainably and delivered the platinum into cancer cells via lymphatic vessels 
surrounding the tumor. However, the precise biological behavior of HA has not yet been 
fully elucidated.  
Currently, in vivo biodistribution of HA is primarily tracked and quantified using 
fluorescent imaging agents, such as near infrared (NIR) fluorescent dyes and quantum 
dots (QDots) (13-16). For example, a HA-OPots800 conjugate synthesized via an adipic 
acid dihydrazide (ADH) linker, and it was orally administrated for real-time bioimaging 
to investigate the optimal molecular weights and extent of chemical modification of HA 
for an efficient drug delivery (13). HA has also been labeled with radioactive isotopes 
including 99mTc, 3H, 111In, 125I and 11C to track its biodistribution with relatively high 
detection sensitivity and specificity (17-21). For instance, Meléndez-Alafort et al. labeled 
a HA-paclitaxel conjugate with 99mTc to evaluate its biodistribution through four different 
administration routes by measuring ex vivo gamma-ray activity in organs and conducting 
in vivo gamma ray image analysis.(22) However, due to fluorescent quenching of dyes in 
physiological environments, high toxicity of QDots and the safety concerns of isotope 
uses, there is a critical need to develop an effective and non-invasive approach to in vivo 
tracking HA.  
In the current study, our goal is to look into the distribution pattern of HA 
nanoparticles and correlate it with the distribution pattern of Pt. Lanthanum chloride 
(LaCl3) has been used by Tohoku et al. to effectively extract HA from the defatted rabbit 
skin (23). We built on this ground work and harnessed the strong binding affinity of the 
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lanthanum(III) [La(III)] to HA and prepared a physiologically stable complex HA-Pt-La 
complex via non-covalently doping a trace amount of La(III) to the HA-Pt conjugates. 
The binding affinity of the La(III) to the HA-Pt conjugates was evaluated using an in 
vitro release test. In addition, after subcutaneous (s.c.) injection of HA-Pt-La 
nanoparticles in HNSCC tumor-bearing mice, the Pt and La content were simultaneously 
tracked and quantified in the plasma, primary tumor, liver and spleen using a highly 
sensitive and reliable inductively coupled plasma-mass spectrometry (ICP-MS) 
technique. The high specificity and sensitivity of the ICP-MS analysis enable this enable 
detecting complex biological matrices with little background interference, which allows 
accurate determination of low-abundance Pt and La [below parts per trillium (ppt)] in the 
native biological samples.  
2. Method and Materials  
2.1 Materials 
All chemicals were obtained from commercial suppliers and used without further 
purification unless otherwise noted. Hyaluronan (HA; 35 kDa) was purchased from 
Lifecore Biomedical (Chaska, MN) as sodium hyaluronate, which was cultured and 
produced by a microbial fermentation process. Cisplatin (CDDP) was obtained from AK 
Scientific (Union, CA). Lanthanum (III) nitrate hexahydrate (La(NO3)3∙6H2O) (puriss. 
p.a., ≥99.0%) was purchased from Sigma-Aldrich Co (St. Louis, MO). All other 
chemicals and cell culture supplies were purchased from Sigma-Aldrich Co (St. Louis, 
MO) or Fisher Scientific (Pittsburgh, PA). Distilled water was used in syntheses, cell 
culture (sterilized by autoclaving) and animal experiments (sterilized by autoclaving). 
Human oral squamous carcinoma cell line MA-1986 was kindly provided by Dr. Jeffery 
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Myers (The University of Texas, M.D. Anderson Cancer Center, Houston, TX). Human 
melanoma cell line A-2058 was obtained from American Type Culture Collection 
(ATCC, MA).  
2.2 Synthesis of hyaluronan-platinum-lanthanum (HA-Pt-La) conjugate 
HA-Cisplatin (HA-Pt) conjugate was prepared as previously described (10). 
Briefly, 100 mg of HA and 45 mg of CDDP were dissolved in a total of 20 mL ddH2O 
and stirred in the dark for 96 hr under argon at ambient temperature (ca. 25°C). By the 
end of the reaction, the mixture was filtered through a 0.22-µm nylon membrane filter 
(Fisher Scientific; Pittsburgh, PA), followed by dialysis (MWCO 10,000 Da; Pierce, IL) 
against ddH2O for 48 h in dark with four water changes. To synthesize the HA-Pt-La, 
1.36 mg of La (NO3)3∙6H2O (1.1 eq to polymer. 3.14 µmol) was added to the HA-Pt 
aqueous solution. The pH of the mixture was adjusted to ca.5.5 using a NaOH solution 
(0.1 N), and the reaction was allowed to proceed overnight protected from light at 
ambient temperature (ca. 25°C). The unreacted La (III) was removed by dialysis against 
ddH2O for 48 h in dark. The crude HA-Pt-La was concentrated under reduced pressure by 
rotary evaporation and then stored at 4 °C in dark. The substitution degrees of Pt and La 
were determined by the ICP-MS (Agilent Technologies 7500a, Santa Clara, CA) using 
terbium as the internal standard. High purity argon (>99.996%) was used as the carrier 
gas. 
2.3 Characterization of HA-Pt-La conjugate 
The molecular weight and the polydispersity index (PDI) of HA-Pt-La were 
determined by Gel Filtration Chromatography (GFC) on a Shimadzu 2010CHT HPLC 
with a refractive index (RI) detector (Shimadzu RID-10A) and UV detector at 210 nm. 
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GFC was performed with a Shodex OHpak SB-804 HQ column (Showa Denko America, 
Inc., New York, NY) at 40 °C using 5-mM ammonium acetate buffer (pH 5.0) as the 
mobile phase at a flow rate of 0.8 mL/min. A calibration curve was generated with HA 
polymers with varying molecular weights ranging from 6400 – 132,000 g/mol.  
To observe the morphology of the HA-Pt-La nano-conjugate, a drop of 10-mg/mL 
HA-Pt-La solution in ddH2O was placed on a lacey carbon coated copper grid (200 mesh, 
TED PELLA, Redding, CA). Transmission electron microscope (TEM) images were 
recorded using a FEI Tecnai F20 XT Field Emission at an accelerating voltage of 200 
ekV. 
2.4 In vitro release profile of Pt and La from the HA-Pt-La nano-conjugate 
  The in vitro release rates of the hydrate form of CDDP (cis-[Pt(NH3)2(OH2)2]
2+) 
and La(III) from the HA-Pt-La conjugate was studied using a dialysis method. Typically, 
1 mL of HA-Pt-La solution was added into the dialysis tubing (MWCO 10,000 Da) and 
then placed in a 2.0-L phosphate-buffered saline (PBS) (pH 7.4) solution at 37 °C with 
stirring at a speed of 300 rpm. The bath volume was replaced every 12 h to maintain the 
sink condition. A 50-µL aliquot was withdrawn from the dialysis tubing at the 
predetermined time points. The Pt and La concentrations in each sample were determined 
by the ICP-MS analysis.   
2.5 Cellular toxicity of HA-Pt-La conjugate in the HNSCC cancer cells 
The MDA-1986 cells cultured in modified Eagle’s medium alpha (supplemented 
with 10% fetal bovine serum and 1% L-glutamine) were seeded into 96-well plates at a 
density of 5000 cells/well. After incubation at 37 °C in a humidified, 5% CO2 incubator 
for 24 h, cells were treated with HA-Pt-La with different concentrations ranging 
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from0.0065 to 195 µM (on cisplatin basis). Seventy-two hours post-treatment, a resazurin 
blue solution was added into each well with a final concentration of 5 µM. After a 4-h 
incubation, fluorescence signal (ex/em, 560/590 nm) in each well was measured using a 
fluorophotometer (SpectraMax Gemini, Molecular Device, Sunnyvale, CA). 100% 
trichloroacetic acid and PBS were used as positive and negative controls, respectively. 
The IC50 value was determined as the midpoint between the positive and negative 
controls. Each experiment was repeated in triplicate.  
2.6 Induction of human xenografts of head and neck tumor and melanoma  
All experimental procedures were approved by the University of Kansas 
Institutional Animal Care and Use Committee (IACUC). Human HNSCC cell line MDA-
1986 cell suspension was prepared at a concentration of 2 × 107 cells/mL. Female Nu/Nu 
mice (20-25 g, Charles River Laboratories; Wilmington, MA) were anesthetized with 2% 
isoflurane in oxygen, and 50 μL of MDA-1986 cell suspension was subcutaneously 
injected into the sub-mucosa of using a 30-ga needle. Tumor growth was monitored twice 
per week via bi-dimensional measurement with a digital caliper, and the tumor volume 
was calculated using the equation: Tumor volume (mm3) = 0.52×(width) 2×(length) 
2.7 Evaluation of pharmacokinetics and tissue distribution of HA-Pt-La in head and 
neck tumor-bearing mice 
HA-Pt-La was first mixed with HA-Pt before administeration with a final loading 
degree of 9.7% for Pt and 0.09% for La on a weight basis. When head and neck tumors 
grew to a size range of ca. 100 to 150 mm3, animals were randomly divided to two 
groups, including a non-treated group (N = 3) and drug-treated group (N = 3 per 
timepoint). In the drug-treated group, HA-Pt-La was administered s.c. peritumorally with 
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a single dose of 1 mg/kg on cisplatin basis. The animals were euthanized at 0.25, 1, 6, 24 
and 48 h post injection. Whole blood was drawn and centrifuged at 2,000g for 5 min to 
collect the plasma. Tumors, livers and spleens were also harvested, washed with PBS and 
stored at -80 °C until analysis. To determine the Pt and La levels in the tissues and 
plasma samples, approximately 20 mg of freeze-dried tumor and spleen tissues, 100 mg 
of freeze-dried liver tissues or 100 µL of plasma were digested with 0.5 mL of aqua regia 
at 130 °C for 2 h. Subsequently, the digested samples were diluted using 1% HNO3 and 
analyzed by the ICP-MS. 
3. Results  
3.1 Syntheses and characterization of and HA-Pt-La conjugates 
The HA-Pt-La was prepared using a two-step synthesis. Pt (II) was first 
conjugated to the HA with a conjugation efficiency of 27% and a loading degree of 9.96 
wt. % through forming a liable ester linkages with the polycarboxyl groups of the HA 
polymer. However, the loading degree of Pt (II) decreased from 9.96 wt. % to 7.40 wt.% 
in the final HA-Pt-La conjugate, probably due to the slow Pt release from the HA 
backbone during the 5-day process of production and purification. In the meantime, the 
release of Pt liberated a number of carboxylate groups on the HA, which in turn 
facilitated the strong binding of La(III) to the oxygen atoms of the carboxylate groups 
(24). The conjugation degree of La(III) was determined to be 0.37 wt.%. 
Compared with the native HA, the obtained HA-Pt-La sample had a comparable 
molecular weight as confirmed by GFC (Figure 1). Specifically, its weight-average and 
number-average molecular weights were 35 kDa and 24 kDa, respectively, resulting in a 
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PDI of 1.44 (Table 1). Both NaHA and HA-Pt-La had broad elution range and thus high 
PDI values. This was probably due to the viscous drag, a non-size exclusion effect found 
on viscous polymers (25). TEM images of the HA-Pt-La conjugate showed a spherical 
shape with a size of approximately 10 nm (Figure 2), which was within the optimal range 














Figure 1. Chromatograms of NaHA (dashed) and HA-Pt-La conjugates (solid) generated 













Table 1. Molecular weights and PDIs of NaHA and HA-Pt-La. 
Polymer Ca. Mw (g/mol) Ca. Mn (g/mol) Ca. PDI 
HA 35,977 ± 5,110 26,601 ± 1,093 1.25 ± 0.11 
























3.2 In vitro release profile of Pt(II) and La(III) from the HA-Pt-La conjugate  
The in vitro release profiles of Pt(II) (7.40 wt.%) and La(III) (0.37 wt.%) in the 
PBS medium are shown in Figure 3. Pt(II) was rapidly released from the HA-Pt-La 
complex, and its releasing pattern could be fit into a pseudo-first-order release kinetics 
with a release half-life of approximately 10 h and a rate constant of 0.068 h-1 (Figure 3A). 
The anions in the PBS, including phosphate and chloride, rapidly displaced the carboxyl 
groups that bind to the platinum, leading to the relatively shorter release half-life of Pt 
upon hydrolysis. In comparison, La(III) exhibited an initial burst release of 
approximately 20 % within first 30 min, and no further La(III) release was detected in the 
following 4 days (Figure 13B). The stable HA-La(III) binding suggests that the La-
labeled HA-Pt conjugate, HA-Pt-La, could be used as a detection probe to monitor the in 









Figure 3. In vitro release profiles of (A) Pt(II) and (B) La(III) from HA-Pt-La conjugate 














3.3 Cellular toxicity of HA-Pt-La conjugate 
The cytotoxicity of HA-Pt-La in the highly metastatic HNSCC cell line was 
presented as the reduction in cell proliferation and viability (Figure 4). The result showed 
that HA-Pt-La conjugates have an in vitro toxicity with an IC50 value of ca. 7.81 ± 0.24 
µM on cisplatin basis, which was not significantly different from the reported IC50 values 













Figure 4. Inhibition of HNSCC MDA-1986 cell growth by the HA-Pt-La conjugates after 












3.4 Pharmacokinetics and tissue distribution of HA-Pt-La conjugates 
A sub-therapeutic level of 1 mg/kg (on cisplatin basis) (10) was used to 
investigate the in vivo pharmacokinetics and tissue distribution of the HA-Pt-La 
conjugate. The La contents in tumor, liver and spleen samples were measured at different 
time points to capture the bio-distribution pattern of HA in living mice (Figure 5). In the 
tumor and plasma samples, peak concentrations of La and Pt following the s.c. 
administration both occurred at 15 min, due to their initial burst-release from the 
disintegrated HA in the tumor region. As expected, the released Pt was rapidly cleared 
and its concentration in the tumor and plasma samples decreased to near-baseline levels 
within 24 h post-injection. In comparison, the concentrations of La in the plasma 
decreased in a much slower rate, which indicated that HA had a higher plasma residence 
time and slower clearance in the blood circulation. Moreover, within the first hour post-
injeciton, only a small amount of Pt and La accumulated in the liver and spleen, which 
correlated with their low levels detected in tumor and plasma. As liver and spleen are the 
major organs for macromolecular accumulation, disintegration and clearance by the 
hepatobiliary system (16), the released Pt and the La-labeled HA gradually accumulated 




Figure 5. Tissue and plasma concentration of Pt (II) and La (III) after subcutaneous 
injection of the mixture of HA-Pt and HA-Pt-La conjugates (1.0 mg/kg on cisplatin basis) 
into the tumor area. Of note, La data was not presented in the figure of spleen samples as 










The lanthanides (Ln) is a series of metallic chemical elements, which include 15 
elements from La through Lu. The most attractive property of lanthanide for biomedical 
application is the capability of its trivalent ions to bind with oxygen-donor ligands or less 
stable nitrogen-donor ligands to form a coordination complex, Ln(III), which is 
kinetically and thermodynamically stable in the blood. The unique fluorescence 
properties of Ln ion complexes [Ln(III) chelates], such as large Stokes shifts and long 
emission lifetimes, make them well-suited for biomedical imaging with the minimum 
self-fluorescence interference from biological fluids and tissues. In addition, due to its 
high magnetic moment and long electron relaxation time, the Ga(III) ion has been 
employed in the noninvasive radiological examination technique-nuclear magnetic 
resonance imaging (NMRI) (24). Among the chelates for Ln(III), macrocyclic 
polyaminocarboxylic ligands, such as DOTA (1,4,7,10-Tetrakis(carboxymethyl)-
1,4,7,10-tetraazacyclododecane), are capable of forming most stable complexes due to  
the size of their internal cavities, their conformation, as well as their rigidity (27). 
Recently, a Ln-chelating carbohydrate conjugate based on a phenylene diamino 
tetraacetic chelating unit was explored to characterize the carbohydrate formation and its 
interactions with proteins in solutions, and it has demonstrated the successful formation 
of stable Ln(III) ion complex with four carboxylic groups (28). HA-La complex, on the 
other hand, can been synthesized by reacting La(III) ion to the oxygen atoms of the 
carboxylic groups on the D-glucuronic acid units. Although there was no further binding 
to nitrogen atoms of the macrocycle, HA-La complex has shown an excellent stability of 
up to 4 days in the physiological pH and ionic strength in our study. This result could be 
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explained by the nature of HA structure, where the negatively charged carboxylate 
groups and the spatial restrictions around the glycosidic bonds coil up into a stiff 
structure that is called random coil in biological environments (29). This arrangement 
creates a spatial allowance for more carboxylate groups binding to La(III) and provides a 
barrier to prevent the diffusion of hydrolyzed La(III) from the “HA cage”. Moreover, 
forming the HA-Pt-La complex did not induce the intermolecular cross-linking of HA 
polymers, which was verified by the negligible difference in molecular weights and PDIs 
between the native HA and HA-Pt-La complex. 
HA exists in the cartilage scaffolding, the synovial fluids of joints and the 
extracellular matrix. HA-specific receptors enable the targeted delivery of anti-cancer 
drugs via conjugating to HA nanocarriers, thus reducing the systemic toxicity. These 
receptors include CD44, the receptor for HA-mediated cell motility (RHAMM), and HA 
receptor for endocytosis (HARE) to mediate the HA uptake in the liver (30). In addition, 
HA-drug bioconjugates give rise to the enhanced drug solubility and stability, improved 
localization and controlled release. Previously it has been shown that after the i.v. 
administration to rodents or rabbits, HA enters the blood stream, from where it was taken 
up and removed by the endothelial cells. HA is mainly degraded mainly in the liver and is 
also concentrated in the spleen and lymph nodes (31). However, due to the rapid 
sequestration of injected compound in the liver, intravenous administration route was not 
considered as a suitable approach for the systemic treatment of tumors and metastases 
spreading out in the body. In our previous studies, HA-Pt conjugates were peritumorally 
injected, and the tumoral uptake of Pt was substantially improved as evidenced by the 
increased AUC when compared with the i.v. cisplatin route (32). 
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We proposed that upon the loco-regional administration, the HA-Pt conjugate 
might be retained in the close anatomical district from where Pt was sustainably released 
from the HA depot, and then delivered into cancer cells via then lymphatic vessels and 
eventually form a Pt-DNA adduct inside the nucleus (12). As shown in Figure 5, Pt was 
cleared from primary tumor region with a comparable rate as HA, which is in line with 
our proposed tumoral uptake mechanism. Once entering the systemic circulation, HA 
level in the plasma, however, decreased much slower than Pt with a stable level reached 6 
h post-injection. Nonspecific uptake of HA nanoparticles is mainly by the 
reticuloendothelial system (RES), which is particularly represented in the liver and 
spleen. In addition, HARE receptors that interact with the HA backbone are primarily 
present in the hepatic tissues. Moreover, subcutaneous injected HA is naturally taken up 
by the lymphatics, followed by the transport to the systemic circulation, and finally 
enzymatically degraded in the liver. Indeed, HA exhibited gradual accumulation in the 
liver.  
5. Conclusion 
In this work, a novel chemotherapeutic agent, HA-Pt, was directly tagged with 
traceable amount of La (III) to form a 10-nm nanoconjugate. The in vitro release study 
confirmed that La was strongly bound to HA, and the cytotoxicity of the HA-Pt-La 
conjugate against cancer cells was comparable as the HA-Pt. The feasibility to use the 
HA-Pt-La nanoconjugate to achieve the simultaneous chemotherapeutic delivery and HA 




6. Future work (not complete) 
In order to observe the formation of HA-Pt drug depot after local injection, 
migration of HA-Pt nanoparticle via lymphatic vessels surrounding the tumors, and 
finally the improved tumor tissue deposition of HA-Pt real-timely, positron emission 
tomography (PET) imaging will be applied to visualize HA-Pt at pre-determined time 
points post injection. PET is a non-invasive diagnostic imaging technique with good 
resolution, high sensitivity, and especially its accurate quantification for pharmacological 
processes in living subjects.  
To acquire PET images, a significant accumulation of a positron-emitting 
radionuclide in a tissue or organ of interest is required. In contrast to nonmetal 
radionuclides, radiometal isotopes have obtained considerable interest due to increased 
production and availability.(33) Among all the metallic radionuclides, 64Cu chelation 
complexes have shown promising applications in diagnostic PET imaging because of its 
favorable nuclear characteristics. The relative long 64Cu half-life of 12.7 h allows for 
sufficient uptake and decay to yield considerable contrast and quality images. In addition, 
64Cu has the advantage of emitting very low energy positrons (an average energy of 0.28 
MeV and maximum β+ energy of 0.655 MeV), which is almost identical to the energy of 
clinically used nuclide 18F and appropriate for detection by PET.(34) Furthermore, good 
in vivo stability of 64Cu complexes is highly desired in order to minimize the release of 
radiometal, and thus reduce background signal and exposure of normal tissues to 
radiation energy. Therefore, bifunctional chelators (BFC) were widely used for a stable 
attachment of 64Cu to targeted biomolecules.(35) In our study, one of the most commonly 
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used 64Cu chelators, a macrocyclic ligand DOTA, was attached to the terminal of HA 
polymer via a short dPEG® linker.  
6.1 Preparation and characterization of HA-PEG-DOTAGA conjugate 
A solution of DOTAGA anhydride (100 mg, 0.218 mmol) in 4-mL of anhydrous 
DMF was mixed with a solution of amino-PEG-t-boc-hydrazide (165.5 mg, 0.436 mmol, 
2 eq.) in 1-mL of anhydrous DMF in the presence of triethylamine (121.6 µL, 4 eq.). The 
reaction was allowed to proceed at 50 °C under argon for 24 hours. The solvent was 
removed under reduced pressure to give the desired product as yellowish oil, which was 
then use without further purification. HRMS (ESI): m/z: calculated for 
C35H63N7O16+H
+/Na+ : 838.4410/860.4229; found: 838.4356/860.4232. The de-protection 
of t-boc was completed in 2-mL of TFA at 0 °C in an ice bath for 3 hours. After the 
removal of TFA, the crude solid was purified by a C18 reverse-phase column (Discovery 
HS F5 and conventional C18, 15cm x 4.6mm). Mobile phase A: ACN; B: H2O + 0.4% 
HCOOH (0 – 10 min, B: 90 – 60%); flow rate: 0.8 mL/min; column temperature: 40 °C. 
The desired compound was detected using a UV detector at 250 nm. The fraction with at 
6.7 min was collected and dried. HRMS (ESI): m/z: calcd for C30H55N7O14+H
+ : 









Sodium hyaluronate (35 or 75 KDa, 100 mg) was dissolved in 5-mL of acetate 
buffer (10 mM, pH 5.6) to a homogeneous solution. After DOTAGA-PEG (45 mg, 21 
eq.) and sodium cyanoborohydride (NaBH3CN, 13.5 mg, 75 eq.) were added, the mixture 
was stirred at 50 °C for two day under argon. The resulting solution was filtered through 
a nylon syringe filter (0.22-µm) and purified by dialysis (10,000 MWCO) against ddH2O 
with four water changes in 2 days. The degree of substitution was determined to be 1.2% 
on molar basis by 1H-NMR (400 MHz, D2O) δ = 4.46 (d, J = 7.6 Hz, 1H), 4.38 (d, J = 6.5 
Hz, 1H), 3.74-3.25 (m, 10H), 2.55 (m, 2H), 1.93 (s, 3H).  
As shown in Scheme 1, only the terminal D-N-acetylglucosamine ring was 
opened and conjugated covalently to DOTAGA-PEG molecules. This is due to the 
mutarotation equilibrium, which exists naturally and ordinarily in carbohydrates.(36) In 
other words, the terminal hydroxyl group was able to form the only aldehyde group in the 
molecule and thus form a Schiff-base in the presence of the amino group in DOTAGA-
PEG. The resulting Schiff-base was converted to a C-N bond immediately when it met a 
reducing agent like NaBH3CN. This reaction strategy permitted the attachment of DOTA 
chelator to HA polymer in a quantitatively controlled manner that one mole of DOTA 
compounds per mole of polymer chain. Assuming that HA nanoparticles are uniform 
with a molecular weight of 35,000 g/mol, the theoretical molar ratio of DOTAGA to HA 
is 0.0108 to 1 in the final nanoconjugate. However, polymers possess a distribution of 
molecular mass, which probably resulted in a slightly higher loading degree of 
DOTAGA-PEG to HA of 1.2% on molar basis as calculated in 1H-NMR spectrum.  
Due to previous reports that HA depolymerisation could be produced chemically 
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by reducing agents, such as ascorbic acid with or without catalysts,(37, 38) the molecular 
weight distribution of the HA-PEG-DOTAGA nanoconjugate was characterized by GFC, 
and was compared to that of sodium hyaluronate, on a Shimadzu 2010CHT HPLC with a 
refractive index (RI) detector (Shimadzu RID-10A) and UV detector at 210 nm. GFC was 
performed with a Shodex OHpak SB-804 HQ column (Showa Denko America, Inc., New 
York, NY) at 40 °C using ddH2O as the mobile phase at a flow rate of 0.8 mL/min. The 
HA-PEG-DOTAGA conjugate exhibited a same retention time on the GFC column as 
that of sodium hyaluronate, demonstrating that the use of NaBH3CN did not induce any 










Figure 6. Chromatograms of sodium hyaluronate (solid) and HA-PEG-DOTAGA 












6.2 64Cu labeling 
HA-PEG-DOTAGA (35 KDa, 9.2 mg) was dissolved in 400-µL H2O, followed 
by the addition of 400-µL of ammonium acetate buffer (0.2 M, pH 5.5). Eight-microliter 
of 64CuCl2 in 0.1-N HCl solution was added (2.12 mCi, 103.21 mCi/µg Cu, 10:34 am). 
The reaction was allowed to proceed at 47 °C for 1 hour with stirring. After it cooled 
down to r.t., 10-µL of DTPA solution (10 mg/mL, pH 8.0) was added, after which the 
mixture was incubated for another 5 min at r.t. without stirring. The resulting solution 
was then transferred to an equilibrated PD-10 column (equilibrated with 25 mL PBS 24 
hours before using). Another 5-8 mL of PBS was added to elute the HA-PEG-DOTAGA-
64Cu. The first 2.4 mL was collected in a 15-mL tube, and the rest was collected in 
eppendorf tubes with 500 µL aliquot in each tube (Eluent #1-12). Ethanol precipitation 
method was used to determine the conjugation efficiency of 64Cu to HA-PEG-DOTAGA. 
Briefly, 100 µL from the highest intensity vial (Eluent #5) with 500 µL HA-PEG-
DOTAGA-64Cu eluent was transferred to another vial, which had 20 µL of HA solution 
in water (25 mg/mL, 35 KDa), followed by the addition of 1 mL of cold ethanol. The 
mixture was put in an ice bath for 15 min then was centrifuged at 12,000 rpm for 10 min. 
The supernatant and pellet were separated and counted for radioactivity separately. The 
yield of labeling was calculated to be 30.6% by the following equation: 
Yield of labeling (%)  = 
𝑃𝑒𝑙𝑙𝑒𝑡 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (µ𝐶𝑖)
𝑃𝑒𝑙𝑙𝑒𝑡 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (µ𝐶𝑖)+𝑆𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (µ𝐶𝑖)
∗ 100% 
The radioactivity was measured on a radioisotope calibrator (Capintec CRC-7, 
Ramsey, NJ). However, an extremely low total yield of labeling (~ 1%) was obtained 
when calculated simply by the equation: 
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Where, initial radioactivity was 2.12 mCi. Since HA-PEG-DOTAGA was present 
in a 1000-fold excessive amount against 64CuCl2, such a low labeling yield was 
unreasonable. Therefore, the reaction must to be further optimized to improve the 
















Table 1. Radioactivity of samples. 
Sample Name Radioactivity (µCi) Time 
Reaction Vial 
(after solution removal) 
134.3 12:22 pm 
First 2.4 mL Eluent 0 12:23 pm 
Eluent #1 0 12:38 pm 
Eluent #2 3.06 12:39 pm 
Eluent #3 71 12:37 pm 
Eluent #4 184 12:34 pm 
Eluent #5 259 12:40 pm 
Eluent #6 78 12:36 pm 
Eluent #7 357 12:33 pm 
Eluent #8 340 5:06 pm 
Eluent #9 179 5:07 pm 
Eluent #10 95 5:08 pm 
Eluent #11 31.6 5:04 pm 
Eluent #12 10.8 5:05 pm 
Column after Elution 860 12:42 pm 
Supernatant 50 2:58 pm 
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Chapter VII  




1. Introduction  
Significant research efforts have focused on designing carrier systems that deliver 
drugs specifically to disease sites, thereby minimizing side effects. Hyaluronic acid (HA) 
is attractive as a tumor-targeted delivery system because of its ability to specifically bind 
to various cancer cells that overexpress the CD44 receptor. Specifically, the endosomal 
processing of HA after CD44 receptor mediated uptake has been shown to degrade HA, 
which allows the selective release of drug molecules to the cancer cells. 
Hyaluronic acid is an anionic polysaccharide comprising alternating 1,4-linked 
units of 1,3-linked glucuronic acid and N-acetylglucosamine that has many medical 
applications as a biomaterial. HA has been recognized for its immunological 
biocompatibility, high water adsorption property, high permeability and biodegradability. 
Therefore, HA has been used as a primary constituent in drug delivery systems as HA-
drug conjugates, nanocomplexes, and nanoparticles.(1) However, some drawbacks exist, 
such as the loss of binding affinity to receptors because of excess drug conjugation and a 
short residence time in vivo. For example, conventional chemical modification by 
conjugating drug molecules to carboxyl or hydroxyl groups in HA polymer alters its 
physical and chemical characteristics. Moreover the carboxyl group is known as the 
target site of hyaluronidase, a family of enzymes that degrade HA. The biodegradability 
of HA is critical in maintaining the framework necessary for HA to act as a drug carrier. 
In addition, the loss of carboxyl or hydroxyl groups decreases the HA solubility in an 
aqueous environment and also affects its affinity to the receptors on the cell membranes, 
such as CD44 receptors. It has been reported that structural modification with more than 
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a 25% degree of substitution on carboxyl groups interfered with its receptor mediated 
uptake, in addition to inducing a cytotoxic effect.(2-4)  
Since CD44 interaction is critical when HA-based drug delivery is targeted to 
cells overexpressing the CD44 marker, a straightforward modification of HA is described 
in this work that maintains CD44 specificity. One way to achieve this is by N-
deacetylation of the N-acetyl group of HA to recover an amino group. Various HA 
derivatives and cross-linked HA can be produced via amide formation or Schiff base 
methods with an acid, aldehyde or ketone.(5, 6) N-deacetylation was usually achieved 
using hydrazine sulfate over a couple of days at a temperature of 50-100 °C, in which 
severe chain fragmentation is induced via β-elimination of the glucuronic moiety.(7-9) 
Duncan et al. have demonstrated the enzymatic activities of N-deacetylase/N-
sulfotransferase (NDST) on removing the acetyl group from the N-acetylglucosamine 
moiety of heparin and heparin sulfate, which provided a possibility for HA 
deacetylation.(10)  However, the extraction of the N-terminal domain of NDST that 
retains N-deacetylase activity from Origami-B cells was too complicated to achieve with 
a large amount. Therefore, to our best knowledge, we proposed for the first time a novel 
enzymatic N-deactylation method using acylases that were applied in the deprotection of 
N-acetyl amino acids.(11) This approach encouraged us to explore new synthetic routes 
for the development of HA derivatives to meet specific needs. 
Sulfated HA derivatives have been investigated widely in their interaction with 
proteins and their potential for promoting bone and skin regeneration and thus tissue 
repair.(12-14) Sulfate groups on glycosaminoglycans can interact with basic amino acid 
residues in proteins electrostatically so as to bind, stabilize, and control the activity of 
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proteins. In addition, sulfated HA showed good biocompatibility and influence on cell 
activity in vitro.(15-17) While sulfated HA has been used to functionalize biomaterial 
surfaces and has been incorporated into hydrogels for the delivery of proteins (17, 18), it 
has not been previously employed for drug delivery. In this chapter, I describe the 
synthesis, characterization and investigation of sulfated HA for biomedical application, 
especially CD44-targeted drug delivery.     
2. Materials and Methods 
2.1 Materials 
Sodium hyaluronan was purchased from Lifecore Biomedical (Chaska, MN). 
1,1’-carbonyldiimidazole (CDI), tetrabutylammonium hydroxide solution (TBA-OH, 55-
60% in H2O), acylase I from porcine kidney (PK, grade I, ≥ 2,000 units/mg), acylase I 
from Aspergillus melleus (AM, > 0.5 U/mg), 7-oxooctanoic acid, hydrazine, hydrazine 
sulfate salt, iodic acid (HIO3), hydriodic acid (HI), N-(3-Dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (EDC•HCl), adipic acid dihydrazide (ADH) and sulfur 
trioxide pyridine complex (So3Py) were purchased from Sigma-Aldrich Co. (St. Louis, 
MO). Dowex W51-X8 cation ion exchange resin was purchased from Bio-Rad 
Laboratories, Inc. (Hercules, CA). Cyanine7 NHS ester (Cy7 NHS ester) was purchased 
from Lumiprobe Corp. (Hallandale Beach, FL). Other chemicals and organic solvents, 
CD44/H-CAM antibody, and cell culture supplies were purchased from Fisher Scientific 
(Pittsburgh, PA). Dulbecco's Modified Eagle's Medium (DMEM) was purchased from 
Lonza (Allendale, NJ). The MDA-1986 human oral squamous carcinoma cell line was 
kindly provided by Dr. Jeffery Myers (The University of Texas, M.D. Anderson Cancer 
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Center, Houston, TX).  Double distilled water (ddH2O) was used for preparing all of the 
aqueous solutions.  
2.2 Preparation of sulfated HA  
Sodium hyaluronate (132 kDa, 200 mg) was dissolved in 40 mL of ddH2O at 
room temperature, followed by the addition of 2-g of cation exchange resin (Dowex 
W51-X8). After stirring overnight, resin beads were removed by filtration, and the 
resulting filtrate was neutralized with TBA-OH solution (54.0-56.0% in H2O) and freeze-
dried to obtain orangish polymer, HA-TBA. One hundred milligrams of HA-TBA was 
dissolved in 50 mL of DMF for 20-30 min. After 3 equivalents of SO3Py (77 mg) powder 
were added slowly, the reaction was allowed to proceed at room temperature for 4 or 8 
hours. DMF was removed under reduced pressure from the mixture, which was then 
dissolved in ddH2O. The solution pH was adjusted from 1.2 to 7.0 using 2-N NaOH 
solution, followed by extensive dialysis (MWCO 10,000) against ddH2O for two days 
with four water changes. The degree of sulfation was determined by estimation of the 
sulfur content using an elemental analyzer. 
2.3 Preparation of N-deacetylated HA using hydrazine sulfate 
Twenty milligrams of sodium hyaluronate (2 MDa) was added to a flame-dried 
flask, and then was dissolved in 2-mL of anhydrous hydrazine containing 1% (v/v) of 
hydrazine sulfate under argon protection. The reaction was conducted at 105 °C for 1 or 2 
hours. The polymeric product was precipitated in 30-mL of cold ethanol and re-dissolved 
in 2-mL of acetic acid (5%, v/v) and 2-mL of HIO3 (0.5 M in ddH2O). The mixture was 
left at 4 °C for 2 hours. The excess HIO3 was quenched by the addition of 57% HI (640 
µL). The resulting brownish solution was washed with ethyl acetate until the aqueous 
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layer turned colorless. The aqueous layer was collected and neutralized using 2-N NaOH 
solution before dialysis against ddH2O, and finally freeze-dried. The degree of N-
deacetylation was determined by 1HNMR using the decreased percentage of N-acetyl 
protons.  
2.4 Preparation of N-deacetylated HA using an enzymatic method 
To 50 mg of hyaluronic acid (43KDa) in 5 mL of potassium phosphate buffer (0.1 
M, pH 7.5), 600 units of enzyme were added, followed by stirring at 35 °C for 24 hrs. 
The mixture was adjusted to pH 5 with 1-N HCl and heated to 60 °C with Norit for 2 hrs. 
The Norit was filtered out and the filtrate was dialyzed (MWCO 10,000) against ddH2O 
for two days. The N-deacetylation degree was determined by 1H NMR.  
2.5 Preparation of N-deacetylated HA-7-oxooctanate (NDHA-OO) 
7-oxooctanoic acid (20 equivalents to the amino group on HA) and CDI (22 
equivalents of the amino group on HA) were dissolved in anhydrous DMF and the 
mixture was stirred for 2 hours under argon at room temperature. This was followed by 
the addition of a solution of 50 mg of N-deacetylated HA in 6-mL ddH2O-DMF mixture 
(5:1, v/v). The reaction proceeded for another 3 days. Finally, impurities were removed 
by dialysis (MWCO 10,000) against a mixture of ethanol and ddH2O (1:4, v/v). The 
substitution degree of the keto-linker was determined by 1HNMR using the ratio of acetyl 










2.6 Characterization of modified HA polymers 
1HNMR was conducted on a Bruker 400-MHz NMR spectrometer. Molecular 
weight determination was performed by gel permeation chromatography (GPC) on a 
Shodex HQ-806 M column at 40 oC with ddH2O as the mobile phase at a flow rate of 0.8 
mL/min. An evaporative light scattering detector (ELSD, 70 oC) and an UV/Vis detector 
at 210 nm were used for detection.  
2.7 Preparation of Cy7-labeled HA polymers and intracellular imaging 
The conjugation of Cy7 to the HA polymer was accomplished by using an ADH 
linker. Sodium hyaluronate or sulfated HA or N-deacetylated HA (100 mg) was dissolved 
in 20 mL of ddH2O, followed by the addition of ADH (200 mg) and EDC•HCl (24 mg). 
The pH of the mixture was adjusted to ca. 5.0 using 1-N HCl, and the mixture was stirred 
at room temperature (ca. 20 oC) for 20 min to form the HA-ADH intermediates. The 
resulting solution was neutralized using 1-N NaOH, dialyzed against ddH2O (MWCO 
10,000) for 24 hr and lyophilized (Labconco 2.5 Plus FreeZone, Kansas City, MO). To 
synthesize Cy7-labeled HA, Cy7 NHS ester was dissolved in DMSO before being added 
to the HA solutions in water. The reaction was allowed to proceed overnight protected 
from light at room temperature. The unreacted Cy7 was removed by dialysis (MWCO 
10,000) against a 25% (v/v) ethanol-water mixture for 48 hours in the dark. UV/Vis 
spectrophotometry (675 nm, Molecular Devices SpectraMax Plus, Sunnyvale, CA) was 
used to determine the degree of Cy7 conjugation. A solution of Cy7-labeled HA (1 
mg/mL) was prepared in a mixture of DMSO/ddH2O (1:10). Calibration solutions were 
prepared by dissolving Cy7 NHS ester in the mixture of DMSO/ddH2O.  
244 
 
All cell imaging experiments were performed using a Nikon Eclipse 80i 
epifluorescence microscope (Melville, NY) with a 60x 1.40 oil objective. A Hamamatsu 
ORCA ER digital camera (Houston, TX) was used to acquire images. The MDA-1986 
cells were seeded onto poly-L-lysine precoated glass coverslips (BD, Franklin Lakes, NJ) 
in 12-well culture plates at a density of 50,000 cells per well and allowed to grow 
overnight. Subsequently, cells were treated with Cy7-labeled HA polymers with the same 
concentration of Cy7 (0.3 µg/mL) for a pre-determined time period, and stained with 
LysoTracker® Blue DND-22 (4 µM) for 30 min. After three washes with 3 mL of PBS, 
the coverslips were placed on glass slides for imaging. The live cells were immediately 
imaged using a Cy7 filter set (Chroma Technology Corp., Bellows Falls, VT) and a UV-
2E/C filter set (Nikon, NY) for LysoTracker® Blue.   
2.8 Cytotoxicity 
 Cell growth inhibition was determined in 96-well plates using head and neck 
squamous cell carcinoma cells, MDA-1986. Plates were seeded with 3,000 cells/well in 
90 uL of media (6 replicates/sample). Ten microliters of HA polymer solutions were 
applied after 24 hours. Resazurin blue in 10 µL of PBS was applied to each well with a 
final concentration of 5 µM after another 72 hours. After 4 hours, the well fluorescence 
was measured (ex/em 560/590 nm) (SpectraMax Gemini, Molecular Devices), and the 
IC50 concentration was determined as the midpoint between the drug-free medium 
(negative) and cell-free (positive) controls.  
2.9 CD44 Specificity 
Specificity of Cy7-labeled modified HA to the CD44 receptor was investigated 
using MDA-1986 cells that overexpress CD44. Cells were seeded in 96-well plates at a 
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density of 10,000 cells per well and pretreated with 10-µg/mL anti-CD44 antibody 1 h 
before the addition of 10-µg/mL Cy7 labeled HA polymers (on a polymer basis) or 0.14 
µg/mL Cy7 solution in DMSO and subsequent incubation for 6 h. Cells were washed 
with PBS three times, and treated with 500 µL of 1% Triton-100 solution per well for 10 
min on a shaker at a speed of 100 rpm. The cell lysate was collected and centrifuged at 
10,000 rpm × 10 min, and the supernatant was diluted 20 fold prior to fluorescence 
intensity analysis at 570/606 nm (ex/em).   
3. Results 
The sulfated HA was prepared as previously reported by first converting sodium 
hyaluronate to its TBA salt through a protonated resin exchange.(12) When the reaction 
was performed with the SO3Py complex in DMF for 4 or 8 hours, a higher degree of 
sulfation was observed in the 8-hour product (SHA-8). SHA-8 was determined to have 
7.0 wt% of sulfur per HA disaccharide, while there was only 3.6 wt% of sulfur per 
disaccharide of the 4-hour product (SHA-4). The cellular toxicities were evaluated by 
incubating MAD-1986 cancer cells with SHA-4 or SHA-8 in relatively high 
concentrations up to 10 mg/mL. As shown in Figure 2, compared to SHA-4, SHA-8 
exhibited a lower cellular toxicity when concentrations were above 0.1 mg/mL and 
inhibited less than 20% cell proliferation within 72 hours at a the highest concentration. 
However, SH-4 inhibited 60% cell growth within the same period of time at 10 mg/mL. 
The decreased cell toxicity of SHA-8 has not been fully understood yet, but will be 
investigated extensively in the future work. 
In addition, there was an expected and significant depolymerization of HA, during 
which the molecular weight of SHA-8 was reduced from 132 to 18.7 kDa as determined 
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by GPC using PEG as standards, following the sulfate reaction (data not shown). This 
was likely due to the hydrolysis of HA in the presence of H2SO4 formed by reaction of 
SO3Py with water in DMF.   
The HA N-deacetylated products, NDHA-1 and NDHA-2 were obtained after 1 
and 2 hour-hydrazinolysis of 2 MDa sodium hyaluronate. As shown in Figure 3, within a 
monomer of native HA polymer, the integral ratio between the anomeric protons and 
acetyl protons is 2 to 3 theoretically, and the ratio between the protons on the HA 
backbone and acetyl protons is 10 to 3. As expected, successful N-deacetylation was 
demonstrated by the reduced molar ratio of acetyl and HA backbone protons. As 
calculated from 1HNMR spectra in Figure 3, the N-deacetylation degree of NDHA-1 and 
NDHA-2 were 35.3% and 47.6%, respectively.  
In addition to deacetylation, depolymerization of the hyaluronate chains was 
noticeable upon reducing with hydrazine at an elevated temperature. The molecular 
weights of the recovered HA polysaccharides showed a significant decrease from 2 MDa 
to 127 and 78 kDa within 1 to 2 hours, respectively. Moreover, a decrease in 
polydispersity was observed after deacetylation, as indicated by narrower peaks (smaller 
polydispersity index) of NDHA-1 and NDHA-2 in Figure 4. In addition, there were two 
changes in NMR spectra due to the depolymerization that were observed (Figure 3). First, 
anomeric protons partially shifted to a lower magnetic field, and thus the integral values 
of the signals at 4.3-4.7 ppm decrease proportionally to acetyl protons. Second, signals 





Figure 2. Anti-cell proliferation study of SHA-4 and SHA-8 on MDA-1986 HNSCC 














In order to circumvent the degradation of the HA chain during the N-deacetylation 
process, an enzyme-catalysed deprotection of N-acetyl group were applied to sodium 
hyaluronate. Acylases, extracted from Aspergillus oryzae and porcine kidney, have 
shown the ability to remove N-acetyl groups from amino acids readily and gently without 
any substrate specificity. The N-deacetylation degree varied with different enzymes, 
molecular weights of HA, temperature, and the length of time, under which the enzymatic 
reactions were conducted. As shown in Table 1, the acylase from porcine kidney 
exhibited a better activity over the acylase from AM on 43 kDa HA no matter the 
temperature or length of time (Entry 1vs2, 3vs4). Therefore, acylase I from PK was used 
for future studies. It was also seen that higher temperatures rendered a higher enzymatic 
activity for the amide hydrolysis even within a shorter reaction time (Entry 1vs3, 2vs4). 
Moreover, a higher dose of acylase I from PK improved the conversion from N-acetyl to 
the amino group substantially at 37 °C (Entry 4vs5). In order to investigate the effect of 
molecular weights on the deacetylation, larger HA polymers, 752 and 132 kDa, were 
incubated with a 4 fold larger amount of acylase I than the 43 kDa polymer. A longer 
reaction time was also used, which provided more opportunity for enzyme to catalyze the 
hydrolysis sufficiently. Based on the N-deacetylation degree, no difference was observed 
resulting from the polymer molecular weight. However, when the same amount of 
acylase was added repetitively and continuously for 10 days, a turbid reaction mixture 
was observed starting from the third day, which was very likely due to the aggregation of 
proteins. Surprisingly, when larger accumulative doses were used to catalyze the reaction 
on 752 and 132 kDa HA polymers, neither obtained a significantly enhanced hydrolysis. 
This drop in activity was possibly because of the rapid adsorption of the free enzyme 
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macromolecules on its aggregates and hence loss of its hydrolytic activity, or may have 
been due to the limited accessible N-acetyl groups to react with enzymes. Furthermore, 
the N-deacetylation degree was not further improved as the reactions were carried out at 
40 °C.  
It has been reported that the relaxation of HA tertiary structure could be achieved 
at an elevated temperature as high as 100 °C avoiding any damage to the HA chain. It 
was suspected that limited degree of N-deacetylation was because enzyme 
macromolecules could not approach the hydrophobic core owing to the steric hindrance 
of the HA matrix. Consequently, 752 kDa HA was heated up to 100 °C for 20 min 
followed by a rapid freeze down to -78 °C, which is a known strategy to unfold the 
tertiary structure of HA and hence to expose N-acetyl groups to acylases.(19) Since 
relaxed HA is usually transformed back to the coiled state rapidly when the temperature 
is increased to ambient temperature, acylase was added immediately following the 752 
kDa HA being thawed at 37 °C. Unsurprisingly, more acetyl groups were removed in 2 
days from HA that underwent a freeze and thaw cycle compared to treating HA with 
acylase directly for 4 days. 
In addition, the remarkable advantage of an enzyme catalyzed N-deacetylation 
reaction over hydrazinolysis was that the HA backbone was preserved, as demonstrated 
by the same elution time of 43 kDa HA before and after specific hydrolysis on acetyl 
groups by acylase I from PK (Epk-NDHA, Figure 5).  
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Table 1. N-deacetylation of HA using acylases under various reaction conditions. 
Entry Molecular Weight (kDa) Temp (°C) Acylase Amount of Enzyme  Length of Time (days) N-deacetylation Degree (%) 
1 43 r.t. PK 300 units 3 9.7 
2 43 r.t. AM 300 units 3 6.4 
3 43 37 PK 300 units 1 14.5 
4 43 37 AM 300 units 1 11.4 
5 43 37 PK 6000 units 1 18.8 
6 752 37 PK 1200 units 4 15 
7 132 37 PK 1200 units 4 15 
8 752 37 PK 1200 units/day 14 10.5 
9 132 37 PK 1200 units/day 14 12 
10 43 40 PK 1200 units/day 10 14.4 
12 132 40 PK 1200 units/day 10 12.6 
13 752 Freeze & thawa PK 1200 units 2a 16.4 
a Heated to 100 °C, snap freezing to -78 °C, then warmed to 40 °C within 10 min, followed by the addition of PK enzyme. The 





Figure 5. Gel permeation chromatographs of 43 kDa HA and PK acylase enzymatic 




In order to explore the possibility of modifying via amide formation on liberated 
amino groups, an alkyl ketone linker, 7-oxooctanoic acid, was grafted to HA using CDI-
mediated conjugation. The successful conjugation was demonstrated by 1HNMR spectra 
in Figure 6. In contrast to a physical mixture (Figrue 6c), α-hydrogens of carboxylate in 
7-oxooctanoic acid shifted from 2.73 ppm to a lower frequency of 2.20 ppm, which 
confirmed the formation of an amide bond with primary amines on N-deacetylated HA. 
The bound formation was also responsible for shielding some protons on the alkyl chain 
of the linker. Specifically, the multiple peaks between 1.56 and 1.52 ppm in Figure 6c 
were shifted to be lower than 1.53 ppm in Figure 6b.  
 The cellular uptake of HA-Cy7 (47 or 215 kDa), PK enzymatic catalyzed N-
deacetylated HA-7-oxooctanate-Cy7 [Epk-NDHA43k-OO-Cy7 (10% substitution degree) 
or Epk-NDHA215k-OO-Cy7 (12% substitution degree)] and Cy7 was monitored at 15 min, 
1, 2, 6, and 24-hours after the addition of each treatment. The MDA-1986 cell life cycle 
is 24 hours, thus the cellular traffic of HA polymers was investigated up to 24 hours. The 
Cy7 labeled HA polymers were found internalized in 15 min and retained in the cytosol 
at 24 hours. Except HA215kDa-Cy7, the highest fluorescence intensities of low molecular 
weight HA and modified HA were reached in the first 2 hours (Figure 7). Not 
surprisingly, due to less than 20% modification on HA, there was no significant 
difference observed between 43 kDa HA and its ketone linker conjugate, Epk-NDHA43k-
OO-Cy7. However, although the modification on 215 kDa HA was also no more than 
20%, the resulting conjugate exhibited a substantial increase within one hour after 
treatment and then a slow decrease from 1 to 6 hours. In contrast, the fluorescence 
intensity of 215 kDa HA continued to increase from 15 min until 24 hours, indicating the 
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continuous cellular uptake of larger molecular weight HA. The shortened Tmax in Epk-
NDHA215k-OO-Cy7 was possibly attributable to the presence of the lipophilic linker, 
which affected the tertiary structure so as to reduce its hydrodynamic diameter, resulting 
in a faster internalization of smaller polymer nanocomposite.    
 Lysosomes are known to be the major cell organelle that contains hydrolytic 
enzymes capable of breaking down biological polymers, such as carbohydrates and 
bioconjugates.(20) Lysosomes play an important role in the digestion of materials taken 
up from outside the cell by endocytosis. Both free Cy7 and Cy7 labeled HA polymers 
were found to be co-localized with the fluorescence generated by lysoTracker blue 
(Figure 8). Whereas, compared with Cy7, HA polymers were also distributed to the 
cytosol and other organelles in addition to lysosomes as shown in the overlaid pictures in 
Figure 8. This is consistent with our previous finding that Cy7 labeled HA was 





Figure 6. 1HNMR spectra of a) NDHA, b) NDHA-OO, c) physical mixture of 7-







Figure 7. The relative fluorescence intensity of Cy7 labeled HA polymer treated cells at 




Figure 8. Fluorescence images of Cy7 labeled HA polymers treated cells, co-stained with lysoTracker-blue: bright field images 
(grey), Cy7 (green), LysoTracker-Blue (blue) and overlaid images.
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In order to investigate the CD44 receptor specificity of sulfated HA, cells were 
pretreated with anti-CD44 antibody (CD44 mAb), which binds to the CD44 receptor on 
the cell membrane to inhibit the receptor-mediated endocytosis of HA. In the SHA-4-Cy7 
treatment group, CD44 mAb treated cells exhibited a 30% (p = 0.0193) reduction in the 
relative fluorescent intensity in 6 hours (Figure 9).(21) However, cellular uptake of SHA-
8-Cy7 was not inhibited by the addition of CD44 mAb. There was no significant 
difference found in the control, the Cy7 treatment group. The results indicate that 7% 
sulfation of HA may have interrupted the recognition of HA by CD44 receptors, and the 
CD44 pathway may not act as the dominant uptake route for internalization of SHA-8-














Figure 9. The relative fluorescent intensity of SHA-Cy7 and Cy7 treated cells. MDA-
1986 cells were pretreated with or without 10-µg/mL anti-CD44 antibody (-CD44 mAb 












Hyaluronic acid is one of the carbohydrate polymers called glycosaminoglycan 
(GAG). It is naturally occurring, highly water soluble, and an important component of the 
extracellular matrix (ECM). HA is a linear polysaccharide composed of a repeating 
disaccharide of N-acetyl-D-glucosamine and D-glucuronic acid with 1 → 4 
interglycosidic linkages, with the disaccharide monomers linked by β (1 → 3) linkages. 
The large number of carboxyl and hydroxyl groups in HA allows chemical modification 
with a high loading efficiency. Except these two functional groups, the reducing end of 
HA can liberate an aldehyde that is used to conjugate therapeutic agents at the terminus 
via reductive amidation. The pKa of the carboxyl groups on the glucuronic acid is 3-4, 
thus HA exists as a polyanion under physiological conditions. HA is a natural ligand that 
binds to various cell surface receptors such as the CD44, receptor for HA-mediated 
motility (RHAMM) and the intercellular adhesion molecule-1(ICAM-1). These distinct 
characteristics attract researchers’ attention to develop HA as a transportation vehicle for 
targeted intracellular delivery of drugs, peptides and macromolecules.(22)    
 HA shows an expanded random coil structure (tertiary structure) in aqueous 
solution, which is composed of 2-fold helices (secondary structure), formed and 
stabilized by the intra- and inter-molecular H-bonding of the HA network. The secondary 
structural unit consists of five hydrogen bonds with two adjacent disaccharide units, 
which is a preferred polymeric state in other anionic glycosaminoglycans.(23) HA also 
possesses a hydrophobic component of eight or nine CH units extending over three 
neighboring monomers that results in the chain-chain intermolecular hydrophobic 
interactions in the tertiary structure. The secondary and tertiary structures of HA may 
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explain a high viscosity and elasticity with a large hydrodynamic volume in physiological 
solution.  In addition, the hydrophobic feature provides a reliable explanation for the 
affinity of HA to some lipids and membranes.(24) It has been demonstrated that HA self-
aggregates into an antiparallel tapelike structure resulting from the hydrophobic patches 
of HA. The intermolecular H-bonding is between acetamido NH on one chain and 
carboxylate on the corresponding antiparallel chain.(25) Due to the highly ordered state 
of HA macromolecules in solution, especially high molecular weight HA, and to the 
strictly oriented acetamido groups, accessibility for other macromolecules may be 
extremely limited. The molecular weight of acylase I from porcine kidney is approximate 
86 kDa. The tertiary structure of HA must be disassembled to provide enough space to 
enable the entrance of the PK enzyme. The occurrence of a reversible chain coupling-
decoupling is dependent upon temperature, pH, ionic strength and solvent composition. 
For example, comparing Entry 1 and 3 in Table 1, the N-deacetylation degree on 43 kDa 
HA increased by 5% with 1-day incubation, which was probably attributable to the 
temperature increase from room temperature (approximate 20-22 °C) to 37 °C.   
As reported by other investigators, the tertiary structure can be disassembled upon 
heating to > 40 °C or upon alkalizing in a solution of pH > 12.(26) However, enzymes 
may be degraded and thus lose their catalytic activity at either of the above conditions. 
Chang et al. proposed that the HA conformation could be altered by a series of physical 
treatments in a sequence of heating at 100 °C, snapfreezing to stabilize the relaxed HA 
and thawing promptly just prior to the addition of enzymes.(19) Following this 
procedure, a similar deacetylation degree was achieved in 2 days in contrast to a 37 °C 
incubation for 4 days (Table 1, Entry 6 vs 13). This was because the intermolecular 
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structure of HA was decoupled after undergoing a heating and rapid cooling cycle.(27) It 
was also demonstrated in Chang’s research that no significant molecular degradation was 
caused during the vigorous heating of HA to 100 °C up to 90 min. However, when HA 
was frozen slowly, the decoupled strands of heated HA tended to recouple. Therefore, it 
was concluded that N-deacetylation of HA is a thermally-dependent activity, and the 
decoupled conformation of the heated HA was responsible for the effective breakdown of 
acetyl groups. Owing to the versatile physiochemical properties of HA, enzymatic 
catalyzed N-deactylation reactions will be further investigated to look at other factors, 
such as pH, ionic strength and type of enzymes. 
The successful development of NDHA-OO nanoconjugates offers a facile 
chemical conjugation method that is free of concerning regarding significant loss of HA’s 
characteristics by the chemical modification of carboxyl or hydroxyl groups. Amines on 
anticancer drugs and proteins can form reversible Schiff bases with aldehydes and 
ketones. It is well-known that drug molecules conjugated through a Schiff base linkage 
could be released in a pH-dependent manner from the polymer scaffold. NDHA-OO was 
expected to release the intact drug more rapidly in vitro under lysosomal acidic 
conditions or in vivo in a hypoxic acidic environment within solid tumor masses but only 
very slowly under physiological conditions. Therefore, drugs are concentrated 
preferentially within the tumor compared to the relatively neutral environment of 
surrounding normal cells. The same strategy has been widely used in pH-triggered 
delivery of doxorubicin by polymers.(28-30) In a similar way, the carbonyl groups of HA 




5. Conclusion  
Thanks to its outstanding physiochemical properties, HA has been extensively 
investigated and is widely used in therapeutic applications. A novel N-deacetylation 
method was proposed for developing innovative HA derivatives with minimum alteration 
of its physiochemical properties. Substantial chain fragmentation occurred when the 
previous hydrazinolysis method was used. This enzymatic modification offers a broader 
spectrum of options for the synthesis of new HA derivatives for the improvement of 
targeted drug delivery and thus drug efficacy. In addition, ketone functionalized N-
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Figure 1. Photo-dissociation of Mn(II) nitrosyl NO prodrug III. UV-Vis absorption 
spectra of Mn (II) nitrosyl NO prodrug I with a concentration of 20 mg/mL in ACN after 









Figure 2. Chronoamperogram generated with NO microsensor upon photo-activation of 
Mn(II) nitrosyl NO prodrug III in 0.1 M CuCl2 under illumination with a fluorescent tube 
light. The vertical line represents the addition of NO prodrug. The solid and hollow 
arrows represent the light off and on, respectively. 
 
 
 
 
 
 
